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Referat :
Human induced pluripotent stem (iPS) cells are potential cell sources for regenerative
medicine; however, clinical applications of iPS cells are restricted because of
genomic modifications associated with most reprogramming approaches. Induced
pluripotent stem cells can be derived from somatic cells through transfection of
mRNA encoding reprogramming factors. The mRNA-based reprogramming is able to
generate integration-free iPS cells and is therefore highly suitable for clinical
translation. However, there are some limitations which must be overcome to enable
mRNA to be used reliably for cellular reprogramming. This thesis demonstrated
generation of two stable mRNA-iPS cell lines by overcoming those limitations.
The potential aging signatures of the iPS cells should be conducted before their use
for clinical applications. Currently, there are controversial data regarding the ability of
reprogramming to reverse age-related changes. Mixed findings have been reported
regarding whether the iPS cells are fully rejuvenated or they might retain some of the
aging hallmarks from the cells which they were derived. This thesis studied those
controversies by investigation of three hallmarks of aging including telomere length,
reprogramming enables reversion of aging signatures to a more youthful state.
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1. Introduction
1.1 Human embryonic stem cells
Human embryonic stem (hES) cells are pluripotent cells that can provide a potential
source of cells for research, regenerative medicine or tissue bioengineering (Gu et al.
2012). The term pluripotency has been assigned to different cell types with a wide range
of functional capacities. In its simplest sense, pluripotent describes a cell that can
generate cell types from each of the three embryonic germ layers: the endoderm,
mesoderm and ectoderm. The exact definition, however, pluripotent describes a cell
that can give rise to an entire organism, generating every cell type within that organism
(Thomson et al. 1998; Vallier & Pedersen 2005).
The study of hES cells has seemed to offer unlimited possibilities such as
understanding of early human development, tissue formation and differentiation in vitro.
Additionally, the opportunity to model diseases, discover disease mechanisms and,
eventually, use cell therapy for previously untreatable conditions was particularly
appealing (Niclis et al. 2009; Vallier & Pedersen 2005; Reubinoff et al. 2000). The
derivation of embryonic stem cells from the human embryos, however, sparked a
controversial ethical debate on the use of hES cells in clinical research. There are
limitations that must be overcome, such as immune rejection as well as ethical and
technical issues surrounding the use of human embryos as source of ES cells for use in
the clinic (Thomson et al. 1998; de Wert & Mummery 2003; Giacomini et al. 2007; Sarić
et al. 2008; Elstner et al. 2009).
1.2 Induced pluripotent stem cells
Due to the obstacles for study and derivation of hES cells over the past decade, the
intention of researchers was to develop an alternative source of pluripotent stem cells
with the same range of functions as ES cells. It was discovered early on that somatic
cells could be reset to a pluripotent state through somatic cell nuclear transfer
(GURDON 1962; Tada et al. 1997; Hochedlinger & Jaenisch 2002; Wilmut et al. 2007)
and cell fusion (Tada et al. 2001). A landmark experiment in the cell reprogramming
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field was performed by Takahashi and Yamanaka, demonstrating that adult somatic
cells could be restored to pluripotency through the exogenous expression of four
transcription factors: Oct4, Sox2, Klf4, and c-Myc. The derived cells were termed
induced pluripotent stem (iPS) cells (Takahashi & Yamanaka 2006). These iPS cells
expressed markers exclusive to ES cells, mimed their morphology and growth
properties, and could differentiate into all three germ layers (Takahashi & Yamanaka
2006; Hanna et al. 2010). This remarkable finding inspired follow-on studies for
successful reprogramming of a wide variety of other cell types including pancreatic β
cells (Stadtfeld et al. 2008), neural stem cells (Eminli et al. 2008; Kim et al. 2008),
mature β cells (Hanna et al. 2008), stomach and liver cells (Aoi et al. 2008),
melanocytes (Utikal et al. 2009), adipose stem cells (Sun et al. 2009) and keratinocytes
(Maherali et al. 2008), demonstrating the universal capacity of reprogramming to alter
cellular identity.
1.3 iPS cells as an alternative cell source for disease modeling and
regenerative medicine
Human iPS cells are promising tools for therapeutics and human disease modelling.
They offer generation of useful cell types for autologous therapies and facilitate
repairing deficits arising from injury, illness, and aging (Lalit et al. 2014; Shtrichman et
al. 2013). Additionally, reprogramming adult somatic cells facilitates the generation of
patient-specific models that have already been used to generate valuable information
regarding disease pathogenesis, drug testing, and drug discovery (Bellin et al. 2012) . In
spite of considerable challenges, generation of disease-specific iPS cells has become a
routine approach. These cells provide a unique platform to identify mechanisms
involved in variety of diseases, to carry out in vitro drug screening, to evaluate potential
therapeutics and to investigate gene repair joined with cell-replacement therapy (Fig. 1).
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Figure 1. Clinical application and disease modeling of iPS cells. Human iPS cells have the
potential to be used as an in vitro model and treat human disease. In this figure, the patient has
a neurodegenerative disorder. The skin biopsy-derived iPS cells can be used in one of two
pathways. In cases which a mutation causes disease, gene targeting could be used to repair the
mutation (right). Then, the repaired patient specific iPS cells would undergo directed
differentiation into the affected neuronal subtype and can then be transplanted into the patient’s
brain. On the other hand, directed differentiation of the patient specific iPS cells into the affected
neuronal subtype (left) can be used as an in vitro model to test potential drugs and discover the
novel therapeutic compounds. The figure modified from Robinton & Daley 2012.
With the successful generation of iPS cells from patients with familial dysautonomia, a
genetic disorder of the peripheral nervous system, Lee et al., found three disease-
related phenotypes for such disorder. After testing with several compounds, they
showed that the disease phenotype could be recovered by kinetin, a plant hormone
(Lee et al. 2009). This report demonstrates how iPS cells can facilitate the discovery of
therapeutic compounds and how these cells provide a platform for in vitro disease
modelling. A study conducted by Moretti and colleagues showed that generation of iPS
cells from patients with type 1 long QT syndrome (a congenital disease associated with
abnormal ion-channel) led to prolonged action potentials in the ventricular and atrial
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cells (Moretti et al. 2010). Using this model, these investigators revealed a dominant-
negative trafficking defect associated with the particular mutation that causes this
variant of long QT syndrome. Furthermore, treatment of the iPS-derived cardiomyocytes
with β- adrenergic receptor blockers was shown to alleviate the long QT phenotype.
This study verified that iPS cells model can be used to identify complex cardiotoxic
effects of drugs.
Although iPS cells are valuable tools for modelling diseases in vitro, the goal of
developing patient-specific iPS cells had been generation of immune-compatible cells
and tissues for autologous transplantation. Recently, some scientists have utilized
repaired iPS cells derived from a sickle-cell anaemia mouse model (Hanna et al. 2007).
They showed that directed differentiation of repaired iPS cells into haematopoietic
progenitors followed by transplantation into the affected mice led to the rescue of the
disease phenotype. Nevertheless, the clinical translation of iPS cells seems more
prospective at present than the in vitro use of iPS cells for research and drug
development.
1.4 Reprogramming methods for generation of iPS cells
Since the initial discovery of iPS cells multiple methods of reprogramming have been
generated. Adult somatic cells have been successfully induced into pluripotency using
viral vectors (Zhou & Freed 2009), non-integrating episomes (Yu et al. 2009), and
minicircle vectors (Jia et al. 2010). iPS cells can also be generated by the use of
recombinant proteins (Zhou et al. 2009) or with extracts derived from cells express
reprogramming factors. More comprehensive listings of reprogramming approaches
have been reviewed elsewhere (González et al. 2011). The delivery methods used so
far for reprogramming can be classified in to three categories depending on host
genome alteration risk: DNA integrative (retrovirus, lentivirus, and transposons), non-
integrative DNA-base (adenovirus, standard and episomal plasmids, and minicircles),
and those that reprogram through a DNA free approach (proteins, Sendai virus, and
modified and non-modified mRNA) (Fig. 2) (González et al. 2011).
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Figure 2. Comparison of different reprogramming methods. The efficiency and safety of
different reprogramming methods are shown here. The methods are classified into three main
categories including integrating, non-integrating and DNA free. mRNA approach proves to be
the most efficient and safest reprogramming method as compared to the viral and DNA-based
methods. The figure modified from Bernal 2013.
1.4.1 Integrating methods
The integrating reprogramming methods have been reported so far include: 1)
retrovirus, 2) lentivirus, including 3) Cre-loxP system, and 4) transposons.
The initial approach for derivation of iPS cells utilized retroviral vectors to deliver
reprogramming factors into the cells (Takahashi & Yamanaka 2006; Takahashi et al.
2007) (Fig. 3). Many researchers in the field of reprogramming use viral methods to
reprogram adult somatic cells into iPS cells, given that they are powerful gene delivery
systems and are easily applied in most research labs. Retroviral vectors can be
transduced into target cells and randomly integrated into the host genome of dividing
cells. The reprogramming efficiency of this approach was reported to be 0.01- 0.02% in
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human cells (Takahashi et al. 2007; Lowry et al. 2008). Although the retroviral-based
method is simple and easily adoptable by labs, therapeutic application of this method
has been prevented because of the risks related to the integration of viral sequences
into the genome.
Figure 3. Generation of iPS cells using viral-based method. The initial method for derivation
of iPS cells was performed using retroviral vectors to deliver Oct4, Sox2, Klf4 and c-Myc into the
cells.
Lentiviral delivery systems are able to infect both dividing and non-dividing cells which
means that they could be applied to a wide variety of cell types. The generation of iPS
cells using lentivirus was originally performed in Thomson’s lab with the use of Oct4,
Sox2, Nanog and Lin28A to generate iPS cells at an efficiency of 0.02 % (Yu et al.
2007). While acceptable gene delivery has been achieved using lentiviral vectors,
concerns were still remained regarding the integration of viral sequences into the iPS
cell genome.
To overcome this concern, Cre/loxP recombination system was used to remove
integrated transgenes from mouse or human iPS cells. In this system, the lentiviral
vectors were prepared with loxP sites in such a way that the integrated reprogramming
factors (Oct4, Sox2, Klf4 and c-Myc) could be excised by the transient expression of
Cre-recombinase (Sauer & Henderson 1988). However, residual vector sequences
were left behind, and therefore insertional mutations remained as a risk factor (Loh et al.
2012). Moreover, some loxP sites remained in iPS cells genomic DNA. The remaining
loxP sites are prone to genome rearrangement (Sauer 1992; Cochrane et al. 2007).
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transposon/transposase was another alternative system to deliver reprogramming
factors into the cells (Woltjen et al. 2009; Kaji et al. 2009; Yusa et al. 2009). PiggyBac
(PB) transposons are the most common transposons used in reprogramming. They are
mobile genetic elements that can be integrated/excised at chromosomal TTAA sites in
the presence of their transposase (Fraser et al. 1996). The PB transposon/transposase
system can be removed following stable genomic integration and are able to generate
iPS cells from human fibroblasts at efficiency between 0.02- 0.05%. Recently, different
laboratories have used this system for iPS generation (Woltjen et al. 2009; Kaji et al.
2009). However, it should be taken into account that transposon reversible
integration/excision approach is complex and time consuming since identification of iPS
cells with minimal-copy insertions, mapping of integration sites, excision of the
reprogramming cassette, and validation of factor-free clones is required.
1.4.2 Non-integrating methods
The initial method for generation of iPS cells applied retroviral vectors to transport
reprogramming factors into the cells (Takahashi & Yamanaka 2006; Takahashi et al.
2007). Although the retroviral-based method is easily adoptable by labs, therapeutic
application of this approach is prevented because of the risks related to the integration
of viral sequences into the host genome. Therefore, a focal point in the reprogramming
field has been the development of methods which avoid integration when delivering the
transcription factors into somatic cells (Warren et al. 2010; Mandal & Rossi 2013).
Different non-integrating methods for generation of human iPS cells have been
published (Stadtfeld et al. 2008; Yu et al. 2009; Gonzalez et al. 2009; Yusa et al. 2009;
Jia et al. 2010; Warren et al. 2010; Narsinh et al. 2011; Hou et al. 2013). The strengths
and weaknesses of these methodologies have been previously discussed (Robinton &
Daley 2012; Zhou & Zeng 2013).
1.4.2.1 Non-integrating DNA-base methods
Different non-integrative DNA-based approaches that have been used for
reprogramming include 1) adenovirus, 2) standard and episomal plasmids, and 3)
minicircles.
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Adenoviral vectors are non-integrating double-stranded DNA vectors that remain in
epichromosomal form in cells. They have been used for generation of iPS cells from
mouse (Stadtfeld et al. 2008) and human (Zhou & Freed 2009) somatic cells. At the first
glance, adenoviral vectors appear to be an outstanding alternative expression vehicle
for generating iPS cells. However, the reprogramming efficiency of this method is low
and only around 0.0002 % in human cells (Stadtfeld et al. 2008). Thus, the
reprogramming efficiency of adenoviral vectors must be notably improved before this
delivery system can be used clinically.
Repeated transfection of the standard plasmids (expression plasmids) containing
reprogramming factors (Yamanaka factors) into mouse embryonic fibroblasts (MEFs)
resulted in iPS cells without integration. However, the reprogramming efficiency was
much lower than viral vectors (Okita et al. 2008).
Another type of non-integrating vectors used for reprogramming of somatic cells is
episomal vectors derived from Epstein-Barr virus. The episomal vectors contain
oriP/EBNA1 sequences which undergo stable extrachromosomal replication only once
per cell cycle, without integrating into the host genome. However, efficiency for iPS
generation using episomal vector was shown to be very low (Yu et al. 2009).
Minicircle vectors are a type of vector where the plasmid backbone has been excised
and only the eukaryotic promoter and cDNA(s) which are to be expressed remain. A
minicircle vector expressing Lin28A, Nanog, Sox2, Oct4, and a GFP marker was able to
reprogram 0.005 % of the human adipose stromal cells (Jia et al. 2010). Surprisingly,
this method was even less efficient for reprogramming of neonatal fibroblasts, and no
other reports have successfully reprogrammed other somatic cells (Narsinh et al. 2011).
Therefore, more validation will be required before this method can be widely used.
Although DNA transfection-based methodologies are apparently safe, they nonetheless
involve in some risk of genomic recombination or insertional mutagenesis (Kaji et al.
2009; Yu et al. 2009). Furthermore, the reprogramming efficiency for most of them is
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very low. Therefore, recently application of some DNA-free methods has been
developed for reprogramming of somatic cells.
1.4.2.2 DNA-free approaches
Rising concerns over the presence of transgene sequences or insertional mutagenesis
in iPS cells has led to the development of a number of DNA-free methods for the
delivery of reprogramming factors into cells. The DNA-free methods that have been
used so far for the generation of iPS cells include 1) protein transduction, 2) Sendai
virus (SeV) and 3) mRNA approach.
Direct protein transduction of reprogramming factors allows generation of transgene-
free iPS cells. This method could be another good choice for the creation of iPS cells
and could be suitable for studies in translational medicine. However, technically it is
challenging to synthesize large amounts of bioactive proteins which are able to cross
the plasma membrane. Consequently, very low efficiencies of this method (0.00001-
0.001%) in human cells have been reported (Zhou et al. 2009; Kim et al. 2009).
Sendai virus-based vectors can reprogram the cells without entering the nucleus of an
infected cell. Importantly, with the use of this approach the viral genome remains as
RNA in the cytoplasm and therefore avoids any DNA phase (Li et al. 2000). Transgene-
free iPS cells have been generated from human fibroblasts using this approach. The
reprogramming efficiency was reported to be over 1.5% (Fusaki et al. 2009). Different
cell types have been successfully reprogrammed using SeV (Seki et al. 2010; Seki et al.
2012; Nishishita et al. 2011). With the use of SeV technology, there is no risk of viral
integration into the host genome. Furthermore, such approach has high infection
efficiency in dividing and non-dividing cells. However, there are some limitations that
prevent SeV technology to be used generally. Indeed, the use of SeV requires strict
steps to clear reprogrammed cells of replicating virus. The sensitivity of the viral RNA
replicase to transgene sequence content may also limit the generality of this
reprogramming vehicle (Fusaki et al. 2009).
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Recently, effective reprogramming was achieved using mRNA (Warren et al. 2010), an
integration-free technique our group has used to derive iPS cells from diseased and
healthy donors (Arnold et al. 2012) (Patent: US20110236978, EP2192174 A1). The
method contains repeated administration of reprogramming factors encoding-mRNA
into the somatic cells so that the reprogramming proteins reach the level required for
generation of iPS cells (Fig. 4). The mRNA used for reprogramming will be transcribed
in vitro and has 5′-cap and 3′-Poly (A) tail structures to increase the translation
efficiency and stability of the molecule inside of the cells (Fig. 4).
Figure 4. mRN-based approach for generation of iPS cells. Repeated transfection of
reprogramming factors-encoding mRNA makes footprint-free iPS cells which are applicable in
translational research. The mRNA used for reprogramming has 5′-cap and 3′-Poly (A) tail
structures to increase the translation efficiency and stability of the molecule inside of the cells.
The mRNA-based reprogramming has a lot of advantages compared to the other non-
integrating methods (Table 1). The non-integrating methods that rely on repeated
administration of transient vectors, whether DNA or protein-based, have so far shown
very low reprogramming efficiencies (Okita et al. 2008; Stadtfeld et al. 2008; Kim et al.
2009; Yu et al. 2009; Zhou et al. 2009; Jia et al. 2010), probably due to weak or
inconstant expression of reprogramming factors. However, the mRNA-based approach
allows exact control over levels and timing of protein expression. To our knowledge, no
other reprogramming technology allows such control over reprogramming factor
expression. Furthermore, using of mRNA technology for reprogramming offers
efficiencies notably superior to established viral and non-viral protocols (Table 1).
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Table 1. Advantages of mRNA-based reprogramming compared to other reprogramming
methods. The mRNA-based approach provides efficiencies more than 1% over existing
reprogramming methods. Furthermore, the method generates high-quality iPS cell lines that do
not require additional screening to check for viral contaminants or insertional mutagenesis into
the genome.
Efficiency Integrating Screening
mRNA >1% No No
Sendai virus 0.01-1.5% No Yes
Protein 0.00001-0.001% No No
Lentivirus/Retrovirus 0.01-0.02% Yes Yes
Transposon 0.02-0.05 % Possible Yes
Adenovirus 0.0001-0.001% Possible Yes
Episomal/minicircle 0.0001-0.005 % Possible Yes
1.5 RNA-technology-future perspective in cell-fate derivation
mRNA-based reprogramming as a simple, non-mutagenic and highly controllable
technology is applicable to a range of tissue engineering tasks. Indeed, this technique
can open up the opportunity to develop safe artificial tools to generate diverse cell types
and lineage conversion. Transfection of mRNA encoding differentiation factors could be
used to reset the epigenetic signatures of a specific cell type to another cell type. This
process can be done through indirect lineage conversion (progenitor- like state) or direct
lineage conversion (trans-differentiation).
Indirect lineage conversion requires an activation state that leads to the generation of
cellular intermediates. Indeed, upon indirect lineage conversion, activated cells acquire
a precursor-like feature with multipotent differentiation capacity. The method has useful
applications in regenerative medicine and translational research, particularly in cases
which progenitor transplantation might be an advantage over fully differentiated cells.
Recent publications have shown that short temporal expression of pluripotency factors
was enough to induce a partially de-differentiated state suitable for conversion into
specific cell types by extracellular developmental signals (Efe et al. 2011). In this case,
the temporal expression of transcription factors is important since it has been shown
extensive exposure of the cells to pluripotency factors diminished their lineage
conversion efficiency toward cardiomyocyte differentiation (Ieda et al. 2010).
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These data indicate that indirect lineage conversion itself must be regulated in order to
achieve partial reprogramming and start the differentiation process on time to obtain the
target cell of interest. mRNA technology offers a number of traits which make it a
potentially powerful tool for this type of indirect linage conversion. Indeed, the short-half
life of mRNA inside the cells would be an outstanding characteristic which allow
temporary existence of pluripotency factors in the cells, and make it an eligible
candidate for partial de-differentiation and indirect lineage conversion.
In direct lineage conversion (trans-differentiation), one adult cell type can be directly
reprogrammed to another cell type by the addition of specific factors. Therefore, the
process largely depends on whether certain factors are able to remodel epigenetic signs
of a particular cell type to another cell type (Graf & Enver 2009; Vierbuchen et al. 2010;
Sekiya & Suzuki 2011; Qian et al. 2012; Song et al. 2012).
Transdifferentiation could be a valuable source for clinical application and cellular
transplantation, since it occurs in the absence of a pluripotent state and generates post-
mitotic populations. Therefore it could theoretically reduce the risk of uncontrolled post-
transplantation cell proliferation. However, finding the best cellular source in
combination with specific factors to directly convert one cell type into another is a large
challenge. RNA-mediated directed differentiation would be an eligible candidate to
eliminate such obstacles. Indeed, RNA allows robust translation of almost any protein in
different cell types. Moreover, since RNA combinations of multiple factors can be
transfected into cells at once, co-translation of several factors at a desired stoichiometry
is simply controlled by changing the dose of the relevant RNA (Papapetrou et al. 2009).
Directed differentiation of fibroblasts to terminally differentiated myogenic cells has been
reported using RNA encoding myogenic factors (Warren et al. 2010).
Altogether, it seems that RNA-based technology could become an ideal implement to
temporally and quantitatively control the expression of any given combination of factors
for generating diverse cell types, either by direct or indirect lineage conversion. This
technology is an outstanding tool to alter the cellular fate for future therapeutic
applications.
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1.6bmRNA technology-cell-based therapies and therapeutic
application
RNA technology permits safe reprogramming of somatic cells without integration of viral
sequences. This feature makes it a prominent option for cell-based therapies in
translational research (Mandal & Rossi 2013). Recent reports have demonstrated that
mRNA can be used to express therapeutically active proteins in vivo (Kormann et al.
2011). Using a mouse model of congenital lung disease caused by a lack of the
surfactant protein B, Kormann and colleagues have been able to rescue such mice by
pulmonary delivery of mRNA encoding surfactant protein B (Kormann et al. 2011).
Furthermore, two groups have demonstrated that mRNA can be used to produce
systemic, biologically active erythropoietin in vivo (Kormann et al. 2011; Karikó et al.
2012).
Recently, it has been reported that intramyocardial injection of mRNA encoding human
vascular endothelial growth factor-A (VEGF-A) resulted in the expansion and directed
differentiation of endogenous heart progenitors in a mouse myocardial infarction model
(Zangi et al. 2013). VEGF-A-mRNA obviously improved heart function and enhanced
survival of recipients. In fact, VEGF-A-mRNA increased epicardial progenitors and
organized their migration into the myocardium and redirected their differentiation toward
cardiovascular cell types (Zangi et al. 2013).
Taken together, mRNA technology might provide an effective means to control the
spatial and temporal delivery of gene products to enhance tissue repair or regeneration
after injury. It might also offer a novel therapeutic paradigm for application in regen-
erative medicine and beyond.
1.7 mRNA-based reprogramming-limitations and hurdles
Several groups have attempted to use mRNA for reprogramming with various degrees
of success (Plews et al. 2010; Yakubov et al. 2010; Tavernier et al. 2012; Warren et al.
2012; Heng et al. 2013; Mandal & Rossi 2013). The method, however, is not considered
well established, and despite some achievements (Warren et al. 2012; Mandal & Rossi
2013), the lack of follow-up publications implies that several technical hurdles must be
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overcome before this method well become reproducible and routinely applicable for
successful cellular reprogramming (Wang & Na 2011).
The major obstacles that must be overcome include deficiency for scalable production
of in vitro transcribed RNA, short-term existence of mRNA and mRNA-mediated
proteins within the cells, severe mRNA cytotoxicity, and last but not least immune
response activation following mRNA transfection (Karikó et al. 2005; Hornung et al.
2006).
One of the major technical obstacles for mRNA-based reprogramming has been non-
efficient in vitro transcription (IVT) to produce large amounts of RNA at a reasonable
cost. Using of chemical synthesis to generate efficient in vitro transcribed RNA (IVT-
RNA) was shown to be inappropriate. This problem will become even greater when it is
necessary to do in vitro transcription for difficult templates with a high G/C content such
as c-Myc template or a long sequence like hTERT template. In such cases, yield
reduces exponentially as transcripts grow because coupling efficiencies at each step
are between 90–99%. Thus it was not feasible to synthesize chemically very long RNA
molecules (Lu & Li 2012; Nelissen et al. 2012). The long RNA molecules have recently
been shown as essential reprogramming implements for the generation of iPS cells
(Angel & Yanik 2010).
Due to the short half-life of RNA molecules, it is essential to have highly stable RNA to
minimize the transfection frequency needed to maintain the required level of
reprogramming proteins for iPS cells generation. Previous studies have shown
everyday mRNA transfection to generate iPS cells (Warren et al. 2010; Mandal & Rossi
2013) which renders the method highly stressful for the cells.
The main obstacle of mRNA-mediated reprogramming was found to be the activation of
innate immune response by Toll-like receptors and RNA sensors following mRNA
transfection (Angel & Yanik 2010; Drews et al. 2012) (Fig. 5). Consequently, repeated
transfection of mRNAs along with the cytotoxicity of chemical agents such as
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lipofectamine resulted in severe cytotoxicity and cellular apoptosis (Angel & Yanik 2010;
Drews et al. 2012) (Fig. 5).
Figure 5. mRNA-reprogramming hurdles. The main obstacles of mRNA-based
reprogramming were discussed to be the activation of an innate immune response and severe
cytotoxicity following mRNA transfection.
Exogenous RNA is a pathogen-associated molecular pattern (PAMP) for toll-like
receptor 3, 7/8 (Tlr3, 7/8) which are pattern recognition receptors (PRRs). When RNA is
detected by these receptors, a cascade of signalling pathways will be initiated that result
in upregulation of Interferon β1 (IFNβ1), a cytokine that is secreted into the culture
media. Then this cytokine will be bounded to the membrane associated receptors, and
therefore initiates signalling cascades which make full innate-immune-response,
characterized by growth inhibition, translation inhibition and upregulation of PRRs. All of
these effects make the cells hypersensitive to subsequent exposure to exogenous RNA
(Alexopoulou et al. 2001; Diebold et al. 2004) . Furthermore, they will secrete type I
interferons which amplifies the immune response and acts in an autocrine and paracrine
fashion (Drews et al. 2012). They transduce their signal into neighbouring cells
activating the same innate immune mechanisms in those cells and sensitizing them
toward foreign nucleic acids. If the cells are unable to clear the infection, the innate
immune response can lead to apoptosis.
Previous studies incorporated modified nucleosides into mRNA (substitution of cytidine
and uridine with pseudouridine and 5-methylcytidine) to abrogate the innate immune
response, however residual upregulation of some interferon targets on the gene
expression level was still detected (Warren et al. 2010; Warren et al. 2012; Mandal &
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Rossi 2013). As a result, they used B18R protein as an interferon inhibitor to suppress
immune response.
In this thesis, we have attempted to overcome the obstacles described for mRNA-
mediated reprogramming to make it widely applicable for cellular reprogramming.
1.8 Aging signatures of human iPS cells
1.8.1 Aging process
Human aging is an ongoing process results in gradual defects of the genome,
epigenome, molecular and organelle hemostasis in different cells and tissues (Liu et al.
2012). Aging cells undergo distinct changes in the epigenome, telomere shortening,
dysfunctional mitochondria, increased oxidative stress, DNA damage and numerous
other alterations (Fig. 7) (Kirkwood 2005; Haigis & Yankner 2010; Johnson et al. 2012).
1.8.1.1 Telomere length
Somatic cells have a limited division capacity and senescence in vitro. The inability to
further replicate is termed replicative senescence and can be induced by many factors,
such as short or uncapped telomeres, oxidative stress, and mitochondrial DNA damage
(Chen et al. 2007). The enzyme telomerase, which maintains telomere length, is
inactive in most somatic cells. Therefore, telomere length gradually decreases with
every cell division in a typical somatic cell, eventually resulting in replicative senescence
(Fig. 6) (Harley et al. 1990).
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Figure 6. Replicative senescence. The enzyme telomerase is inactive in most somatic cells,
and therefore, telomere length gradually decreases with every cell division in a typical somatic
cell, eventually resulting in replicative senescence and aging features.
1.8.1.2 Mitochondrial alterations and oxidative stress
Aging in somatic cells is accompanied by mitochondrial dysfunction and oxidative stress
(Passos et al. 2007; Moiseeva et al. 2009). Compared to stem cells, the aged somatic
cells have more mitochondrial mass, increased Adenosine Triphosphate (ATP) levels,
increased reactive oxygen species (ROS), and less active repair mechanisms that can
correct mitochondrial DNA (mtDNA) damage (Cho et al. 2006; Saretzki et al. 2008).
mtDNA then undergoes a high rate of mutations, due to elevated ROS levels and the
lack of efficient repairing mechanisms, and such mutations can accumulate over time
(Cortopassi et al. 1992; Wallace 1994), causing multiple cellular dysfunction such as
defective protein degradation or cellular secretion (Alemi et al. 2007; Prigione &
Cortopassi 2007).
It has been shown that mitochondria have a critical role in replicative senescence.
Increased production of ROS has been reported in cells with short telomeres (Passos et
al. 2007; Passos & Von Zglinicki 2006). Mitochondria-mediated ROS could contribute to
the senescent phenotype by damaging the genomic DNA (Passos and & Zglinicki 2006)
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and therefore can increase the DNA damage signals originally caused by short
telomeres.
Mitochondrial morphology in aged somatic cells has also been reported to be elongated,
has developed cristae, and relies more on aerobic metabolic for energy (Prigione et al.
2010; Suhr et al. 2010).
1.8.1.3 DNA damage response
One of the hallmarks of aging is the loss of regenerative capacity of tissue-specific cells,
following DNA damage and ultimately the impairment of tissue and organ functions.
ROS, the natural by-products of oxidative energy metabolism, are often considered to
be the major endogenous source of DNA damage related to aging (Balaban et al.
2005). DNA damage generated by ROS may induce cell death and lead to tissue
degeneration. Thus, a cell with an induced antioxidant defense might undergo less DNA
damage, resulting in enhanced genomic stability and ultimately greater longevity. Unlike
stem cells, the aged somatic cells display high levels of mitochondrial mass and obtain
energy preferentially through oxidative phosphorylation (St John et al. 2006). Thus, the
use of mitochondrial respiration in aged somatic cells causes generation of large
amounts of DNA damage mainly induced by ROS. The DNA damage as well as
reduced DNA repair mechanisms in the somatic cells may initiate genetic instability,
tumorigenesis, premature senescence, and eventually apoptosis of DNA-damaged cells
(Mandal et al. 2011; Rocha et al. 2013). Consistent with the DNA damage-based theory
of aging, some knockout mice for genes related to DNA repair present symptoms
related to neurological diseases and premature aging (Niedernhofer 2008; Schumacher
et al. 2008). Furthermore, defects in DNA repair mechanisms cause accelerated aging
symptoms and inherited diseases such as Cockayne syndrome, patients with Werner
syndrome, Hutchinson–Gilford progeria syndrome, ataxia telangiectasia,
trichothiodystrophy, and Rothmund-Thomson (Freitas & de Magalhães 2011; Diderich
et al. 2011; Musich & Zou 2011).
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1.8.2 iPS cells and their derivatives as in vitro aging models
The discovery that somatic cells can be induced into iPS cells by expression of
reprogramming factors has enormous potential for therapeutics and human disease
modelling. With regard to aging and age-related disease, the generation of iPS cells and
their derivatives from patients with accelerated aging like those with Hutchinson-Gilford
progeria syndrome may partially recapitulate the aging process in vitro and thus be an
alternative model to study human aging in a dish (Fig. 7). A panel of iPS cell models for
various aging-related disorders including Hutchinson-Gilford progeria syndrome (HGPS)
(Liu et al. 2011), Werner syndrome (Ho et al. 2011), Dyskeratosis congenital (DC)
(Agarwal et al. 2010; Batista et al. 2011), Parkinson’s disease (PD) (Park et al. 2008;
Soldner et al. 2009), Cockayne syndrome group B protein (Andrade et al. 2012) have
emerged. Such iPS cells can be robustly cultured in a dish to re-establish patient-
specific tissues or to study mechanisms involved in aging, drug discovery and testing
(Liu et al. 2012).
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Figure 7. iPS cells and derivatives as aging in vitro models. The use of iPS cells and their
derivatives from patients with accelerated aging may recapitulate the aging process in vitro and
thus can be used as an alternative model to study human aging in a dish. In this figure, the
patient has Hutchinson-Gilford progeria syndrome. The figure modified from Liu et al. 2012.
1.8.3 Reprogramming and resetting of the aging clock
It was previously proposed that the ability to reprogram a cell to a more youthful state
may be an effective strategy to rejuvenate an aged organism (Rando & Chang 2012).
For such purpose, reprogramming would have to reset the aging clock, clearing the
damage that accumulates with age and restoring a cell to a youthful state (Rohani et al.
2014). This would require multiple types of restoration, since somatic cells accumulate
nuclear and mitochondrial DNA mutations as well as damaged macromolecules with
age. Such restoration is not impossible, as indicated by the fertilization process, where
an aged sperm and egg fuse to form a zygote devoid of aging damage or any evidence
of the age of the parental cells (Rando & Chang 2012). However, reprogramming
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process facilitates resetting of the cellular clock and removal of most, but not all, of the
aging-associated hallmarks (Liu et al. 2012; Rohani et al. 2014).
1.8.3.1 iPS cells and epigenetic memory
Epigenetic modifications such as histone acetylation and DNA methylation play a
significant role in regulating gene expression and exhibit unique changes during aging
and age-related disease (Fraga et al. 2007; Johnson et al. 2012). Epigenetic
modifications can impact longevity (Lin et al. 2005) and health (Klein et al. 2011) as well
as avoid differentiation of stem cells into somatic tissues (Bröske et al. 2009). It has
been reported that iPS cells may contain a higher number of genetic and epigenetic
abnormalities than both ES cells and somatic cells that they originate from (Pera 2011).
In addition, there are mixed data regarding the epigenetic memory of the iPS cells.
Controversial reports exist regarding whether or not this memory affects the
differentiation potential of reprogrammed cells (Fig. 8).
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Figure 8. Epigenetic memory and reprogramming. There are controversial data regarding
the epigenetic memory of iPS cells and whether or not this memory affects the differentiation
potential of those cells. It has been reported that iPS cells might feature incomplete epigenetic
reprogramming, retaining residual methylation hallmarks of their tissue of origin. This could
favour them to differentiate into lineages related to the donor cell (Rohani et al. 2014).
It was recently shown that iPS cells can feature incomplete epigenetic reprogramming
compared to ES cells, retaining residual DNA methylation signatures that are
characteristic of their tissue of origin and favour differentiation into lineages related to
the donor cell (Fig. 8). Kim and colleagues demonstrated that the iPS cells derived from
mouse neural progenitors decreased propensity for differentiation into haematopoietic
cell types. Indeed, such iPS cells contain methylomic signatures at loci important for
haematopoietic differentiation which resulted in a decreased tendency for their
differentiation into haematopoietic cells (Kim et al. 2010). Furthermore, conflicting data
exists regarding the retention of these epigenetic methylation signatures with passage
number. Some iPS cells derived from human neonatal keratinocytes and umbilical cord
blood cells were shown to maintain tissue specific methylation memory even at high
passage numbers (Kim et al. 2011), while iPS cells derived from mouse myogenic cells,
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fibroblasts, and hematopoietic cells were shown to lose their epigenetic memory
following continued passage in culture (Polo et al. 2010). More recently, human iPS
cells from dermal fibroblasts and bone marrow stromal cells of the same donor were
generated and differentiated into osteogenic and chondrogenic lineages. The authors
found that the iPS cells exhibited an epigenetic memory characteristic of the donor
tissue used. However, no correlation was found between the cell type of origin and the
tendency of an iPS cell clone to differentiate into bone and cartilage (Nasu et al. 2013).
Further analysis is required to determine whether or not this epigenetic memory affects
the pluripotency of iPS cells and whether this influence declines with passage number
or varies with the donor tissue or iPS cell line used.
1.8.3.2 Aging signatures in iPS cells and their derivatives
For several years a hypothesis existed that aging is a one-way street toward decline,
development of iPS cells could provide a unique platform to reverse some aspects of
aging in somatic cells of old individual. Aging in somatic cells is accompanied by
numerous alterations such as telomere shortening, dysfunctional mitochondria,
increased oxidative stress and DNA damage.
Reprogramming can reverse many aspects of aging (Rohani et al. 2014). Upon
reprogramming, metabolic signatures, mitochondrial networks, handling of oxidative
stress, telomerase expression, telomere length and other factors are all reset to a state
characteristic of pluripotency (Suhr et al. 2009; Prigione et al. 2010; Prigione et al.
2011). However, these data are controversial as different reports have been published
regarding whether reprogramming rejuvenates aged somatic cells or iPS cells exhibit
aging signatures (summarized in supplementary Table 1) (Fig. 9). For instance,
telomere length has been indicated to be shortened (Vaziri et al. 2010), similarly sized,
or even elongated compared to ES cells (Lapasset et al. 2011).
Mitochondrial networks have been reported to be rearranged to a state identical to ES
cells (Prigione et al. 2010; Prigione et al. 2011) or to a mixed phenotype in between ES
cells and somatic cells (Varum et al. 2011). DNA damage, stress defense mechanisms,
and repair processes have been shown to be remarkably similar in iPS cells and ES
cells (Armstrong et al. 2010; Fan et al. 2011). It has been also demonstrated that higher
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expression of DNA repair-related genes was found in iPS cells compared to their
differentiated counterparts (Momcilovic et al. 2010). However, some recent studies
displayed microsatellite instability and reduced DNA repair capacities in analyzed iPS
cell lines (Gore et al. 2011; Luo et al. 2012).
Similar controversies are observed regarding premature senescence of iPS-derived
cells. In fact, mixed findings have been published regarding whether somatic cells
generated from iPS cells are subject to premature senescence (Fig. 9). Feng et al.,
noticed premature senescence in the cells derived from iPS cells (Feng et al. 2010),
while Gokoh et al., observed no early senescence in the iPS-derived cells (Gokoh et al.
2011).
Defects such as those mentioned above would hinder the clinical application of iPS
cells, and therefore more comprehensive testing of iPS cells and their potential aging
signature should be conducted.
Figure 9. Aspects of aging and reprogramming. There is currently conflicting data regarding
the ability of reprogramming to fully rejuvenate an aged somatic cell and reverse age-related
changes such as DNA damage, shortened telomeres, and dysfunctional mitochondria.
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Moreover, contentious data exists suggesting that cells derived from iPS cells may be subject to
premature senescence (Rohani et al. 2014).
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2. Aims of this study
The ability to reprogram adult human cells into induced pluripotent stem (iPS) cells
could provide a promising implement for therapeutics, autologous therapies, repairing
deficits arising from injury, illness, and aging. However, the original iPS cells were
generated by retroviral vectors, and therefore they carried the risk of viral integration
into the host genome. This problem prevents their use for clinical applications and
regenerative medicine. Recently, an effective non-integrating reprogramming was
achieved using mRNA. mRNA-based reprogramming offers the advantage of being
completely free of genomic integration and is therefore highly suitable for clinical
translation. However, mRNA-reprogramming is not yet used routinely, and some of
difficulties must be overcome so that mRNA could be used regularly for successful
cellular reprogramming. The difficulties such as 1) deficiency for scalable production of
in vitro transcribed RNA, 2) immune response activation following mRNA transfection,
3) severe mRNA cytotoxicity, and 4) short-term existence of mRNA and mRNA-
mediated proteins within the cells, must be eliminated so that mRNA could be used
universally for cellular reprogramming. In the current thesis, the goal is to generate
stable mRNA-iPS cells by overcoming those limitations to enable mRNA widely used for
cellular reprogramming.
The first aims of the current thesis are:
- Generation of stable mRNA-iPS cells through robust scalable production of in
vitro transcribed RNA, reduce immunogenicity-cytotoxicity of mRNA, and
increase stability of mRNA within the cells
- Pluripotency characterization of the generated mRNA-iPS cells
- Evaluation of the mRNA-iPS cells with viral-iPS cells (foreskin and Huntington-
derived-iPS) produced by conventional retroviral approach
The potential aging signatures of the iPS cells should be assessed before their use in
clinical applications. Therefore, in the second part of the current thesis, the attempt is to
figure out whether reprogramming would be able to rejuvenate the aging hallmarks of
adult somatic cells. Currently, there are controversial data regarding the ability of
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reprogramming to fully rejuvenate an aged somatic cell and reverse age-related
changes such as DNA damage, shortened telomeres, and dysfunctional mitochondria.
Furthermore, the mixed findings have been published regarding whether the iPS cells
maintain some of the aging markers from their parental somatic cells. The current thesis
will study those controversies by the investigation of three hallmarks of aging including
telomere length, mitochondrial alteration and DNA damage.
The second aim of the current thesis is:
- Study of aging signatures in iPS cells and their parental fibroblasts through
analysis of
o Telomere length
o Mitochondrial alteration
o DNA damage response
In summary, the aims of the current study are first, generation of stable, footprint-free
mRNA-iPS cells which can be used for future clinical application, and second, aging
analysis of the iPS cells to figure out their potential aging signatures before their use for
further translation and laboratory research.
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3. Materials
3.1 Equipments
 Agilent 2100 Bioanalyzer (Agilent Technologies)
 BD FACS Calibur™ (BD Biosciences)
 DNA engine Opticon 2 (Biorad)
 Electrophoresis Supplies (Peqlab)
 Fluorescence microscope Axio Observer (Zeiss)
 LightCycler® 480 (Roche)
 Microplate reader Tecan (Infinite® 200 PRO series)
 ND1000 Spectrophotometer (NanoDrop Technologies)
 Nucleofector® Device (Lonza)
 Stereomicroscope (Leica Microsystem)
 Thermocycler (T Professional, Biometra)
 UV documentation (Kodak imaging system)
3.2 Software
 2100 Bioanalyzer Expert software (Agilent Technologies)
 BD CellQuest Pro (BD Biosciences)
 CometScoreTM15 (TriTek)
 EndNote web (Thomson Reuters)
 GeneASI BandView (Applied Spectral Imaging)
 Leica Software v. 1.4.0 (Leica)
 MS-Office 2007 SP2 (Microsoft)
 Self-Organizing Map (SOM)
 SigmaPlot 11.0 statistical software (Systat Software Inc)
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3.3 Enzymes, Kits and Transfection Reagents
 Agilent RNA 6000 Nano kit (Agilent Technologies)
 DNase I (Life Technologies)
 FuGENE® Transfection Reagent (Roche)
 GeneChip® Fluidics Station 400 (FS 400) (Affymetrix)
 GeneChip® Human Gene 1.0 ST Array (Affymetrix)
 GeneChip® Scanner 3000 7G (Affymetrix)
 GeneJet PCR purification kit (Thermo Fisher)
 GeneJet RNA purification Kit (Thermo scientific)
 jetPEI® transfection reagent (Polyplus)
 Lipofectamine 2000 transfection reagent (Life Technologies)
 LongAmp® Taq DNA polymerase (New England Biolabs)
 Mini ELISA Development Kit (Peprotech)
 Nucleofector® kit (Lonza)
 Platinum Taq DNA polymerase (Life Technologies)
 Restriction enzymes for linearization (Thermo Fisher or New England Biolabs)
 RiboMinus Kit (Life technologies)
 SingleQuot Kit CC-4127 REGM (Lonza)
 StemPro® Accutase® Cell Dissociation Reagent (Life Technologies)
 SuperscriptIII-transcriptase (Life Technologies)
 T7mScript™ Standard mRNA Production System (CELLSCRIPT™)
 Trypsin/EDTA (Life Technologies)
 WT cDNA Synthesis and Amplification Kit (Affymetrix)
 WT Terminal Labeling Kit (Affymetrix)
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3.4 Solutions and reagents
 150mM sodium chloride solution (Polyplus)
 1x PBS- (Life Technologies)
 2x RNA loading dye (Thermo Fisher)
 4% paraformaldehyde (Thermo Scientific)
 4,6-diamidino-2-phenylindole dilactate (DAPI) (Sigma)
 Acetic acid (VWR)
 BSA powder (Sigma)
 Chloroform (VWR)
 Colcemid (Life Technologies)
 DEPC (Invitrogen)
 Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich)
 Dimethylsulfoxide (VWR International)
 EDTANa2 (Carl Roth)
 Eosin (Merck)
 Gelatin from porcine skin, type A (Sigma-Aldrich)
 Giemsa (Dr. K. Hollborn & Söhne GmbH & Co. in Leipzig)
 H2DCFDA (Molecular Probes®) (Life Technologies)
 Hematoxylin (Merck)
 HEPES (Life Technologies)
 Hexadimethrine bromide (Polybrene) (Sigma-Aldrich)
 Hydrogen peroxide solution (Sigma-Aldrich)
 JC-1 Mitochondrial Membrane Potential Dye (eBioscience)
 KCl (B. Braun Medical Inc.)
 Matrigel (BD Biosciences)
 Methanol (VWR)
 MitoTracker® Deep Red FM (Molecular Probes®) (Life Technologies)
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 MTT solution (Applichem)
 Opti-MEM® I Reduced Serum Medium (Life Technologies)
 Paraffin (Carl Roth)
 Penicillin/streptomycin (Life Technologies)
 Propan-2-ol (VWR)
 Propidium iodide (Sigma-Aldrich)
 SDS solution (Merck Millipore)
 Sodium hydroxide (Sigma)
 Trifast reagent (Peqlab)
 Tris-base (Carl Roth or Sigma-Aldrich)
 Triton X-100 (VWR)
 Tween-20 (VWR)
 UltraPure™ Low Melting Point Agarose (Life Technologies)
 Xylen (Carl Roth)
3.5 Buffers
Table 2. Contents of the used buffers.
Buffer Contents Concentration
10x buffer according to restriction
enzymes
Thermo Fisher -
6x loading dye Tris-HCL
Bromphenolblue (Sigma-Aldrich)
Xylene Cyanol (Sigma-Aldrich)
Orange G (Sigma-Aldrich)
Glycerol
EDTA
10mM
0.03%
0.03%
0.15%
60%
60mM
50x TAE-buffer Tris-Base or Trizma base
EDTA (0.5 M, pH 8)
2M
10%
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Glacial acetic acid (100%)
H2O
5.72%
Lysis buffer for comet assay NaCl
EDTANa2
Tris-base
Triton-X
2.5M
0.1M
10mM
1%
pH 10
Electrophoresis buffer for comet
assay
NaOH
EDTANa2
0.03M
2mM
pH 12.5
Soerensen buffer for karyotyping Na2HPO4 × H2O
KH2PO4
136.09 g/mol
177.99 g/mol
pH 6.2
3.6 Plasmids
The plasmids pMXshOct4 (Addgene ID: plasmid 17964) (Lowry et al. 2008), pMXs-
hSox2 (Addgene ID: plasmid 17965) (Lowry et al. 2008), pMXs-hKlf4 (Addgene ID:
plasmid 17219) (Takahashi et al. 2007), pBabe-c-Myc-zeo (Addgene ID: plasmid
17758) (Dai et al. 2007), pMXs-hNanog (Addgene ID: plasmid 18115) (Lowry et al.
2008) and pBabe-hygro-hTERT (Addgene ID: plasmid 1773) (Counter et al. 1998) were
purchased from Addgene.org, a US nonprofit organization.
New plasmids were constructed by direct cloning of the insert into pcDNA3 (Invitrogen).
pcDNA3 served as plasmid backbone, and contains a CMV promoter as well as a
subsequent T7-promoter before the open reading frame (ORF). The ptagGFP-C
(Evrogen) plasmid only has a CMV promoter before the ORF and T7 promoter is added
as overhang in the sense primer.
Cloning was done by Dr. Claire Fabian.
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3.7 PCR reagents and primers
3.7.1 PCR reagents
 1x LongAmp® Taq Reaction Buffer (New England Biolabs)
 1x PCR buffer without MgCl2 (Life technologies)
 1x SybrGreen (Life technologies)
 Agarose powder (Applichem)
 Deoxynucleotide triphosphates (dNTPs) (Thermo Fisher)
 Ethidium bromide (Applichem)
 Express SYBR Green ER qPCR Supermix Universal (Life technologies)
 MgCl2 (Life technologies)
 Oligo(dT)18-Primer (Thermo Scientific)
3.7.2 PCR primers
Primers to create PCR templates for in vitro transcription contained primers for T7-
tagGFP and primers for T7-iPS factors (see tables 3, 4 and 5).
Table 3. Primer sequences for adding T7-promoter to ORF pTag-C Fluorescence
plasmids. The template is ptagGFP-C (Evrogen).These primers are used to create PCR
templates for IVT.
Primer Sense (5´-to-3´) Anti-sense (5´-to-3´)
P-27/T7-
pTagFluos
GCCGGGAATTTAATACGACTCACTATAGGGGCT
AGCGCTACCGGTCGCCACCATG
pTagFluos TGCTTTATTTGTGAAATTTGTGATGCTAT
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Table 4. The sequences of two sense primers for the iPS factor plasmids. The templates
are pcDNA3-hOct4, pcDNA3-hSox2, pcDNA3-hKlf4, pcDNA3-hc-myc, pcDNA3-hNanog and
pcDNA3-hTERT. These primers are used to create PCR templates for IVT.
Primer Sense (5´-to-3´)
P27/T7-ncHIII GCCGGGAATTTAATACGACTCACTATAGGGAGACCCAAGC
(40 nt)
Pc3/T7 GGCTTATCGAAATTAATACGACTCACTATAGGG (33 nt)
Table 5. The sequences of the anti-sense primers for the iPS factor plasmids. The
templates are pcDNA3-hOct4, pcDNA3-hSox2, pcDNA3-hKlf4, pcDNA3-hc-myc, pcDNA3-
hNanog and pcDNA3-hTERT. These primers are used to create PCR templates for IVT.
Primer Anti-sense (5´-to-3´)
hOct4-Esp3I/SpeI CGTCTCACTAGTTCAGTTTGAATGCATGGGAGAGC
hSox2-Esp3I/SpeI CGTCTCACTAGTTCACATGTGTGAGAGGGGCAGT
hKlf4-Esp3I/SpeI CGTCTCACTAGTTTAAAAATGCCTCTTCATGTGTAAGGC
hc-myc-Esp3I/SpeI CGTCTCACTAGTTTACGCACAAGAGTTCCGTAGCTGT
hNanog-Esp3I/SpeI CGTCTCACTAGTCTTCACACGTCTTCAGGTTGCATG
hTert-Esp3I/SalI CGTCTCGTCGACTCAGTCCAGGATGGTCTTGAAGTCTG
Table 6. The primer sequences of pluripotency genes for qRT-PCR.
Primer Sense (5´-to-3´) Anti-sense (5´-to-3´)
hOct4 GAGGAGTCCCAGGACATCAA CATCGGCCTGTGTATATCCC
hSOX2 CAACGGCAGCTACAGCATGATGC CCGTTCATGTAGGTCTGCGAGCTG
hKlf4 GCGCTGCTCCCATCTTTCT TGCTTGACGCAGTGTCTTCTC
hc-Myc TCAAGAGGCGAACACACAAC GGCCTTTTCATTGTTTTCCA
hNanog TTCCTTCCTCCATGGATCTG AAGTGGGTTGTTTGCCTTTG
hsa36B4 CTCGCTTCCTGGAGGGTGTCCGC CTCCACAGACAAGGCCAGGACTCG
Table 7. The primer sequences for quantification of relative telomere length using qRT-
PCR.
Primer 5´-to-3´
mTelo 1 CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT
mTelo 2 GGCTTGCCTTACCCTTACCCT TACCCTTACCCTTACCCT
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3.8 Antibodies
Table 8. Antibodies used for flow cytometry and immunostaining to detect
reprogramming proteins following mRNA transfection.
Antibody Dilution Company Reactivity Host/isotype
Oct-4A (C30A3)
Rabbit mAb
1:600 Cell Signaling
Technology (CST)
Human, mouse Rabbit IgG
Sox2 (D6D9) XP®
Rabbit mAb
1:300 Cell Signaling
Technology (CST)
Human Rabbit IgG
c-Myc (D84C12)
XP® Rabbit mAb
1:200 Cell Signaling
Technology (CST)
Human, mouse,
rat
Rabbit IgG
Nanog (D73G4)
XP® Rabbit mAb
1:400 Cell Signaling
Technology (CST)
Human Rabbit IgG
Telomerase
reverse
transcriptase
Antibody (2D8)
1:50 Thermo Fisher
Scientific
Human Mouse IgM
Klf4 1 µg Thermo Fisher
Scientific
Human, mouse,
rat
Rabbit
Alexa fluor 488 1:2000 Life Technologies Rabbit Goat IgG
Alexa fluor 546 1:2000 Life Technologies Mouse Goat IgG
Table 9. Antibodies used for immunostaining to assess pluripotency markers in iPS
colonies.
Antibody Dilution Company Reactivity Host/isotype
Anti-Oct4
antibody- ChIP
Grade
1:250 Abcam Human, Mouse,
Sheep, Rhesus
monkey
Rabbit IgG
Nanog Antibody
(Affinity Purified)
1:100 Stemgent Human, Mouse Rabbit IgG
TRA-1-60 Antibody 1:100 Stemgent Human Mouse IgM
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(Purified)
Alexa fluor 488 1:1000 Life Technologies Rabbit Goat IgG
Alexa fluor 546 1:1000 Life Technologies Mouse Goat IgG
3.9 Cells
3.9.1 Primary cells
The primary human cells were derived from different tissues including foreskin, skin,
eye lid and urine.
The foreskin fibroblasts were derived from different donors, however; it was not allowed
to label them with the name of patients. Thus, the foreskin-derived fibroblasts were
labelled with different colours in order to make the samples simpler to follow. The
foreskin-derived fibroblasts which were used for generation of viral-iPS cells were not
labelled with colour (ffle13).
The dermal fibroblasts from two Huntington patients were labelled as WC1 and SP
fibroblasts.
The information of primary human cells derived from different tissues has been
summarized in table 10.
Table 10. Primary human cells derived from different tissues.
Sample Donor cell type Donor age Gender Health status
*Amber Foreskin fibro. <18 years Male Healthy
*Brown Foreskin fibro. <18 years Male Healthy
*Pink Foreskin fibro. <18 years Male Healthy
*Red Foreskin fibro. <18 years Male Healthy
*Green Foreskin fibro. <18 years Male Healthy
*Purple Foreskin fibro. <18 years Male Healthy
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*Yellow Foreskin fibro. <18 years Male Healthy
*Ffle13 Foreskin fibro. <18 years Male Healthy
**Eyelid Eyelid fibro. >18 years Female Healthy
§Old dermal fibroblasts Dermal fibro. >18 years Female Healthy
#Huntington dermal fibroblasts Dermal fibro. 56-year-old Male Diseased
#Huntington dermal fibroblasts Dermal fibro. 41-year-old Female Diseased
§§Renal epithelial cells Epithelial cells Anonymous Male/female Healthy
Fibro. = fibroblast
*Foreskin biopsies were obtained from children’s hospital of the University of Leipzig, Leipzig,
Germany. The foreskin-derived fibroblasts were used for the experiments related to mRNA-iPS
cells. The foreskin-derived fibroblasts derived from one donor (ffle13) were used for generation
of viral-iPS cells.
**Eyelid biopsies were obtained from Klinik am Rosenthal GmbH, Leipzig, Germany. The eye lid
fibroblasts were derived from the biopsies of one patient. The eyelid-derived fibroblasts were
used for the experiments related to mRNA-iPS cells.
§Old dermal fibroblasts = dermal fibroblasts derived from an old patient. This sample was
obtained from PromoCell. The old dermal fibroblasts were used for the experiments related to
mRNA-iPS cells.
#Huntington dermal fibroblasts (HDFs) = dermal fibroblasts derived from Huntington patient.
These samples were kindly donated by the Albert Ludwig University of Freiburg. The HDFs
were used for viral transduction to generate viral-iPS cells.
§§Renal epithelial cells (RECs) were obtained from urine samples. The collection of urine
samples and isolation of epithelial cells were performed by Evercyte GmbH in Vienna. The
RECs were used for the experiments related to mRNA-iPS cells.
3.9.2 Cell lines
Table 11. The information of human cell lines used in this thesis.
Sample Donor cell
type
Donor age Gender Reference
*IMR90 Fetal 16 weeks Female **ATCC®CCL-186™
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fibroblast gestation
§Phoenix-GP Epithelial
cells
embryo - Nolan lab/Stanford University
http://web.stanford.edu/group/nolan/
*The tissue of origin is lung. The IMR90-fibroblasts were used for the experiments related to
mRNA-iPS cells.
**ATCC = American Type Culture Collection
§The tissue of origin is kidney. The Phoenix-GP cells were used as a packaging cell line for
retroviral transduction
3.10 Cell culture medium
3.10.1 Fibroblast medium
The fibroblast medium was used for derivation and culture of human foreskin fibroblasts
(HFFs), human eye lid fibroblasts, Huntington dermal fibroblasts (HDFs), human IMR90
fibroblasts and mouse embryonic fibroblasts (MEFs).
Table 12. Fibroblast cell culture medium.
Concentration Company
DMEM high glucose Life Technologies
Fetal bovine serum (FBS) 10% HyClone™
3.10.2 Renal epithelial cell culture medium
The renal epithelial cell culture medium was used for isolation and culture of renal
epithelial cells derived from urine samples.
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Table 13. Renal epithelial cell culture medium.
Concentration Company
DMEM/Ham´s F12 (1:1) HyClone™
Fetal bovine serum (FBS) 10% PAA
SingleQuot Kit CC-4127
REGM
According to the manual Lonza
Amphotericin B Sigma-Aldrich
penicillin/streptomycin 1% Life Technologies
Renal Epithelial Basal
Medium (REBM)
Lonza
3.10.3 iPS culture medium
The iPS culture medium was used for the culture and expansion of both mRNA-iPS and
viral-iPS cells.
Table 14. iPS cell culture medium.
Concentration Company
KnockoutTM DMEM Life Technologies
KnockoutTM serum
replacement
20% Life Technologies
FGF-basic 10ng/ml Peprotech
Nonessential amino acids 1% Life Technologies
L-Glutamine 2mM Life Technologies
Penicillin-Sreptomycin 1% Life Technologies
2-mercaptoethanol 0.1mM Sigma
*ROCK inhibitor Y-27632 10µM Calbiochem
*ROCK inhibitor only used at the time of expansion and passage.
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4. Methods
4.1 Ethic statement
The study was approved by the Institutional Review Board of the Universities of Leipzig
and Freiburg, Germany. All patients provided written informed consent for the collection
of samples and subsequent analysis.
4.2 Generation of DNA templates for in vitro transcription
For the in vitro transcription of mRNA up to 2000 nucleotides (nt), linearized plasmid or
PCR products were used. For the IVT of mRNA longer than 2000nt only PCR products
were used as templates. All PCR products contained the T7-promoter and the coding
region of the gene. The same primers were used for cloning as well as creating PCR
templates for IVT. To create PCR templates of the iPS factors, two different sense
primers were used. Both primers worked comparable to create PCR templates for IVT.
One of the primers had a better binding on the plasmid template pcDNA3 and the other
one had a better binding for T7-RNA-polymerase during IVT. One sense primer was
used for all of the iPS factor plasmids (pcDNA3-iPS factors). The anti-sense primers for
the iPS factor plasmids were specific to the factors. The anti-sense primers contained
SpeI or SalI restriction site overhang. They were different in the overhang but not in the
ORF binding sequence; both variants were used to create PCR templates for IVT.
The data regarding to production of IVT templates using PCR was done with the help of
Dr. Claire Fabian in Fraunhofer Institute for Cell Therapy and Immunology (IZI) Leipzig.
For linearization of the plasmids each plasmid was cut with the appropriate restriction
enzyme (Thermo Fisher or New England Biolabs) after the coding region. Linearized
plasmids and PCR products were purified with GeneJet PCR purification kit (Thermo
Fisher).
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4.2.1 PCR protocol for IVT templates up to 2000 bp
The PCR reaction (25 µl) contained: 1 to 5ng plasmid (hNanog, hOct4, hKlf4, hSox2), 2
units Platinum Taq polymerase (Life Technologies), 1x PCR buffer without MgCl2,
2.8mM MgCl2, 0.5µM of each sense and antisense primer (Sigma-Aldrich) (primer
sequences are listed in “Materials” section 3.7.2) and  200µm of each dNTP (Thermo
Fisher). The PCR was performed using the TProfessional (Biometra) with the following
cycling conditions: 95°C for 3min, 35 cycles at 95°C for 30s, 60°C for 30s, 72°C for 60 s
per 1kb and a final elongation step 72°C for 3min.
4.2.2 PCR protocol for IVT templates over 2000 bp
The PCR reaction (50µl) contained: 10ng plasmid (hc-Myc & hTERT), 5 units LongAmp
Taq DNA polymerase (New England Biolabs), 1x LongAmp Taq Reaction Buffer, 300µm
of each dNTP (Thermo Fisher), 2µM of each sense and antisense primer (Sigma-
Aldrich) (primer sequences are listed in “Materials” section 3.7.2). PCR was performed
using the TProfessional (Biometra) with the cycling conditions: 95°C for 3min, 35 cycles
at 94°C for 10s, 60°C for s, 65°C for 50s per 1 kb and a final elongation step 65°C for 3
min.
4.3 mRNA in vitro transcription
Either 1µg linearized plasmid or 0.5µg PCR product (for c-Myc and hTERT only PCR
product) was used as template for the in vitro transcription reaction using the T7mScript
Standard mRNA Production System (CELLSCRIPT™). The schematic representation of
IVT procedure has been shown in figure 10 (Fig. 10). The reaction time for the T7-RNA-
polymerase transcription step was increased to 3h for all templates. For the long and
difficult to transcribe template hTERT different temperatures were used: 32°C, 37°C and
42°C.
The purification of the RNA between and after the IVT procedure was performed using
the GeneJet RNA purification kit (Thermo Fisher). The RNA concentration was
measured by UV spectrophotometry using the NanoDrop1000 photometer (Peqlab).
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Figure 10. Standard mRNA production system. The figure shows a schematic representation
of in vitro transcription procedure for production of 5′-capped & 3′-poly-A tailed-mRNA encoding
reprogramming factors.
4.4 Quality control of IVT-RNA
The quality of IVT-mRNA is crucial for generation of mRNA-iPS cells. Therefore, IVT-
RNAs were checked for their size and quality before transfection into the cells. This
quality control was done either by agarose gel electrophoresis or by Agilent
Bioanalyzer.
4.4.1 Agarose gel electrophoresis
Agarose gel electrophoresis was performed to assess the quality and size of IVT-RNA.
RNA samples can be separated by the size in gel electrophoresis. They are negatively
charged by their phosphate backbone, and thus they can migrate from negative to the
positive pole of an electric field. The quality and size of the IVT-mRNA was controlled by
electrophoresis in a 1% agarose gel stained with ethidium bromide. The 1% agarose gel
consisted of agarose powder mixed with 1xTAE buffer. After heating in microwave, 0.5
μg/ml ethidium bromide was added to the agarose solution and the gel stored in room
temperature (RT) to become cold. The RNA samples (5 μl) were loaded on the gel with
2x RNA loading dye (Thermo Fisher) directly or after a heat denaturation for 10min at
70°C followed by incubation on ice for 3min.
4.4.2 Agilent Bioanalyzer
The quality of IVT-RNA was controlled by capillary electrophoresis. The data regarding
to Agilent 2100 Bioanalyzer (Agilent Technology) was kindly provided by RNomics
group in Fraunhofer Institute for Cell Therapy and Immunology. For the capillary
electrophoresis the Agilent RNA 6000 Nano kit was used according to the manufactures
protocol.
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4.5 Derivation and culture of primary human fibroblasts
The primary human fibroblasts were derived from different tissues including foreskin,
skin and eye lid (see “Materials” section 3.9.1). For the derivation of primary human
fibroblasts, the tissues were washed with 1x PBS- contained 1% penicillin/streptomycin,
and then cut into small pieces with the scalpel. The pieces were then cultured in
fibroblast growth medium contained DMEM high glucose (Life Technologies)
supplemented with 10% FBS (Hyclone) (see “Materials”, section 3.10.1).
The outgrowths of fibroblast cells were visible between 4-7 days after culture of
biopsies. The fibroblasts were expanded using 0.05% trypsin/EDTA (Life Technologies)
for 3 passages before use.
4.6. Derivation and culture of urine-derived cells
The collection of urine samples and isolation of urine-derived cells were performed by
Evercyte GmbH in Vienna. Urine samples were collected and centrifuged at 400 g for
10 minutes at RT. The supernatant was carefully discarded and the pellets were
suspended in 10 ml PBS- containing Amphotericin B (Sigma-Aldrich) and
penicillin/streptomycin (Life Technologies) to prevent contamination. The samples were
centrifuged at 400 g for 10 minutes, and then the supernatant was discarded. Around 1
ml of primary medium was added to the cell pellet. The primary medium contained
DMEM/Ham´s F12 1:1 (Hyclone) supplemented with 10 % fetal bovine serum (FBS)
(PAA), SingleQuot Kit CC-4127 REGM (Lonza), Amphotericin B (Sigma-Aldrich) and
penicillin/streptomycin (Life Technologies). The cells were then transferred onto L-
gelatine (Sigma-Aldrich) pre-coated 12-well plates containing primary medium. The
medium was not changed the first 2 days after cell seeding, and only a few of primary
medium was added to retain the antibiotics concentration and keep the nutrition for the
cells. The next days, the medium was changed to Renal Epithelial Basal Medium
(REBM) (Lonza) containing SingleQuot Kit CC-4127 REGM (Lonza). The medium of the
cells was never aspirated completely to maintain factors secreted by the RECs and
avoid unnecessary stress. The first epithelial cells appeared around 3-6 days after
isolation. The first full media change was done after observation of the first cells in
culture. When the cells were confluent, they were passaged by 0.05% Trypsin/EDTA
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(Life Technologies) into the bigger culture flasks. They were passaged 2-3 times before
their use for transfection.
4.7 mRNA transfection using different transfection systems
Different transfection systems were checked to find the most efficient system with high
cell survival for repeated mRNA transfections. RNA transfections were carried out with
Nucleofector® kit and device (Lonza), FuGENE HD (Roche), jetPEI (Polyplus) and
Lipofectamine 2000 (Life Technologies).
4.7.1 mRNA transfection using Nucleofectin and FuGENE HD
Transfections with Nucleofectin and FuGENE HD were done by Antje Arnold in
Fraunhofer Institute for Cell Therapy and Immunology (IZI) Leipzig (Arnold et al. 2012).
Briefly, the human foreskin fibroblasts were transfected with 3 μg of mRNA by
nucleofection (NHDF-VPD-1001, Lonza). Four hours after transfection, the media was
changed to fibroblast media. The adherent cells were transfected with FuGENE HD at
72 h, 144 h, and 216 h after initial nucleofection according to the manufacturer’s
instructions. The ratio of FuGENE HD and mRNA was 8 μL per 3 μg of mRNA.
Transfection efficiency and condition was controlled using GFP-mRNA. The cells further
used for microscopic analysis.
4.7.2 mRNA transfection using Lipofectamine 2000 reagent
For mRNA-Lipofectamine 2000 transfection, green, pink and red foreskin fibroblasts
were used. The human foreskin fibroblasts were seeded on 6-well-plates (200,000
cells/well) at passage 3 one day prior to the experiment. The next day, 3μg of mRNA for
Oct4 (O), Sox2 (S), Klf4 (K), c-Myc (M), Nanog (N), hTERT (T) and GFP were diluted in
Opti-MEM basal media (Life Technologies) and mixed gently. The Opti-MEM was used
as diluent. Lipofectamine 2000 was diluted in Opti-MEM as well. After 5 min of
incubation in room temperature, the diluted RNA added to the diluted Lipofectamine
2000 (1:1 ratio), and incubated 20 min at room temperature. Afterwards, the RNA lipid
complexes were delivered to the cells. 4h after transfection the medium was changed to
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fibroblast medium. Transfection efficiency and condition was controlled using GFP-
mRNA. The cells further used for either MTT assay or microscopic analysis.
4.7.3 mRNA transfection using jetPEI reagent
For mRNA-jetPEI transfection, three different cell types including foreskin human
fibroblasts, human IMR90 fibroblasts and urine-derived cells (RECs) were used. The
human foreskin fibroblasts used for jetPEI transfection were amber, brown, pink, red,
green, purple and yellow.
For transfections, the cells were seeded on 6-well-plates (200,000 cells/well) at passage
3 one day prior to the experiment. The next day, the culture media was changed to Opti-
MEM basal media (Life Technologies) before transfection. Either 3μg of mRNA for Oct4
(O), Sox2 (S), Klf4 (K), c-Myc (M), Nanog (N), hTERT (T) and GFP or 3μg mixture of the
reprogramming factors-mRNA (equal amounts of each factor) were diluted in 150mM
sodium chloride solution (PolyPlus). JetPEI reagent (Polyplus) was dispersed in 150
mM sodium chloride solution as well. These components were pooled and incubated 30
min at room temperature before being dispensed to culture media. 4 h after transfection
the medium was changed to either fibroblast or iPS medium. Transfection efficiency and
condition was controlled by GFP-mRNA. The cells further used for MTT assay, ELISA,
flow cytometry, detection of pluripotency proteins and reprogramming.
4.8 Toxicity assay
To assess the cytotoxicity of transfection reagents as well as mRNA factors toxicity, the
MTT assay was done. For this purpose, the human foreskin fibroblasts isolated from
three different donors were transfected with the mRNAs of different factors. The donor
cells used for analysis were green, pink and red foreskin fibroblasts. JetPEI and
lipofectamine 2000 transfection reagents were used for toxicity assessment of
transfection reagent. For the assay, the cells were seeded on 48-well plates in triplicate
at a density of 20,000 cells per well. One day after seeding, the cells were incubated
with mRNA-jetPEI (polyplex) and mRNA-lipofectamine 2000 (lipoplex) prepared as
described above (sections 4.7.2 & 4.7.3). Then, cell viability was detected 24h, 48h and
72h after transfection. For detection of cell viability, the medium of the cells were
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replaced with 250 µl of fresh fibroblast medium and 25 µl of MTT solution (Applichem)
for each well (48-well plate), followed by 4h incubation at 37◦C. MTT solution was
aspirated after 4h and the reaction was stopped by the addition of 250 µl of stop
solution containing 50% dimethylsulfoxide (VWR International) and 50% SDS solution
(Merk Millipore). The plates were incubated at 37◦C for 1 h, and then the absorbance
was measured using a microplate reader (Tecan Infinity Pro 200 series) at 550nm and
630nm as reference wavelength. Data were presented as percentage of cell viability
compare to non-transfected cells which set as a value = 100.
4.9 Measurement of interferons by ELISA
To detect innate immune response following mRNA transfection, the level of human
interferon gamma (hIFN-γ) and interferon alpha (hIFN-α) was detected by enzyme-
linked immunosorbent assay (ELISA) (Mini ELISA Development Kit, Peprotech)
according to the manufacturer’s instructions. For this purpose, the human foreskin
fibroblasts isolated from three different donors were transfected with either single factor-
mRNA or factor combinations-mRNA. The supernatant of mRNA-transfected cells were
collected after the first transfection, and the amount hIFN-γ and hIFN-α in the
supernatant was measured by ELISA. The donor cells used for analysis were purple,
red and yellow foreskin fibroblasts. JetPEI reagent was used for transfection.
4.10 Flow cytometry
To detect reprogramming proteins following mRNA transfection, the human foreskin
fibroblasts isolated from three different donors were transfected with the mRNAs of
different factors. The donor cells used for analysis were purple, green and yellow
foreskin fibroblasts. JetPEI reagent was used for mRNA transfection. The transfection
procedure was mentioned above in section 3.7.3. The mRNA-transfected cells were
trypsinized 24h, 48h and 72h after transfection, washed twice with 1x PBS- and fixed in
4% paraformaldehyde (Thermo Scientific) for 15min. Fixed cells were washed three
times with PBS-1% BSA (Sigma) and then permeabilized with 0.2% Tween 20 (VWR) in
PBS- at 37°C for 10min. Cells were blocked with PBS- containing 10% BSA at 37°C for
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30 minutes, then incubated for 1h at 4°C with the following primary antibodies: Oct4
(1:600, Cell Signaling), Sox2 (1:300, Cell Signaling), c-myc (1:200, Cell Signaling),
Nanog (1:400, Cell Signaling), Klf4 (1 µg, Thermo Scientific), and hTERT (1:50, Thermo
Scientific). Thereafter cells were incubated with secondary antibody (Alexa fluor 488;
1:2000, Invitrogen) and (Alexa fluor 546; 1:2000, Invitrogen) for 1h at 4°C. The cells
transfected with GFP-mRNA were used for analysis as well. The cells afterward were
suspended in PBS- and analyzed by flow cytometry (BD FACS Calibur). Control non-
transfected cells were used to gate for forward and side scatter. The cells stained with
secondary antibody were used as a control group. All other data were referred to this
value. Ten thousands gated events were collected per sample. Single cell suspensions
were passed through a 488nm laser for excitation. The fluorescence emissions were
collected at 530nm for Alexa fluor 488 and 590 nm for Alexa fluor 546.
4.11 mRNA transfection of different human donor cells
Several human donor cells were transfected with different factor combinations-mRNA in
order to generate mRNA-iPS cells. The donor cells include foreskin fibroblasts derived
from seven different donors (see “Materials”, section 3.9.1, table 10), eye lid fibroblasts,
and RECs derived from urine samples, dermal fibroblasts from an old patient
(PromoCell) and IMR-90 fibroblasts (see “Materials”, sections 3.9.1 and 3.9.2, tables 10
and 11).
In all instances the GFP-mRNA transfection was done to control the transfection
condition. JetPEI reagent was used for transfection.
4.12 Reprogramming to pluripotency
For the establishment of stable mRNA-iPS cells, foreskin fibroblasts (donor: amber) and
IMR90 fibroblasts were reprogrammed to form HFF-mRNA-iPS and IMR90-mRNA-iPS
cells respectively. For this purpose, the cells were seeded on 6-well-plates pre-coated
with 0.1% gelatin (Sigma-Aldrich). The cells were transferred to hypoxic condition (5%
O2) one day prior to the experiment. Repeated mRNA transfections were performed
using jetPEI reagent. The transfection procedure was mentioned above in section 4.7.3
The factor combinations used for generation of mRNA-iPS cells were ONT, OSK and
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OSKMNT. 4h after transfection the medium was changed to iPS medium. The iPS
medium was equilibrated at 5% O2 for approximately 2h before use. Repeated
transfections were performed every 48h (6 times) in a period of two weeks. The mRNA-
iPS colonies derived from these transfections were manually picked and transferred on
irradiated MEFs under low oxygen condition (5% O2) for further expansion. The iPS
cells derived from foreskin fibroblasts and IMR90 fibroblasts were called HFF-mRNA-
iPS and IMR90-mRNA-iPS cells respectively. At the end of repeated transfections (day
13 after transfection), the reprogramming efficiency for different factor combinations was
calculated by dividing the average count of colonies per well by the initial number of
cells plated.
4.13 Mouse embryonic fibroblasts derivation and irradiation
Mouse embryonic fibroblasts (MEFs) were used as feeder cells to maintain the iPS cells
in an undifferentiated state. They established from dissociated CD1 mouse embryos
(13.5–14 d gestation). To isolate MEFs from mouse embryos, a pregnant CD1 mouse
(Charles River, Japan) was scarified by cervical dislocation, and the uterine horns were
dissected out, and washed with PBS- containing 1% penicillin/streptomycin (Life
Technologies). The uterine horns were placed into the culture plates and transferred to
the sterile bench. The following experiments were performed under sterile condition.
Afterwards, the placenta and embryonic sac were removed from each embryo, and the
head and red organs were dissected out. Then, the embryos were washed with PBS -,
and were cut into small pieces using a sterile razor blade, and were incubated with
0.05% trypsin/EDTA (Life Technologies) for 15 min at 37°C. After each 5 min of
incubation, dissociate cells by pipetting up and down thoroughly. The trypsin was
inactivated by adding of freshly MEF medium (for MEF medium see “Materials” section
3.10.1, table 12). The cells were centrifuged at 200 g for 5 min, and then the
supernatant was removed carefully and the cell pellet resuspended in warm MEF
medium. A number of cells which was equivalent to 3-4 embryos were plated onto T150
tissue culture flasks pre-coated with 0.1% gelatin. The fibroblast outgrowths were visible
2 days after culture. When the cells were 80-90% confluent, they were expanded till
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passage 3-4, and then inactivated by gamma irradiation (25 Gy) to be used for the iPS
co-culture.
Preparation of MEFs for the iPS culture was done one day before the experiment. The
plates were coated with 0.1% gelatin for 30 min at 37°C followed by washing with PBS-
and then irradiated MEFs were seeded at the density of 0.4 x 106 cells in each 60 x 10
mm tissue culture plates.
4.14 Cultivation and expansion of iPS cells
All of the iPS cells whether viral or mRNA-iPS cells were expanded mechanically on
irradiated MEFs. For mechanical passaging of the iPS cells, the old media was
aspirated and an appropriate amount of pre-warmed fresh iPS medium was added to
the culture plates. The iPS medium contained Knockout TM DMEM (Life Technologies)
supplemented with 20% KnockoutTM serum replacement (KSR) (Life Technologies),
10ng/ml FGF-basic (Peprotech), 1% nonessential amino acids (Life Technologies),
2mM L-Glutamine (Life Technologies), 1% penicillin-streptomycin (Life Technologies)
and 0.1mM 2-mercaptoethanol (Sigma-Aldrich) (for iPS medium see “materials” section
3.10.3, table 14). The differentiated parts of the iPS colonies were removed, and the
undifferentiated parts were cut manually into small pieces with nearly the same size.
The pieces were lifted up with a filter tip (10µl) and transferred onto a new plate with
pre-coated fresh irradiated MEF cells. The mechanical passage was done in the
presence of 10µM rho-associated kinase (ROCK) inhibitor Y-27632 (Calbiochem). The
iPS cells were then cultured under hypoxic conditions (5% O2). The iPS medium was
changed at day 2 after cell seeding and then every day until the cells were ready for the
next passage. The viral-iPS cells were passaged every 4 days, while the mRNA-iPS
cells were expanded once a week.
4.15 Teratoma formation assay
Teratoma assay was performed to assess the in vivo differentiation potential of the iPS
cells. The assay was done with the help of Prof. Ralf Dressel at Department of Cellular
and Molecular Immunology in University of Göttingen. Three viral-iPS cell lines and one
mRNA-iPS cells were used for teratoma formation assay. The viral-iPS used for the
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teratoma formation were foreskin-derived-iPS cells (ffle13-iPS cells, donor: ffle13) and
two different Huntington-derived-iPS cells (WC1 & SP-iPS cells, donors: WC1 & SP).
The mRNA-iPS cells used for the assay were IMR90-mRNA-iPS cells. The donor
fibroblasts of each iPS cell lines were used as controls. The teratoma formation assay
was performed as previously described by Dr. Dressel and his colleagues (Dressel et al.
2009; Dressel et al. 2010). The Immunodeficient RAG2-/-γc-/- mice, housed under
pathogen-free conditions in the central facility for animal experimentation at the
University Medical Centre Göttingen, were injected subcutaneously with 1×106 cells in
50µl PBS- mixed with 50µl Matrigel (BD Biosciences). Tumour growth was monitored
weekly by palpation and size was recorded using linear calipers. Animals were
sacrificed when a tumour diameter was reached to 1 cm or after 3 months. Autopsies
were performed and tumour tissue was placed in phosphate-buffered 4 % formalin for
16 h and then embedded in paraffin. For histological examination, tissue sections (2μm)
were stained with haematoxylin and eosin. For Haematoxylin-eosin staining, paraffin
sections incubated overnight at 37°C or 30 min at 60°C. Then, paraffin (Carl Roth) was
removed from the sections based on the following procedure:
2 x 7 min xylen (Carl Roth)
1 x 5 min propanol
1 x 5 min 98% alcohol
1 x 5 min 75% alcohol
1 x 5 min 60% alcohol
1 x 5 min demineralized water
For the staining, the sections were placed 1 x 5 min in haematoxylin (Mayer's
haematoxylin, Merck), and then rinsed with demineralized water. Next, the sections
were placed in eosin (1% in distilled water, and 1-2 drops of acetic acid) (Merck) for 5
min, and then short time in demineralized water, 60% and 75% alcohol. After that, the
sections were put for 5 min in each 98% alcohol and propanol, and 2 x 5 min in xylene,
and then mounted and visualized under the microscope.
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4.16 Immunostaining and microscopic analysis
To visualize the nuclear localization of the reprogramming proteins, the human foreskin
fibroblasts were transfected with the mRNAs of different factors. The donor cells used
for analysis were yellow foreskin fibroblasts. JetPEI reagent was used for mRNA
transfection. The cells were transfected with mRNAs of Oct4, Sox2, c-Myc and Nanog.
The transfection procedure was mentioned above in section 4.7.3. The mRNA-
transfected cells were fixed with 4% paraformaldehyde 24 h after transfection, washed
three times with 1x PBS- and permeabilized with 0.5% Triton X-100 in 1x PBS- for 30min
in RT. The cells were then blocked with 10% FCS in PBS- for 1h in RT. Afterwards, the
cells were incubated with primary antibodies in 1xPBS-, 1% FCS, and 0.5% Triton-X-
100 at 4°C for 1h. After washing three times, cells were incubated with secondary
antibodies in 1x PBS- for 30min at 4°C. Primary antibodies were Oct4 (1:400, Cell
Signaling), Sox2 (1:400, Cell Signaling), c-Myc (1:800, Cell Signaling) and Nanog
(1:400, Cell Signaling). Secondary antibodies were Alexa fluor 488 (1:1000, Invitrogen)
and Alexa fluor 546 (1:1000, Invitrogen). Nuclei were counterstained with 4, 6-
diamidino-2-phenylindole dilactate (DAPI) (1:10000, Sigma). Cells were visualized using
a fluorescence microscope (Axio Observer, Zeiss).
For the assessment of pluripotency markers expression, three viral-iPS and one mRNA-
iPS cells were immunostained with the markers. The viral-iPS cell lines used for
immunostainig were foreskin-derived-iPS cells (ffle13-iPS cells, donor: ffle13) and two
different Huntington-derived-iPS cells (WC1 & SP-iPS cells, donors: WC1 & SP). The
mRNA-iPS cells used for analysis were foreskin-mRNA-iPS cells (donor: amber). The
donor fibroblasts (donor: amber) of mRNA-iPS cells were immunostained as well. The
cells were fixed with 4% paraformaldehyde, and stained using the above procedure.
The primary antibodies were Oct4 (1:250, Abcam), Nanog (1:100, Stemgent), and Tra-
1-60 (1:100, Stemgent). Secondary antibodies were Alexa fluor 488 (1:1000, Invitrogen)
and Alexa fluor 546 (1:1000, Invitrogen). Nuclei were counterstained with DAPI
(1:10000, Sigma). Cells were visualized using a fluorescence microscope (Axio
Observer, Zeiss).
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4.17 Karyotype analysis
Karyotype analysis was performed to assess the possible chromosomal aberrations and
genetic stability of the iPS cells. The cytogenetic analysis of the iPS cells and the
parental fibroblasts was done with the help of Dr. Heidrun Holland in Translational
Centre for Regenerative Medicine (TRM) in University of Leipzig.
The mRNA-iPS cells used for karyotyping were IMR90-mRNA-iPS cells. The IMR90-
mRNA-iPS cells (passage 37) and IMR90 parental fibroblasts (passage 14) were
incubated with 0.1 ml Colcemid (100mg/l isotonic NaCl solution) (Life Technologies)
for 3h at 37°C. After that, cells were collected by cell scraper and placed in a hypotonic
solution (0.075M KCl solution) (B. Braun Medical Inc.) at RT. The cells were collected
by centrifugation and fixed with methanol (VWR) and acetic acid (VWR) (3:1) for 5min
(two times) followed by spreading the cells on microscopic glass slides and let air dry.
Trypsin-Giemsa (Dr. K. Hollborn & Söhne GmbH & Co. in Leipzig) staining (GTG-
banding) of the chromosomes was performed by treating the glass slides with trypsin
solution (0.5g trypsin in 250ml isotonic NaCl solution) for 20 sec, washed twice with
0.9% NaCl and stained using Giemsa solution (5ml Giemsa stock solution in 150ml
Soerensen buffer) for 5min. Karyotype analyses were performed using GeneASI
BandView software (Applied Spectral Imaging).
4.18 RNA isolation
Total RNA was isolated using Trifast reagent according to the manufacturer´s
instructions (Peqlab) and was treated with DNaseI (Life Technologies) to remove
possible genomic DNA contamination. The mRNA-iPS cells and the parental fibroblasts
used for RNA isolation contained two different foreskin-derived-mRNA-iPS cells (HFF-
mRNA-iPS, donors: amber & brown), two different human foreskin fibroblasts (HFF,
donors: amber & brown), IM90-derived-mRNA-iPS cells (IMR90-mRNA-iPS, donor:
IMR90 fibroblast) and human IMR90 fibroblasts.
The viral-iPS cells used for RNA isolation contained foreskin-derived-iPS cells (HFF-
viral-iPS, donor: ffle13) and Huntington-derived-iPS cells (Huntington-viral-iPS, donor:
WC1).
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The isolated RNA from the above samples were used for either RT-PCR or gene array
analysis.
For the isolation, chloroform was added to the sample lysates, and centrifuge at 12000
g, 15 min, RT. The clear upper layer was transferred to a new tube and propan-2-ol
(VWR) was added to precipitate the RNA. The precipitated RNA was washed twice with
75% ethanol, followed by centrifugation at 12000 g, 10 min, 4°C. The RNA was then
dried about 10 min at room temperature and solved in 50 μL H2ODEPC. The quality
control of isolated RNA was done with NanoDrop. The 260/280 ratio was used to
assess the purity of the RNA samples.
4.19 DNA isolation
DNA was isolated using Trifast reagent according to the manufacturer´s instructions
(Peqlab). Three viral-iPS cells and their parental fibroblasts including 1) foreskin-
derived-iPS cells (ffle13-iPS, donor: ffle13), 2) human foreskin fibroblasts (donor:
ffle13), 3) two different Huntington-derived-iPS cells (WC1 & SP-iPS, donors: WC1 &
SP), and 4) Huntington dermal fibroblast (donors: WC1 & SP) were used for DNA
isolation. The isolated DNA from the above samples was used for telomere length
analysis.
For the isolation, chloroform was added to the sample lysates, and centrifuge at 12000
g, 15 min, RT. The clear upper layer containing RNA was removed and the leftover
containing DNA and proteins was transferred to a new tube. DNA was precipitated with
ethanol absolute, and incubated for 5 min at RT, followed by centrifuge at 2000 g, 15
min, 4°C. The supernatant containing protein was removed and the pellet was washed
twice with 75% ethanol, followed by incubation (15 min, RT) as well as centrifugation
(2000 g, 5 min, 4°C). The isolated DNA was solved in 8 mM sodium hydroxide and 100
mM HEPES to ensure a pH of 8.0 as recommended in the peqlab manual. The quality
of isolated DNA was assessed by agarose gel. The samples were stored at 4°C for
further analysis.
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4.20 quantitative RT–PCR
The quantitative RT–PCR was done with the help of Dr. Claire Fabian in Fraunhofer
Institute for Cell Therapy and Immunology (IZI) Leipzig. The RNA isolated from foreskin-
derived-mRNA-iPS cells (HFF-mRNA-iPS, donor: amber), human foreskin fibroblasts
(HFF, donor: amber), IMR90-derived-mRNA-iPS cells (IM90-mRNA-iPS, donor: IMR90
fibroblast), and human IMR90 fibroblasts were used for qRT-PCR analysis. The
products were further used for detection of pluripotency related genes.
The RNA isolation procedure was followed by genomic DNA digestion using DNAseI.
Next, cDNA synthesis was performed using SuperscriptIII-transcriptase (Life
Technologies) and Oligo (dT)18-Primers (Thermo Scientific) at 50°C for 1h. For PCR
template, cDNA was used in a 1:10 dilution and all samples were run as triplicate.
Quantitative PCR was done using Express SYBR Green ER qPCR Supermix Universal
(Life technologies), additional 1x SybrGreen (Life technologies) and 0.2 µM sense and
anti-sense primers (primer sequences are included in “Materials” section 3.7.2, table 6).
The quantitative PCR was done in DNA engine Opticon 2 (Biorad) with the following
cycle conditions: primary denaturation at 95°C for 3 min, 35 cycles with 30s at 95°C, 30s
at 60°C (36B4 & Sox2) / 55°C (Oct4, Nanog, Klf4, c-myc) and 30s at 72°C followed by
fluorescence measurement. Absolute quantification was done for every single gene by
dilution series of plasmid positive controls and set in relation to the reference gene
36B4.
4.21 Transduction using viral vectors
Transduction was done with the help of Dr. Claire Fabian in Fraunhofer Institute for Cell
Therapy and Immunology (IZI) Leipzig to generate three different viral-iPS cell lines.
The plasmids as well as viral vectors were kindly provided by Dr. Claire Fabian.
The parental fibroblasts of the viral-iPS cell lines were human foreskin fibroblasts
(donor: ffle13) and Huntington dermal fibroblasts (donors: SP & WC1).
Phoenix-GP cells were used as packaging cell line for production of viral particles. For
the viral particles production, both pHIT-G and MOMLV-based shuttle vectors
containing reprogramming factors were transfected into Phoenix-GP cells. The Phoenix-
GP cells were plated at a density of 200,000 cells per well (6-well plate) one day before
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co-transfection. One day after, the co-transfection was done with 0.75 µl Lipofectamine
2000 (Life Technologies), 1.8 µg shuttle vector and 1 µg pHIT-G pseudotyping vector.
Afterwards, the Phoenix-GP cells were incubated for 4 h in the incubator 37°C, and then
the medium was replaced with DMEM low glucose. After 48 h, the supernatant
containing the retroviral particles for each reprogramming factor was collected, mixed in
equal proportions, and filtered through a 0.45μm cellulose acetate filter before it was
added to the fibroblasts.
The human fibroblasts were seeded at a density of 200,000 cells per well (6-well plate)
24 h prior to transduction. One day after, the fibroblasts were checked to be 50-90%
confluent. Then, the supernatant containing viral particles and 4 µg/ml polybrene
(Sigma-Aldrich) were added to the human fibroblasts. To increase the transduction
efficiency, the cells with viral particles and polybrene were centrifuged at 200g for 1.5 h
in 22°C. After the centrifugation step, the virus particles were removed and the cells
were fed first with fresh fibroblast growth medium and then with iPS growth medium.
After transduction, the cells were cultured in hypoxia condition (5% O2) until the
granulated colony-like structures were observed. The colony-like structures were then
selected and expanded on irradiated MEF cells for the establishment of stable viral-iPS
cell lines.
4.22 Differentiation of iPS cells to fibroblasts
Three viral-iPS cell lines contained foreskin-derived-iPS cells (ffle13-iPS, donor: ffle13)
and two Huntington-derived-iPS cells (WC1 & SP-iPS, donors: WC1 & SP) were used
for differentiation to fibroblasts. The viral-iPS cells were expanded on irradiated MEFs
as described above (see section 4.14). When the iPS cells were reached to the size
which was ready for the next passage, the differentiated parts of the colonies were
removed. Then the medium was changed, and the undifferentiated parts of colonies
were cut manually into big pieces with nearly the same size. The pieces were lifted up
with a filter tip (10µl) and transferred onto new gelatine 0.1% coated plates. The
medium was switched from iPS to fibroblast medium (see “Materials” sections 3.10.1 &
3.10.3) at the beginning of differentiation procedure. The medium was not changed the
first 2 days after cell seeding, and then changed every 2 days. After 10 days, the
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differentiation procedure was finished and the cells were collected for either freezing or
aging analysis. The resulting cells were termed iPS-derived fibroblast (iPS-DF).
4.23 Gene expression profiling
Sample preparation and microarray assays were done at the core facility “DNA
technologies” of the Interdisciplinary Centre for Clinical Research (IZKF) Leipzig
(Faculty of Medicine, University of Leipzig). For gene expression analysis eight different
samples including 1) human foreskin fibroblasts (HFF-donor, donor: Brown), 2) foreskin-
derived-mRNA-iPS cells (HFF-mRNA-iPS, donor: Brown), 3) IMR90 fibroblasts, 4)
IM90-derived-mRNA-iPS cells (IM90-mRNA-iPS, donor: IMR90 fibroblast), 5) foreskin-
derived-viral-iPS cells (HFF-viral-iPS, donor: ffle13), 6) Huntington-derived-viral-iPS
cells (Huntington-viral-iPS, donor: WC1), and 7) hES cells # 1& 2 (two biological
replicates of hES cells as controls, H9 cell line) were used. For the iPS samples, at least
30 iPS colonies were used for the assay.
Total RNA was extracted with TriFast reagent (Peqlab), and then was purified using
GeneJet RNA purification kit (Thermo scientific) according to the RNA clean-up
protocol. RNA integrity was confirmed using Agilent 2100 bioanalyzer (Agilent
technologies). The ribosomal RNA was taken out of total RNA using “RiboMinus Kit”
(Life technologies) followed by first and second cDNA synthesis. Afterwards, the
intermediate in vitro transcription was done using “WT cDNA Synthesis and
Amplification Kit” according to the manufacturer’s instructions (Affymetrix). Next, cDNA
was fragmented and labelled with the “WT Terminal Labeling Kit” (Affymetrix) and
hybridized to Human Genome 1.0 ST Arrays (Affymetrix). Washing and staining steps
were done with an Affymetrix Fluidics Station FS400. Arrays were scanned with a third-
generation Affymetrix “GeneChipScanner 3000” equipped with the “7G” upgrade.
4.24 Expression portraying using self-organizing maps
The Self-Organizing Map (SOM) has been trained and analyzed by Dr. Henry Wirth in
Interdisciplinary Centre for Bioinformatics of Leipzig University (Wirth et al. 2011; Wirth
et al 2012). The total gene expression matrix of (N=8 samples) X (M=32,321 genes) is
transformed into a reduced matrix where the genes are clustered into K=900
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microclusters called metagenes after appropriate normalization and centralization of the
input expression data (Wirth et al. 2011). SOM-machine learning provides strong
visualization capabilities: The expression values of the metagenes in each of the
samples are transferred into a two-dimensional 30x30 mosaic picture ‘portraying’ the
expression landscape of each sample using an appropriate colour gradient: red reflects
strong over-expression compared to the mean expression of a metagene; yellow and
green tones indicate intermediate levels with low or no differential expression; and blue
corresponds to under-expression. Each metagene collects similar ‘profiles’ of single
genes in the N samples measured. Moreover, similar metagene profiles are usually
arranged in neighboured pixels in the maps thus forming extended over- and under-
expression spots. Importantly, each gene is associated with one and the same
metagene and thus with the same position in all individual sample images.
4.25 Sample clustering
The sample clustering and analysis of similarity among the samples were done by Dr.
Henry Wirth in Interdisciplinary Centre for Bioinformatics of Leipzig University. To detect
the similarity between the samples, the neighbour-joining algorithm was applied based
on the Euclidean distances between the samples as phylogenetic trees (Saitou & Nei
1987). The distances between the sample pairs in phylogenetic tree are in scale. The
algorithm was applied based on the metagenes and not based on the original single
genes. Therefore, the similarity analysis compares the expression landscapes as
characterized by the SOM portraits. The use of metadata as the basal data has the
advantage of improving the representativeness and resolution of the results as shown
previously (Wirth et al. 2011; Guo et al. 2006).
4.26 Telomere length analysis by qPCR
To assess the alteration of telomere length upon reprogramming, relative quantification
of telomere length was performed using the qPCR based on the modified protocol
according to Cawthon RM, 2009 (Cawthon 2009). The genomic DNA was isolated as
described in section 4.19. The samples used for telomere length analysis have already
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been mentioned in section 4.19. The qPCR for the measurement of telomere length was
carried out in 96-well PCR plates, on LightCycler® 480 (Roche). For quantification of
relative telomere length, 14 ng of isolated DNA was used for both telomere length and
36B4 PCRs. 36B4 was used as housekeeping gene (reference gene).
The PCR reaction (20µl) for telomere length contained: 14 ng DNA, 0.27 µl primer tel1
(10 pmol/ µl), 0.9 µl primer tel2 (10 pmol/ µl) (primer sequences are included in
“Materials” section 3.7.2, table 7), 1 µl DMSO (Sigma), 10 µl Sybr Green Express 2xMM
(Life technologies) and H2O. The PCR reaction was performed using the following
program: 1 cycle of 95°C for 10 min followed by 22 cycles of 95°C for 15 sec and 54°C
for 2 min.
The PCR reaction (20µl) for 36B4 housekeeping gene contained: 14 ng DNA, 0.5 µl
36B4 sense primer (10 pmol/ µl), 0.5 µl 36B4 anti-sense primer (10 pmol/ µl), 1 µl
DMSO (Sigma), 10 µl Sybr Green Express 2xMM (Life technologies) and H2O. The
PCR reaction was performed according to the following program: 1 cycle of 95°C for 10
min followed by 30 cycles of 95°C for 15 sec and 58°C for 1 min.
Telomere length was determined by following the equation:
(Efficiency 34B6 standard curve x Cp 34B6) x (Efficiency ts standard curve x Cp ts).
4.27 MitoTracker staining
To assess the mitochondrial morphology, localization and distribution, the cells were
stained with MitoTracker Deep Red (Molecular Probes®) (Life Technologies).
MitoTracker Deep Red is a far red-fluorescent dye that stains mitochondria in live cells
and can be used for mitochondrial localization. Three viral-iPS cell lines and their
differentiated counterparts as well as one mRNA-iPS cells and their parental fibroblasts
were used for the MitoTracker staining. The viral-iPS cells and differentiated
counterparts used for the staining were 1) foreskin-derived-iPS cells (ffle13-iPS, donor:
ffle13), 2) foreskin fibroblasts (donor: ffle13), 3) foreskin-iPS-derived fibroblasts (ffle13-
iPS-DF, donor: ffle13), 3) Huntington-derived-iPS cells (WC1 & SP-iPS, donors: WC1 &
SP), 4) Huntington dermal fibroblasts (donors: WC1 & SP), and 5) Huntington-iPS-
derived fibroblasts (WC1- iPS-DF & SP- iPS-DF, donors: WC1 & SP).
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The mRNA-iPS cells and their parental fibroblasts used for the staining were IMR90-
derived-mRNA-iPS cells (IMR90-mRNA-iPS, donor: IMR90 fibroblasts) and IMR90
fibroblasts.
For preparation of staining solution, the dye was diluted in DMEM basal medium to the
final concentration of 1 µM. Because some of the MitoTracker probes are susceptible to
potential oxidases in serum, the dye was diluted in DMEM basal medium and not in
complete medium.
For the live staining with MitoTracker Deep Red, the medium of the cells was removed
and pre-warmed (37°C) staining solution containing MitoTracker was added to the cells.
The cells were then incubated in 37°C, 5% CO2 for 30 min. After incubation, the staining
solution was replaced with fresh pre-warmed complete media (specific for each cell
type) and the stained mitochondria were observed under the fluorescence microscope.
4.28 H2DCFDA staining for ROS production
In order to measure ROS production, the cells were treated with H2DCFDA (Molecular
Probes®) (Life Technologies), and the level of produced ROS was analysed by flow
cytometry. H2DCFDA is a chemically reduced form of fluorescein used as an indicator
for reactive oxygen species (ROS) in cells.
The samples used for analysis were similar to the sample used for MitoTracker staining
(see section 4.27).
For the cell treatment, H2DCFDA was diluted in DMEM basal medium to the final
concentration of 10 µM, and then the medium of the cells was aspirated and pre-
warmed (37°C) DMEM medium containing H2DCFDA was added to the cells. The cells
were incubated in 37°C, 5% CO2 for 30 min, and subsequently DMEM was removed,
and the cells were washed with PBS-, harvested by Trypsin/EDTA (Life Technologies)
(for fibroblasts cells) or Accutase (Life Technologies) (for the iPS cells), suspended in
PBS- and analyzed by flow cytometry (BD FACS Calibur).
Single cell suspensions were passed through a 488nm laser for excitation. The
fluorescence emissions were collected at 530nm. The cells treated with ethanol were
served as negative control for ROS production.
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4.29 JC-1 staining for mitochondrial membrane potential
For the measurement of mitochondrial membrane potential (MMP), the cells were
treated with JC-1 dye (eBioscience). JC-1 is a membrane permeable dye widely used
for determining mitochondrial membrane potential. The dye can enter the mitochondria
where it changes color based on membrane potentials. This change is due to the
formation of JC-1 aggregates at higher membrane potential that causes shift from 530
nm (JC-1 monomeric form) to 590 nm (JC-1 aggregate form). Indeed, at higher
mitochondrial membrane potential, JC-1 dye forms aggregate and exists in the red-
fluorescent conformation whereas with lower membrane potential JC-1 remains in the
monomeric, green-fluorescent conformation.
The samples used for analysis were similar to the sample used for MitoTracker staining
and ROS production measurement (see sections 4.27 & 4.28). For treatment of the
cells, JC-1 was diluted in DMEM basal medium at concentration of 1 µg/ml and then
added to the cells followed by 30 min incubation at 37°C. Afterwards, the cells were
washed with PBS-, harvested by Trypsin/EDTA (Life Technologies) (for fibroblast cells)
or Accutase (Life Technologies) (for iPS cells), suspended in PBS- and analyzed by flow
cytometry (BD FACS Calibur). Single cell suspensions were passed through a 488nm
laser for excitation. The fluorescence emissions were collected at 530 nm for FL1
channel (emission of JC-1 monomeric form) and 590 nm for FL2 channel (emission of
JC-1 aggregate). The ratio of aggregate probe (measured in the FL2 channel) to
monomeric probe (measured in the FL1 channel) was an indicator of mitochondrial
membrane potential. Thus, the mitochondrial membrane potential was measured as
FL2/FL1 ratio. The cells treated with DMSO were served as negative control for JC-1.
4.30 Alkaline Comet Assay
To assess the DNA damage response, the cells were exposed to H2O2, and then the
DNA damage was measured using come assay. Three different viral-iPS cell lines and
their parental fibroblasts were used for the assay. These cells were foreskin fibroblasts
(donor: ffle13), foreskin-derived-iPS cells (ffle13-iPS, donor: ffle13), Huntington dermal
fibroblasts (donors: WC1 & SP) and Huntington-derived-iPS cells (WC1 & SP-iPS,
donors: WC1 & SP).
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One day before the experiment, the fibroblasts were seeded at the density of 150000
cells per well (6-well plate). 10-12 undifferentiated iPS colonies (4 day-old-colonies)
should be prepared as well.
The comet assay was divided into 7 steps. Solutions and slides preparation was done
one day before the experiment (step 1). Two different solutions were prepared including
lysis buffer (2.5M NaCl, 0.1M EDTANa2, 10mM Tris and 1% Triton-X-100, pH 10) and
electrophoresis solution (0.03M NaOH and 2mM EDTANa2, pH 12.5). For the slide
preparation, slides were dipped into a vertical jar containing 1% agarose, and the
excess of agarose was removed and the slides were let dry at RT (step 1). On the day
of experiment, the cells were treated with 100mM H2O2 (DNA damaging agent) (Sigma)
for 30-45 min (depending on the cell type for efficiency of H2O2) at 37°C (step 2). The
cells were not treated with H2O2 used as control group. After the incubation, the cells
were washed with PBS-, harvested by Trypsin/EDTA (for fibroblast cells) or Accutase
(for iPS cells) and centrifuge at 200 g for 5 min. After that, between 1-1.5 x 105 cells
were diluted in 250 µl PBS- and then 750 µl of 1.3% low melting point agarose (LMP)
(Life Technologies) was added to the cell suspension (step 3). A 100 µl of the mixture
(cells/ agarose solution) was then added to the slide and covered with a cover slip.
Slides were incubated for 5 min at 4°C to allow agarose solidification. Subsequently, the
cells were lyzed for 1 hr at 4°C with lysis buffer (step 4). After lysis of the cells, the DNA
was denatured by alkaline treatment (step 5). The slides were placed in the
electrophoresis chamber and immerse in cold electrophoresis solution for 40 min at 4°C.
Then, DNA was run at 25V for 30 min (step 6), and after that, slides were washed 3x
with distilled water for 5 min at RT (step 7). Next, DNA was stained with 2.5 µg/ml
propidium iodide (Sigma), and pictures were taken using Leica system at a 10x
magnification. The comets were analyzed by CometScoreTM15 software.
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4.31 Statistical analysis
One-way analysis of variance (ANOVA) followed by Tukey test was used to determine
whether observed differences were statistically significant between different
experimental conditions. P< 0.05 was considered statistically significant using Sigma
plot. Data were presented as mean ± SEM.
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5. Results 
 
5.1 Producing mRNA 
To produce mRNA of different reprogramming factors, in vitro transcription procedure 
was performed. The quality control of IVT-RNA was done by Agilent Bioanalyzer. For 
most factors (Oct4, Nanog, Klf4, Sox2) the use of linearized plasmid as well as PCR 
product as IVT templates lead to a high yield of full-sized IVT-RNA (Fig. 11A). 
For c-Myc and hTERT the use of PCR product as template was superior to linearized 
plasmid which gave no (hTERT) or minimal (c-Myc) yield of IVT-RNA. Especially for c-
Myc the use of PCR products as IVT template allowed for a high and efficient mRNA 
production (Fig. 11A). The ORF of c-Myc is a difficult IVT template due to the high G/C 
content with >80%. Hence, the reduction of the template size just to the essential 
elements of the T7-promoter and the ORF sequence allowed for an efficient 
transcription. All factors used had ORFs below 1,5kb except for the ORF of hTERT with 
over 3kb.  
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Figure 11. Quality control of IVT-RNA. A) Comparison of IVT-RNA made by two derivation 
method, linearization vs. PCR. B) Quality control of IVT-RNA measured by Agilent Bioanalyzer. 
Comparison of stored IVT-RNA vs. fresh RNA (right side, upper box), IVT-RNA with and without 
PolyA tail (right side, upper box), and high quality vs. low quality IVT-RNA (right side, lower 
box). The single peaks indicate that only one type of RNA is produced. These data are 
generated by Dr. Claire Fabian and Antje Arnold in Fraunhofer Institute for Cell Therapy and 
Immunology (IZI) Leipzig.   
 
While the in vitro transcription produced full length hTERT-RNA, there were also smaller 
RNA fragments produced. This could be attributed to either a sequence inside the ORF 
resembling a T7 RNA polymerase termination signal or secondary structures that may 
be problematic for the T7-RNA-polymerase to resolve. Hence, a lower reaction 
temperature was tested for the IVT to enable the T7-RNA-polymerase to override the 
termination signal and a higher reaction temperature to denature possible secondary 
structures. While the lower temperature yielded the same IVT-RNA products mixture of 
small and full-length IVT-RNA, the higher temperature led to the full-length IVT-RNA 
product without smaller fragments. This suggests that secondary structures were 
interfering with IVT (Fig. 12). 
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Figure 12. Optimization of hTERT IVT-RNA production.  Agarose gel electrophoresis of heat-
denatured hTERT IVT-RNA using either 32°C, 37°C or 42°C for IVT-RNA production. This data 
is generated by Dr. Claire Fabian in Fraunhofer Institute for Cell Therapy and Immunology (IZI) 
Leipzig.   
 
The single production steps were controlled by Agilent 2100 bioanalyzer for assessment 
of the RNA quality (Fig. 11B), size (Fig. 11B) and before and after PolyA-tailing (Fig. 
11B). IVT-mRNA was aliquoted in single-use aliquots after quantification to avoid 
repeated thawing and freezing. These aliquots were stable over 18 months at -80°C 
(Fig. 11B). 
 
5.2 Transfection efficiency using different transfection systems  
Uptake of mRNA using different transfection systems was determined by GFP-mRNA. 
At the beginning of this project, electroporation followed by Fugene® HD were used for 
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mRNA transfections (done by Antje Arnold, in Fraunhofer Institute for Cell Therapy and 
Immunology IZI Leipzig); however the company (Promega) changed Fugene® HD to an 
alternative product which yielded very low transfection efficiency. This led us to test the 
transfection efficiency of other transfection reagents such as Lipofectamine 2000 and 
jetPEI.  
As shown in Figure 13, mRNA transfection using electroporation resulted in high cell 
toxicity confirming the results of our previous work (Arnold et al., 2012). Furthermore, 
comparison of electroporation, FUGEN HD, Lipofectamine 2000 and jetPEI transfection 
reagents showed a significant higher cell transfection rate (higher transfection 
efficiency) using jetPEI transfection reagent and Lipofectamine 2000 (Fig. 13). However, 
more toxicity (less viable cells) after transfection with Lipofectamine 2000 was 
observed. This led us to assess the cytotoxic effects of jetPEI and Lipofectamine 2000 
as well as testing the mRNA factors toxicity.  
 
 
Figure 13. Transfection efficiency using different transfection systems. The pictures show 
GFP-mRNA expression and efficiency 24 h post-transfection using electroporation, FUGEN HD, 
Lipofectamine 2000 and jetPEI transfection reagents. The data regarding to electroporation and 
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FUGEN HD were generated by Antje Arnold in Fraunhofer Institute for Cell Therapy and 
Immunology (IZI) Leipzig. Lipofect. 2000 = Lipofectamine 2000. Scale bars represent 100μm. 
 
5.3 Cytotoxicity 
 
5.3.1 Cytotoxicity of mRNA using different transfection reagents  
The two transfection reagents lipofectamine 2000 and jetPEI were compared regarding 
their effect on cell viability in combination with each mRNA factor introduced.  
As can be observed in Fig. 14A and 14B, some mRNA factors have a tendency to 
cause greater cell toxicity (GFP and hTERT-mRNA) when paired with both jetPEI and 
Lipofectamine 2000 but overall, no clear outlier emerged. Therefore, all mRNA factors 
were considered as in-principle viable for use in mRNA reprogramming (Fig. 14A and 
14B). Overall, comparing lipofectamine 2000 and jetPEI based transfections revealed 
no significant differences in the viability of the transfected cells during the period up to 
72h post-transfection (Fig. 14A and 14B). However, the cells were transfected with 
Oct4, Sox2, Klf4-mRNAs and jetPEI reagent showed cell viability comparable to non-
transfected cells 72 h after transfection (Fig. 14A). 
Regarding to Lipofectamine 2000, the level of cell viability for none of the 
reprogramming factors-mRNA reached to the level of non-transfected cells 72h post 
transfection (Fig. 14B). Consequently, jetPEI was used in all following experiments as a 
tendency for more cell viability was observed in the cells transfected with jetPEI.  
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Figure 14. Cytotoxicity of mRNA using different transfection reagents. A) Cell viability after 
mRNAs-jetPEI transfection. B) Cell viability after mRNAs-lipofectamine 2000 transfection. 
Graphs represent means ± SEM. n=3. No trans. = Non-transfected cells. Lipofect. = 
Lipofectamine 2000. Data were presented as percentage of cell viability compared to non-
transfected cells (red columns) which set as a value = 100. The cells used for analysis were 
green, pink and red foreskin fibroblasts. 
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5.3.2 Immune response activation following mRNA transfection 
To determine the immune response activation following mRNA transfection, the levels 
of hIFN-γ and hIFN-α emitted by the transfected cells were measured by ELISA. 
Overall, in comparison to non-transfected cells, no significant differences in levels of 
hIFN-γ and hIFN-α in the supernatant of transfected cells using various factor 
combinations or single factors were found (Fig. 15A and 15B). However, we could 
observe a tendency for higher level of hIFN-γ and hIFN-α in the supernatant of the cells 
transfected with single mRNA factors compared to the cells transfected with factor 
combinations.  
 
Figure 15. Immune response activation following mRNA transfection. A) The level of 
human IFN-gamma in the supernatant of transfected cells following mRNA transfection. B) The 
level of human IFN-alpha in the supernatant of transfected cells following mRNA transfection. 
The cells used for analysis were purple, red and yellow foreskin fibroblasts. Graphs represent 
means ± SEM. n=3. No trans. = Non-transfected cells. ONT= Oct4, Nanog, hTERT. OSK = 
Oct4, Sox2, Klf4. OSKMNT = Oct4, Sox2, Klf4, c-Myc, Nanog, hTERT.  
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5.4 Protein expression of reprogramming factors 
 
5.4.1 Expression efficiency and persistence of reprogramming 
proteins  
Expression efficiency and persistence of reprogramming proteins in the transfected cells 
were monitored using flow cytometry. The high expression efficiencies was found for all 
factors following mRNA transfection (Fig. 16), and it was observed that between 50% 
(GFP) to over 90% (c-Myc) of the cells expressed the reprogramming proteins (Fig. 16).  
 
Figure 16. Expression efficiency in the transfected cells following mRNA transfection. 
The graphs show expression efficiency of reprogramming proteins after mRNA transfection. The 
efficiency varied from 50% for GFP to over 90% for c-Myc. The cells stained with secondary 
antibody were used as a control group. All other data were referred to control value. Ten 
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thousands gated events were collected per sample. The GFP graphs represent the data related 
to green foreskin fibroblasts. The c-Myc graphs represent the data related to yellow foreskin 
fibroblasts. 
 
Maximal protein expression of reprogramming factors was between 24h to 48h after 
transfection (Fig. 17). In all instances the percentage of positive cells remained stable 
between 24h and 48h but decreased 72h after transfection (Fig. 17).  
 
Figure 17. Persistence of reprogramming proteins in the transfected cells. The persistence 
of reprogramming proteins was monitored by time course analysis using flow cytometry. The 
cells used for analysis were purple, green and yellow foreskin fibroblasts. Graphs represent 
means ± SEM. n=3. *P< 0.01 = The percentage of hTERT positive cells 24h, 48h, and 72 h after 
transfection compared to the other factors (Oct4, Sox2, Klf4, c-Myc and Nanog) at 24h and 48h 
after transfection. +P< 0.01 = The percentage of hTERT positive cells 72 h after transfection 
compared to the other factors (Sox2, Klf4, c-Myc and Nanog) at 72 h after transfection. §P<0.01 
= The percentage of GFP positive cells 72h after transfection compared to the other factors 
(Oct4, Sox2, Klf4, c-Myc and Nanog) at 24h and 48h after transfection. 
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More than 90% of the fibroblasts were positive for Oct4, Sox2, Klf4, c-Myc and Nanog 
proteins 24h and 48h after transfection (Fig. 17). GFP and hTERT were expressed 
significantly less efficient compared to the other factors. The percentage of GFP positive 
cells was significantly (§p<0.01) lower compared to the other factors 72h after 
transfection (Fig. 17). The expression of hTERT-mRNA was significantly (*P< 0.01, +P< 
0.01) lower compared to the other factors at 24h, 48h and 72h after transfection (Fig. 
17).  
The above results were confirmed using mean fluorescent intensity (MFI) of positive 
cells. It was found that the protein level for all factors was maximal 24h and 48h after 
transfection and decreased significantly (**P< 0.01) 72h after transfection for Sox2, Klf4, 
c-Myc and Nanog (Fig. 18).  
 
Figure 18. Mean fluorescence intensity of reprogramming proteins. The mean fluorescence 
intensity (MFI) of positive cells represents the protein level for all factors at different time points 
after mRNA-transfection. The cells used for analysis were purple, green and yellow foreskin 
fibroblasts. Graphs represent means ± SEM. n=3. (**P< 0.01).  
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5.4.2 Nuclear localization of reprogramming proteins  
To confirm that the reprogramming proteins correctly localize as the endogenous 
protein, the mRNA-transfected cells were immune stained against Oct4, Sox2, c-Myc 
and Nanog proteins using immunocytochemistry 24h following transfection. The results 
demonstrated that each of the factors was robustly expressed and correctly localized to 
the nucleus (Fig. 19A). No reprogramming proteins were detected in non-transfected 
fibroblasts (Fig. 19B).  
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Figure 19. Nuclear localization of reprogramming proteins. A) Proteins of reprogramming 
factors-mRNA localized as the endogenous proteins in nucleolus of transfected cells 24h after 
transfection. B) Detection of reprogramming proteins in non-transfected cells. Both transfected 
and non-transfected cells were immunostained against Oct4, Sox2, c-Myc and Nanog proteins. 
Alexa fluor 488 used as secondary antibody. The cells used for immunostaining were yellow 
foreskin fibroblasts. Scale bars represent 100μm. 
 
5.5 Generation of iPS colonies using mRNA   
After the toxicity assessment of transfection reagents, cytotoxicity of mRNAs, and 
persistence of reprogramming proteins, we tried to investigate the ability of 
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reprogramming-mRNAs for generation of iPS cells. For this purpose, several human 
donor cells were transfected with different mRNA-factor combinations. In all instances 
the GFP-mRNA transfection was done to control the transfection condition. 
 
5.5.1 mRNA-transfection of different human donor cells 
For mRNA transfection ten different human donors were used. The results have been 
summarized in figure 20 and table 15. Among all of the donors, the human dermal 
fibroblasts from an old donor were so sensitive even to GPF-mRNA and no viable cells 
were observed after GFP-mRNA transfection. Therefore, this donor was further 
removed from the experiments. The same result was observed in one of the foreskin 
fibroblasts (donor: purple), and no GPF positive cells were detected under the 
microscope. Another foreskin fibroblasts (donor: yellow), were used only for the 
optimization of the experiments such as flow cytometry and ELISA and not for the 
generation of iPS cells.  
 
Table 15. mRNA transfection of different human donor cells. 
 
Donor  Factor combination  Cellular aggregates  No. of 
passage on 
MEFs 
*Amber 1 foreskin 
fibro. 
ONT, OSK, OSKMNT Yes/ for ONT & OSKMNT 
factor combinations  
5 
*Amber 2 foreskin 
fibro. 
ONT, OSK, OSKMNT Yes/ for ONT & OSK 
 factor combinations 
3 
**Brown foreskin fibro. ONT, OSK, OSKMNT Yes/ for OSK factor 
combination 
1 
**Pink foreskin fibro. ONT, OSK, OSKMNT Yes/ for OSKMNT factor 
combination 
1 
Red foreskin fibro. ONT, OSK, OSKMNT No   0 
Green foreskin fibro. ONT, OSK, OSKMNT No   0 
Eye lid fibro. ONT, OSK, OSKMNT No   0 
§RECs ONT, OSK, OSKMNT Yes/ for OSK factor 
combination 
0 
IMR90 fibro.  ONT, OSK, OSKMNT Yes/ for OSKMNT factor 
combination 
Over 37 
passages  
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Fibro. = fibroblasts 
RECs = renal epithelial cells 
Amber 1 & Amber 2 = same donor used for two different experiments  
*All of the factor combination formed colony-like structures but only the best colonies have been 
shown in figure 20. 
**Small cell aggregates were formed which grew very slowly and could not be passaged.  
§Small island-like structures were formed which grew very slowly and could not be passaged. 
 
The formation of cellular aggregates from mesenchymal to epithelial (MET) transition 
was not observed in all transfetced donor cells, and only five of them (amber 1, amber 
2, brown, pink, RECs and IMR90 fibro) formed such structures after 2-4 times 
transfections (Fig. 20 and table 15). However, not all of the cellular aggregates were 
stable, and only the aggregates generated from foreskin fibroblast (amber 1) and fetal 
fibroblast (IMR90) could be passaged several times on mouse embryonic fibroblasts 
(MEFs). For some of the donors (brown & pink) only small cell aggregates were formed 
which grew very slowly and could not be passaged more than once on MEFs. In case of 
RECs, repeated mRNA transfection caused the formation of small island-like structures 
and not cellular aggregates. The mentioned structures could not be pssaged on MEFs. 
The cellular aggregates generated from IMR90 fibroblasts showed the highest stability 
among other donor’s cellular aggregates thus they were used for different pluripotency 
characterization tests. Mostly, OSK and OSKMNT factor combinations could trigger 
cellular aggregates formation (Fig. 20 and table 15).  
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Figure 20. mRNA-transfection of different human donor cells. The pictures show cellular 
aggregates formation after repeated mRNA transfection of different donor cells (lower pictures). 
The upper pictures show GFP positive cells as control of transfection condition. The factor 
combinations used for repeated mRNA transfections were ONT, OSK & OSKMNT. ONT= Oct4, 
Nanog, hTERT. OSK = Oct4, Sox2, Klf4. OSKMNT = Oct4, Sox2, Klf4, c-Myc, Nanog, hTERT. 
Fibro. = fibroblasts. Amber 1 & Amber 2 = same donor used for two different experiments. RECs 
= renal epithelial cells. Scale bars represent 100μm.  
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5.5.2 Reprogramming of human fibroblasts using mRNA 
Since foreskin fibroblasts (amber) and IMR90 fibroblasts were the only donors formed 
stable cellular aggregates, for the establishment of stable mRNA-iPS cells we 
transfected them with mRNA-reprogramming factors using jetPEI, every 48h in a period 
of two weeks. The cells undergo MET transition and the morphological changes were 
observed during mRNA repeated transfections. Transformation of fibroblast morphology 
to a compact, epithelioid morphology was observed 4 days after the first transfection, 
followed by the emergence of typical hES cell-like colonies with tight morphology at day 
6. Well-defined border colonies appeared at day 8 and mature colonies with prominent 
nucleoli were visible at day 12 (Fig. 21). The derived colonies from two iPS cell lines 
(foreskin-mRNA-iPS and IMR90-mRNA-iPS) were selected and expanded on irradiated 
MEF cells (Fig. 21). Meanwhile, the reprogramming efficiency was calculated at the end 
of two weeks repeated transfections (day 13 post-transfection), and the results revealed 
0.09% efficiency for ONT and 0.06% efficiency for OSKMNT (Supplementary fig. 1). 
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Figure 21. Reprogramming of human fibroblasts using mRNA. Morphological changes 
observed during repeated transfections with jetPEI. The transfection condition was controlled 
with GFP-mRNA (left- lower picture). The arrows indicate the timing for repeated transfections 
with jetPEI. The images of schematic picture show human foreskin fibroblasts (Amber 1) on day 
of transfection (day 0), small clusters with more compacted morphology (epitheliod morphology) 
(day 4), observation of first mRNA-iPS colony-like structure (day 6), morphology of mRNA-iPS 
colony with defined borders (day 8), and appearance of mature mRNA-iPS colony (day 12) 
(upper pictures). The right- lower pictures represent HFF-mRNA-iPS and IMR90-mRNA-iPS 
colonies expanded on irradiated MEF cells. HFF = human foreskin fibroblasts (donor: Amber 1). 
HFF-mRNA-iPS = mRNA iPS cells derived from human foreskin fibroblasts (donor: Amber 1). 
IMR90-mRNA-iPS = mRNA iPS cells derived from human IMR90 fibroblasts. Scale bars 
represent 100μm. 
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5.5.3 Establishment of mRNA-iPS cell lines 
To establish the mRNA-iPS cells lines, the poor quality iPS colonies were taken from 
the culture dishes, since they might affect the quality of undifferentiated colonies and 
switch them to differentiate spontaneously. The morphology of poor and high quality iPS 
cells has been shown in figure 22. The high quality iPS cells displayed densely packed 
defined borders colonies containing small round cells with large nuclei, small amount of 
cytoplasm, high ratio of nucleus to cytoplasm, and tight intercellular contacts, whereas 
the poor quality iPS colonies did not show such features, for instance they displayed the 
colonies with not defined borders which lost the network of the cells inside (Fig. 22). 
Afterward, the high quality iPS colonies were chosen, and the undifferentiated parts 
inside of colonies were picked up manually while the differentiated parts of the colonies 
in the border were removed and not transferred on the new MEFs (Fig. 22).  
 
Figure 22. Mechanical passage of iPS cells. The upper pictures represent the morphology of 
poor and high quality iPS cells on MEFs. The example pictures shown here are IMR90-mRNA-
iPS colonies. The lower pictures show manual splitting of human iPS cells for selection of 
undifferentisted clones. A) iPS colonies cultured on mouse feeder cells (MEFs). B) The iPS 
colonies are manually cut into small pieces with nearly equal size. C, D & E) select the 
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undifferentiated parts of colonies and lifted them up to transfer onto new irradiated MEFs. iPSCs 
= iPS cells. Scale bars represent 100μm. 
 
5.6 Gene expression pattern in donor fibroblasts formed cellular 
aggregates 
The gene expression profile of different donor cells was analyzed using RT-PCR to see 
whether there is a pattern in donors formed aggregates. The results of RT-PCR 
demonstrated low expression of pluripotency genes Oct4, Nanog and Sox2 in donor 
cells, however, Klf4 was highly expressed in the donors which formed cellular 
aggregates (Amber, Brown, and IMR90) (Fig. 23).  
 
Figure 23. Gene expression analysis of different donor cells. Expression of pluripotency-
associated genes in different human donor cells analyzed by RT-PCR. 36B4 was used as 
housekeeping gene. Fibro. = fibroblasts. IMR90 1 fibro. & IMR90 2 fibro. = same donor used for 
two different experiments. This data is generated by Dr. Claire Fabian in Fraunhofer Institute for 
Cell Therapy and Immunology (IZI) Leipzig.   
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5.7 Pluripotency characterization of mRNA-iPS colonies 
  
5.7.1 Teratoma assay 
In vivo differentiation potential of mRNA-iPS colonies was confirmed by teratoma 
formation following IMR90-mRNA-iPS injection into immunodeficient mice. The results 
of hematoxylin-eosin staining showed cell types of the three germ layers in teratoma 
sections (Fig. 24).  
 
 
Figure 24. Teratoma formation assay. The pictures show hematoxylin-eosin staining of 
teratoma sections derived from IMR90-mRNA-iPS colonies (passage 8). IMR90-mRNA-iPS = 
mRNA iPS cells derived from human IMR90 fibroblasts.  
 
5.7.2 Immunostaining  
To confirm the expression of pluripotency markers in mRNA-iPS cells, the foreskin-
mRNA-iPS colonies (donor: Amber 1) and their parental fibroblasts (Amber 1) were 
immunstained with the antibodies against Oct4, Nanog and Tra-1-60. The results of 
immunostaining showed the expression of pluripotency markers in mRNA-iPS colonies 
at passage 5 compared to their donor fibroblasts (Fig. 25). Furthermore, nuclear 
localization of Oct4 and Nanog was confirmed (Fig. 25).  
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Figure 25. Immunostaining for pluripotency markers. mRNA-iPS colonies and donor 
fibroblasts immunostained with pluripotency markers. The pictures show the expression of 
pluripotency markers in foreskin-mRNA-iPS colonies (donor: Amber 1). Scale bars represent 
100 µm. 
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5.7.3 Karyotype analysis 
To determine possible chromosomal aberrations, GTG-banding analysis was 
performed. The results have been summarized in figure 26 and table 16. In general, the 
results of karyotype analyses revealed similar chromosomal aberrations in IMR90-
mRNA-iPS cells as compared to parental IMR90 fibroblasts, and more structural 
aberrations were not observed upon reprogramming (Table 16).  
 
Table 16. Karyotype analysis of mRNA-iPS cells and the parental fibroblasts.  
 IMR90 fibroblast IMR90-mRNA-iPS 
Analyzed metaphases  25 20 
Numerical chromosomal 
aberrations: 
23 (total) 17 (total) 
 Hyperdiploidy 3 (49-54 chromosomes) 9 (48-55 chromosomes) 
Hypotriploidy 13 (58-68 chromosomes) 6 (60-68 chromosomes) 
Triploidy 3 (69 chromosomes) 1 (69 chromosomes) 
Hypertriploidy 1 (71 chromosomes) 0 
Hypotetrapoidy (not 
complete) 
1 (68 chromosomes) 1 (61 chromosomes) 
Hypertetraploidy 1 (103 chromosomes) 0 
Hypohexaploidy 1 (128 chromosomes) 0 
Structural chromosomal 
aberrations: 
37 (total) 25 (total) 
 Recurrent structural 
chromosomal 
aberrations 
t(1;2)(q21;?), t(1;15)(q42;?), 
del(2)(q21), t(3;12)(p11;?), 
t(5;15)(p11;?), 
t(10;3;4)(q11;?;?), 
t(13;13)(q10;q10) 
t(1;2)(q21;?), t(1;15)(q42;?), 
t(13;13)(q10;q10),  
t(20;X)(q13;?) 
 
The total analyzed metaphases for IMR90 fibroblasts were 25 and for IMR90-mRNA-
iPS cells were 20. The parental IMR90 fibroblasts (passage 14) displayed numerical 
chromosomal aberrations in 23 out of 25 metaphases. These numerical chromosomal 
aberrations include hyperdiploidy (3 out of 23), hypotriploidy (13 out of 23), triploidy (3 
out of 23), hypertriploidy (1 out of 23), hypotetrapoidy (1 out of 23), hypertetraploidy (1 
out of 23) and hypohexaploidy (1 out of 23). However, IMR90-mRNA-iPS cells (passage 
37) showed a trend to reduce numerical chromosomal aberrations (Fig. 26 and table 
16).  
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Figure 26. Karyotype analysis of mRNA-iPS cells. The chromosomal GTG-banding analysis 
of IMR90-mRNA-iPS cells and IMR90 parental fibroblasts are shown. The total analyzed 
metaphases for IMR90 fibroblasts are 25 and for IMR90-mRNA-iPS cells are 20. The pictures 
show presence of hyperdipoloidy and hypotetraploidy in both IMR90 fibroblasts and IMR90-
mRNA-iPS cells. The data regarding to sky analyses have not been shown in the figure. This 
data is generated by Dr. Heidrun Holland in Translational Centre for Regenerative Medicine 
(TRM) in University of Leipzig. 
 
Indeed, some of the numerical chromosomal aberrations such as hypertriploidy, 
hypertetraploidy and hypohexaploidy were not observed anymore in IMR90-mRNA-iPS 
cells (table 16). Among 25 analyzed metaphases, the IMR90 fibroblasts demonstrated 
37 total structural chromosomal aberrations, whereas IMR90-mRNA-iPS cells revealed 
25 total structural chromosomal aberrations among 20 analyzed metaphases (table 16). 
Moreover, we could observe 7 recurrent structural chromosomal aberrations in IMR90 
fibroblasts while IMR90-mRNA-iPS cells showed only 4 structural chromosomal 
aberrations (table 16). Most of the structural chromosomal aberrations were 
translocation or deletion.  
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5.7.4 Analysis of pluripotency associated genes using qRT-PCR 
mRNA-iPS-colonies were passaged at least 3 times before the analysis of pluripotency- 
related genes by qRT-PCR. Using the non-integrating mRNA-reprogramming approach 
offers the advantage that the mRNA will degrade after the reprogramming procedure 
and does not interfere with analyzing mRNA-expression levels. In foreskin-mRNA-iPS 
colonies, Nanog, Oct4 and Klf4 were abundantly expressed compared to the foreskin 
donor fibroblasts which showed no Nanog and very low expression of Oct4 and Klf4 
(Fig. 27). However, the parental foreskin fibroblasts demonstrated basal level of c-Myc 
expression. While the corresponding mRNA-iPS cells showed lower expression level of 
c-Myc. 
 
 
Figure 27. Pluripotency associated genes in foreskin-mRNA-iPS cells analyzed by qRT-
PCR. Expression of pluripotency-related genes in foreskin-mRNA-iPS colonies (donor: amber 1 
& amber 2) at passage 3 and 5 and the parental foreskin fibroblasts (donor: amber 1 & amber 2) 
at passage 10. 36B4 was used as housekeeping gene. HFF = human foreskin fibroblasts. HFF 
donor #1 = human foreskin fibroblasts derived from donor fibroblast #1 (donor: amber 1). HFF 
donor #2 = human foreskin fibroblasts derived from donor fibroblast #2 (donor: amber 2). HFF-
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mRNA-iPS = mRNA iPS cells derived from human foreskin fibroblasts. HFF-mRNA-iPS # 1 = 
mRNA-iPS cells derived from HFF donor # 1 (donor: amber 1). HFF-mRNA-iPS # 2 = two 
different mRNA-iPS cells derived from HFF donor # 2 (donor: amber 2). HFF-mRNA-iPS cells # 
1 were generated by ONT factor combination. HFF-mRNA-iPS cells # 2 were generated by OSK 
factor combination. This data is generated by Dr. Claire Fabian in Fraunhofer Institute for Cell 
Therapy and Immunology (IZI) Leipzig.   
 
In contrast IMR90 fibroblasts already had a high basic expression of Oct4, Sox2 and 
Klf4. In IMR90-mRNA-iPS colonies the expression of Sox2 and Oct4 increased upon 
reprogramming. Klf4 expression went down at early passages but increased at later 
passages again. Like in the foreskin fibroblasts, Nanog expression was induced in the 
IMR90-mRNA-iPS cells and increased with higher passages (Fig. 28). 
 
Figure 28. Pluripotency associated genes in IMR90-mRNA-iPS cells analyzed by qRT-
PCR. Expression of pluripotency-related genes in IMR90-mRNA-iPS colonies (passage 3 & 
passage 36) and IMR90 parental fibroblasts (passage 6). 36B4 was used as housekeeping 
gene. IMR90-mRNA-iPS = mRNA iPS cells derived from human IMR90 fibroblasts. P.3= 
passage 3. P.36= passage 36. IMR90-mRNA-iPS cells were generated by OSKMNT factor 
combination. This data is generated by Dr. Claire Fabian in Fraunhofer Institute for Cell Therapy 
and Immunology (IZI) Leipzig.   
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5.8 Generation of human viral-iPS cells 
 
5.8.1 Transduction of human fibroblasts using viral vectors 
For generation of human viral-iPS cells, the human foreskin fibroblasts (donor: ffle13), 
and human Huntington dermal fibroblasts (donors: SP & WC1) were transduced with 
viral particles containing reprogramming factors. The reprogramming factors used for 
transduction were OSKMNT. Approximately one week after transduction, morphological 
changes from mesenchymal to epithelial (MET) transition were observed. Furthermore, 
the cells from all three samples formed granulated colony-like structures two weeks (13 
days) after transduction (Fig. 29). The granulated colonies were then selected and 
expanded on irradiated MEF cells for the establishment of stable viral-iPS cell lines.  
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Figure 29. Generation of human viral-iPS cells using viral vectors. A schematic 
representation of viral production and transduction (upper part of the picture). The human 
fibroblasts were transduced with viral particles contain reprogramming factors (the middle 
picture). The human fibroblasts used for transduction were human foreskin fibroblasts (donor: 
ffle13), and human Huntington dermal fibroblasts (donors: SP & WC1). The HDF were derived 
from two different donors. The granulated colonies were observed in all of the samples two 
weeks (13 days) after transduction (lower pictures). The reprogramming factors used for 
transduction were OSKMNT. The Scale bars represent 100μm. 
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5.8.2 Establishment of viral-iPS cell lines 
Following transfer of granulated colonies on MEFs, the poor quality iPS colonies were 
removed from the culture dishes and the high quality undifferentiated colonies were 
selected for the establishment of viral-iPS cell lines. As shown in figure 30, the high 
quality viral-iPS colonies showed well-defined borders, small round cells with large 
nuclei, high ratio of nucleus to cytoplasm, and tight intercellular contacts, while poor 
quality iPS colonies lost the defined borders and showed the large cells inside of 
colonies. The high quality iPS colonies from all three cell lines; foreskin-derived-iPS 
cells (ffle13-iPS, donor: ffle13) and two different Huntington-derived-iPS cells (WC1 & 
SP-iPS donors: WC1 & SP); were picked and expanded on irradiated MEFs for several 
passages in order to further characterization (Fig. 30).  
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Figure 30. Establishment of viral-iPS cell lines. The upper pictures represent the morphology 
of poor and high quality iPS cells on MEFs. The example pictures shown here are Huntington-
derived-iPS colonies (SP-iPS cells, donor: SP). The high quality viral-iPS colonies from all three 
cell lines were picked and expanded on irradiated MEFs. The lower pictures show different 
passages of three viral-iPS cell lines on MEFs. The viral-iPS cell lines shown in the pictures are 
foreskin-derived-iPS cells (ffle13-iPS, donor: ffle13), two different Huntington-derived-iPS cells 
(WC1 & SP-iPS, donors: WC1 & SP). Scale bars represent 100μm. 
 
5.9 Pluripotency characterization of viral-iPS colonies  
 
5.9.1 Teratoma assay 
In order to confirm the in vivo differentiation potential of viral-iPS cells, the three cell 
lines including foreskin-derived-iPS cells (ffle13-iPS, donor: ffle13) and two different 
Huntington-derived-iPS cells (WC1 & SP-iPS donors: WC1 & SP) were injected to 
5. Results 
92 
 
immunodeficient mice. The results revealed formation of teratomas for all three cell 
lines. The hematoxylin-eosin staining of teratoma sections revealed the presence of cell 
types related to three germ layers in teratoma sections derived from all three cell lines 
(Fig. 31).  
 
Figure 31. Pluripotency characterization of viral-iPS colonies using teratoma formation 
assay. The pictures show hematoxylin-eosin staining of teratoma sections formed from injection 
of three different viral-iPS colonies into immunodeficient RAG2-/-γc-/- mice. The viral-iPS cells 
used for teratoma assay were foreskin-derived-iPS cells (ffle13-iPS, donor: ffle13) and two 
different Huntington-derived-iPS cells (WC1 & SP-iPS, donors: WC1 & SP). Tissue derivatives 
indicative of the three germ lineages (ectoderm, mesoderm, and endoderm) were observed.  
 
5.9.2 Immunostaining 
To assess the expression of pluripotency markers in viral-iPS cells, the three cell lines 
including foreskin-derived-iPS cells (ffle13-iPS, donor: ffle13) and two different 
Huntington-derived-iPS cells (WC1 & SP-iPS donors: WC1 & SP) were immunostained 
for the known pluripotency markers. The results demonstrated the nuclear expression of 
pluripotency markers Nanog and Oct4 in all three viral-iPS cells (Fig. 32). 
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Figure 32. Pluripotency characterization of viral-iPS colonies using immunostaining. The 
human viral-iPS cells immunostained with known pluripotency markers. The pictures show the 
expression of nuclear pluripotency markers Nanog & Oct4 (green) in foreskin-derived-iPS cells 
(ffle13-iPS, donor: ffle13) and two different Huntington-derived-iPS cells (WC1 & SP-iPS, 
donors: WC1 & SP). As shown in each figure, the DNA in the cell nucleus stained with DAPI 
(blue) as an overlay. Scale bars represent 100μm. 
 
5.10 SOM expression portraits 
To show the reprogramming process and partially versus fully reprogrammed cells, 
SOM expression analysis of the data was performed. The SOM analysis will help us to 
get insights into comprehensive and individual structures of the expression landscapes. 
We trained a SOM using microarray expression data of eight samples. The samples 
include 1) human foreskin fibroblasts (HFF, donor: Brown), 2) foreskin-derived-mRNA-
iPS cells (HFF-mRNA-iPS, donor: Brown), 3) IMR90 fibroblasts, 4) IM90-derived-
mRNA-iPS cells (IMR90-mRNA-iPS, donor: IMR90 fibroblasts), 5) foreskin-derived-viral-
iPS cells (HFF-viral-iPS, donor: ffle13), 6) Huntington-derived-viral-iPS cells 
5. Results 
94 
 
(Huntington-viral-iPS, donor: WC1), 7) hES cells # 1& 2 (two biological replicates of hES 
cells as controls, H9 cell line). The method describes the individual expression 
landscape of each sample by mosaic images using a resolution of 30 x 30 pixels per 
square. The generated portraits are similar within the groups reflecting homogeneity of 
their expression landscapes (Fig. 33). Visual assessment of the generated portraits 
demonstrated two dominant spots of over-expressed (i.e. red) in the bottom-left and top-
right corners of the map for fibroblast and stem cells, respectively. The two viral-iPS cell 
lines (HFF-viral-iPS & Huntington-viral-iPS) as well as IMR90-mRNA-iPS cells exhibited 
the portraits and molecular phenotypes similar to hES cells (Fig. 33). As we expected, 
the portraits of foreskin fibroblasts did not resemble hES cells portraits. The IMR90 
fibroblasts, however, revealed some hES cell signatures.  
 
 
Figure 33. SOM expression portraits. SOM portraying of the microarray expression resulted 
from eight different samples. The samples used contain 1) human foreskin fibroblasts (HFF, 
donor: Brown), 2) foreskin-derived-mRNA-iPS cells (HFF-mRNA-iPS, donor: Brown), 3) IMR90 
fibroblasts, 4) IM90-derived-mRNA-iPS cells (IMR90-mRNA-iPS, donor: IMR90 fibroblasts), 5) 
foreskin-derived-viral-iPS cells (HFF-viral-iPS, donor: ffle13), 6) Huntington-derived-viral-iPS 
cells (Huntington-viral-iPS, donor: WC1), 7) hES cells # 1& 2 (two biological replicates of hES 
cells as controls, H9 cell line). Landscapes reveal two distinct signatures which can be attributed 
5. Results 
95 
 
to fibroblasts and stem cells. Areas referring to over-expressed genes (with respect to the mean 
expression of each gene in all samples studied) are shown in red whereas under-expressed 
genes are colored in blue. 
 
The results of SOM expression portraits were confirmed with a phylogenetic clustering 
approach which analyzes the similarity of the samples in an unsupervised fashion (Fig. 
34). The results of phylogenetic tree revealed clearly separation of the samples with 
fibroblast-like and hES cell-like signatures (Fig. 34). The samples with fibroblast and 
partially reprogrammed signatures remained in the right part of the tree, while, the ones 
with stem cell signatures accumulated in the left part of the phylogenetic tree (Fig. 34). 
As shown in figure 33, the foreskin fibroblasts (HFF) and foreskin-derived-mRNA-iPS 
cells (HFF-mRNA-iPS) remained in right branch (fibroblast-like signature), whereas the 
two viral-iPS cell lines (HFF-viral-iPS & Huntington-viral-iPS) as well as IMR90-mRNA-
iPS were collected in left branch (hES cell-like signature) of phylogenetic tree (Fig. 34). 
The IMR90 fibroblasts accumulated in left branch and showed some hES cell-like 
signatures.  
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Figure  34. Sample clustering using phylogenic tree. Sample clustering shows two separate 
branches containing fibroblast-like and hES cell-like signatures. Euclidean distances between 
pairs of samples are displayed in scale. The samples used for clustering were similar to the 
samples used for SOM expression portraits. 
 
5.11 Aging analysis of iPS cells 
  
5.11.1 Telomere length  
To address whether telomeres are elongated upon reprogramming, the telomere length 
of three different viral-iPS cell lines were measured by qRT-PCR, and the results were 
compared to their corresponding parental fibroblasts. The samples used for analysis 
contained foreskin-derived-iPS cells (ffle13-iPS, donor: ffle13) and two different 
Huntington-derived-iPS cells (WC1 & SP-iPS, donors: WC1 & SP). The results revealed 
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a trend for elongation of telomere in viral-iPS cells compared to their parental donor 
fibroblasts (Fig. 35). The similar pattern was observed for telomere length of all three 
cell lines, and in all cases, telomere length increased upon reprogramming compared to 
their donor fibroblasts. The high passage number did not interfere with telomere 
elongation since the telomere length was observed to be elevated even with high 
passage number (Fig. 35). However, the foreskin-derived-iPS cells displayed a 
tendency for the longer telomere compared to the Huntington-derived-iPS cells (Fig. 
35). 
 
 
Figure 35. Telomere length in viral-iPS cells analyzed by qRT-PCR. The graph shows 
telomere length analysis of foreskin-derived-iPS cells (ffle13-iPS, donor: ffle13) and two different 
Huntington-derived-iPS cells (WC1 & SP-iPS, donors: WC1 & SP) compared to their parental 
fibroblasts. The sample used at the following passages for the telomere length analysis: foreskin 
fibroblast (donor: ffle13) = passage 12, foreskin-derived-iPS cells (ffle13-iPS, donor: ffle13) = 
passage 44, Huntington dermal fibroblast (donor: SP) = passage 10, Huntington-derived-iPS 
cells (SP-iPS, donor: SP) = passage 45, Huntington dermal fibroblast (donor: WC1) = passage 
11, and Huntington-derived-iPS cells (WC1-iPS, donor: WC1) = passage 44. The telomere 
length of each sample was normalized to the telomere length of Hela cells.  
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To examine the pattern of telomere length upon differentiation of iPS cells to fibroblasts, 
the telomere length of foreskin-derived-iPS cells (ffle13-iPS, donor: ffle13), parental 
foreskin fibroblasts (donor: ffle13) and foreskin-iPS-derived fibroblasts (iPS-DF) were 
measured by qRT-PCR. A tendency for telomere elongation was observed upon 
reprogramming (confirmation of telomere length analysis for the three iPS cell lines 
used above), however the telomere length shortened during redifferentiation of iPS cells 
to fibroblasts (Fig. 36). Although the iPS-derived fibroblasts (iPS-DF) exhibited 
shortened telomere compare to the iPS cells, they displayed a tendency for longer 
telomere compared to input parental fibroblasts (Fig. 36).  
 
 
 
Figure 36. Telomere length analysis upon differentiation of viral-iPS cells. The graph 
shows telomere length of parental foreskin fibroblasts (donor: ffle13), foreskin-derived-iPS cells 
(ffle13-iPS, donor: ffle13) and foreskin-iPS-derived fibroblasts (ffle13-iPS-DF) analyzed by qRT-
PCR. The foreskin-derived-iPS cells used at passage 44, parental foreskin fibroblasts used at 
passage 12, and foreskin-iPS-derived fibroblasts used at passage 4. The telomere length of 
each sample was normalized to the telomere length of Hela cells.  
 
5. Results 
99 
 
The foreskin-derived-iPS cells were used as an example to assess the telomere length 
pattern upon differentiation. Furthermore, the fibroblast differentiation was chosen since 
it was the simplest type of differentiation.  
 
5.11.2 Mitochondrial alterations 
 
5.11.2.1 Mitochondrial morphology and localization in viral-iPS cells  
In order to assess the mitochondrial morphology, localization and distribution, the donor 
fibroblasts, viral-iPS cells and iPS-derived fibroblasts, were stained with Mitotracker 
deep red. The samples used for analysis contained foreskin fibroblasts (donor: ffle13), 
foreskin-derived-iPS cells (ffle13-iPS, donor: ffle13), foreskin-iPS-derived fibroblasts 
(ffle13-iPS-DF, donor: ffle13), Huntington dermal fibroblasts (donors: WC1 & SP), 
Huntington-derived-iPS cells (WC1 & SP-iPS, donors: WC1 & SP) and Huntington-iPS-
derived fibroblasts (WC1 & SP- iPS-DF, donors: WC1 & SP). The results suggested a 
change in mitochondrial feature, from tubular morphology in parental donor fibroblasts 
to round-shaped ones in iPS cells (Fig. 37). This pattern was observed in all three iPS 
cell lines and their parental fibroblasts. Upon differentiation of iPS cells to fibroblast-like 
cells, morphology of mitochondria re-acquired tubular morphology comparable to 
parental input fibroblasts (Fig. 37). Such pattern was similar in the derived fibroblasts 
from all three iPS cell lines. Nevertheless, some round-shaped mitochondria persisted 
in iPS-derived fibroblasts from all three cell lines (Fig. 37).  
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Figure 37. Mitochondrial morphology in viral-iPS cells and the differentiated 
counterparts. The pictures show the mitochondrial morphology of donor fibroblasts, viral-iPS 
cells, and iPS-DF following treatment with Mitotracker deep red. The viral-iPS cell lines used for 
evaluation of mitochondrial morphology were foreskin-derived-iPS cells (ffle13-iPS, donor: 
ffle13) and two different Huntington-derived-iPS cells (WC1 & SP-iPS, donors: WC1 & SP). 
Scale bars represent 100μm.  
 
With respect to mitochondrial localization and distribution, the results revealed that in 
fibroblast cells the organelles were distributed in cytoplasm (donor fibroblasts and iPS-
derived fibroblasts), while in iPS cells, the mitochondria were mostly localized around 
the nuclei (peri-nuclear structures) (Supplementary fig. 2). This pattern was similar in all 
three iPS cell lines and their differentiated counterparts.  
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5.11.2.2 Mitochondrial function in viral-iPS cells  
The functional properties of mitochondria were assessed using the measurement of 
ROS production level and mitochondrial membrane potential. The samples used for 
analysis contained foreskin fibroblasts (donor: ffle13), foreskin-derived-iPS cells (ffle13-
iPS, donor: ffle13), foreskin-iPS-derived fibroblasts (ffle13-iPS-DF, donor: ffle13), 
Huntington dermal fibroblasts (donors: WC1 & SP), Huntington-derived-iPS cells (WC1 
& SP-iPS, donors: WC1 & SP) and Huntington-iPS-derived fibroblasts (WC1 & SP- iPS-
DF, donors: WC1 & SP).  
For ROS production measurement, the cells were treated with H2DCFDA, and the level 
of ROS production was analyzed by flow cytometry. The results revealed a trend for 
higher level of ROS in parental fibroblasts compared to the iPS cells (Fig. 38). Indeed, 
the foreskin fibroblasts (donor: ffle13) and Huntington dermal fibroblasts (donor: SP) 
displayed the highest ROS level among other samples (Fig. 38). The three iPS cell lines 
showed a tendency for lower ROS production compared to other samples. Regarding to 
iPS-derived fibroblasts, they mainly showed similar trend to iPS cells.  
 
Figure 38. ROS production. Comparison of produced ROS level in viral-iPS cells and their 
corresponding fibroblasts. The level of produced ROS was measured after treatment of the cells 
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with H2DCFDA the samples used for analysis were foreskin fibroblasts (donor: ffle13), foreskin-
derived-iPS cells (ffle13-iPS, donor: ffle13), foreskin-iPS-derived fibroblasts (ffle13-iPS-DF, 
donor: ffle13), Huntington dermal fibroblasts (donors: WC1 & SP), Huntington-derived-iPS cells 
(WC1 & SP-iPS, donors: WC1 & SP) and Huntington-iPS-derived fibroblasts (WC1 & SP- iPS-
DF, donors: WC1 & SP). Data were presented as percentage of fluorescent intensity compared 
to donor fibroblasts which set as a value = 100. 
 
For mitochondrial membrane potential, the cells were treated with membrane-sensitive 
dye JC-1 and the results were analyzed by flow cytometry. The results exhibited a trend 
for lower membrane potential in iPS cells (remaining of JC-1 in the monomeric green-
fluorescent conformation) compared to their parental donor fibroblasts (Fig. 39). This 
trend was observed in all three iPS cell lines. The highest mitochondrial membrane 
potential was related to the donor fibroblasts in all three cell lines (Fig. 39). The iPS-
derived fibroblasts however, showed different patterns of mitochondrial membrane 
potential. For instance, the foreskin-iPS-derived fibroblasts (ffle13-iPS-DF, donor: ffle13) 
showed mitochondrial membrane potential comparable to foreskin donor fibroblasts, 
while Huntington-iPS-derived fibroblasts (SP-iPS-DF) displayed mitochondrial 
membrane potential even lower than the corresponding iPS cells (Fig. 39). Whereas, 
Huntington-iPS-derived fibroblasts from another Hungtington donor (WC1-iPS-DF) 
revealed mitochondrial membrane potential comparable to their corresponding iPS cells 
(Fig. 39). 
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Figure 39. Mitochondrial membrane potential. Comparison of mitochondrial membrane 
potenial in viral-iPS cells and their corresponding fibroblasts. The mitochondrial membrane 
potential (MMP) was measured after treatment of the cells with membrane-sensitive dye JC-1. 
The samples used for analysis contained foreskin fibroblasts (donor: ffle13), foreskin-derived-
iPS cells (ffle13-iPS, donor: ffle13), foreskin-iPS-derived fibroblasts (ffle13-iPS-DF, donor: 
ffle13), Huntington dermal fibroblasts (donors: WC1 & SP), Huntington-derived-iPS cells (WC1 
& SP-iPS, donors: WC1 & SP) and Huntington-iPS-derived fibroblasts (WC1 & SP- iPS-DF, 
donors: WC1 & SP).  Data were presented as percentage of fluorescent intensity compare to 
donor fibroblasts which set as a value = 100.  
 
5.11.3 DNA damage response in viral-iPS cells 
To assess the DNA damage response, the parental donor fibroblasts and viral-iPS cells 
were exposed to H2O2, and then the DNA damage was measured using come assay. 
The samples used for analysis were foreskin fibroblasts (donor: ffle13), foreskin-
derived-iPS cells (ffle13-iPS, donor: ffle13), Huntington dermal fibroblasts (donors: WC1 
& SP) and Huntington-derived-iPS cells (WC1 & SP-iPS, donors: WC1 & SP). The 
results revealed the existence of comets with small heads and large, broad tails 
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(hedgehog comets), representative of apoptosis, more in iPS cells than their parental 
fibroblasts (Fig. 40). 
 
Figure 40. DNA damage visualized with comet assay. The pictures show the comets of viral 
iPS cells and their parental fibroblasts before (control) and after (30 min) incubation with H2O2. 
The samples used for come assay were foreskin fibroblasts (donor: ffle13), foreskin-derived-iPS 
cells (ffle13-iPS, donor: ffle13), Huntington dermal fibroblasts (donors: WC1 & SP) and 
Huntington-derived-iPS cells (WC1 & SP-iPS, donors: WC1 & SP).  
 
In general, all three iPS cell lines showed less basal level of DNA damage compared to 
their parental fibroblasts (Fig. 41). However, the amount of basal DNA damage was 
lower in foreskin-derived-iPS cells when compared to Huntington-derived-iPS cells (Fig. 
41). The same pattern was observed when the cells were exposed to H2O2 reagent. The 
iPS cells from all three cell lines showed fewer amounts of DNA damage after treatment 
with H2O2 when compared to their parental fibroblasts (Fig. 41). Likewise, the foreskin-
derived-iPS cells exhibited less DNA damage rather than the Huntington-derived-iPS 
cells (WC1 & SP-iPS cells, donors: WC1 & SP) when exposed to H2O2 (Fig. 41). 
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Furthermore, the Huntington dermal fibroblasts showed pre-existing DNA damage 
(basal level of DNA damage) compared to foreskin fibroblasts.  
 
 
Figure 41. DNA damage response in viral-iPS cells. The graph shows quantification of the 
DNA percentage in comet tails in viral-iPS cells and parental fibroblasts before and after 
treatment with 100 mM H2O2. The percentage of DNA in tail represents the amount of damage. 
The samples used for analysis were foreskin fibroblasts (donor: ffle13), foreskin-derived-iPS 
cells (ffle13-iPS, donor: ffle13), Huntington dermal fibroblasts (donors: WC1 & SP) and 
Huntington-derived-iPS cells (WC1 & SP-iPS, donors: WC1 & SP). The sample size is 100000 
cells for each cell type.  
 
5.12 Future perspective for aging analysis using mRNA-iPS cells  
The aging analyses have been so far reported only for viral-iPS cells and not for mRNA-
iPS cells. The initial plan of this project was to analysis of aging signatures first on viral-
iPS cells and then application and comparison of the resulted data to mRNA-iPS cells. 
Thus, some preliminary studies for aging analysis of mRNA-iPS cells were performed. 
The aging analysis of mRNA-iPS cells have not been reported so far by the other 
groups and this is the first report of such analysis in mRNA-iPS cells.  
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5.12.1 Mitochondrial morphology in mRNA-iPS cells 
For the assessment of mitochondrial morphology, the IMR90-mRNA-iPS cells and the 
parental IMR90 fibroblasts were stained with Mitotracker deep red. We could not 
observe a clear change in mitochondrial morphology from tubular to round-shaped ones 
upon mRNA-reprogramming like what we observed in viral-iPS cells (Fig 37 and Fig. 
42). Indeed, the round-shaped mitochondria were also observed in IMR90 fibroblasts. 
However, the fluorescent intensity of Mitotracker deep red was more in IMR90-mRNA-
iPS cells compared to IMR90 fibroblasts (Fig. 42).  
 
 
Figure 42. Mitochondrial morphology in mRNA-iPS cells. The pictures show the 
mitochondrial morphology of IMR90-mRNA-iPS cells and IMR90 parental fibroblasts. The cells 
were treated with Mitotracker deep red. Scale bars represent 100μm.  
 
 
 
5.12.2 Mitochondrial function in mRNA-iPS cells 
The functional analysis of mitochondria in mRNA-iPS cells were assessed using the 
measurement of ROS production level and mitochondrial membrane potential.  
For measurement of produced ROS, the IMR90-mRNA-iPS cells and the parental 
IMR90 fibroblasts were treated with H2DCFDA, and the level of ROS production was 
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analyzed by flow cytometry. The results demonstrated significantly (*P<0.050) lower 
ROS production in IMR90-mRNA-iPS cells compared to their IMR90 parental fibroblasts 
(Fig. 43).  
 
Figure 43. ROS production in mRNA-iPS cells. Comparison of produced ROS level in IMR90-
mRNA-iPS cells and IMR90 parental fibroblasts. The cells were treated with H2DCFDA. Graphs 
represent means ± SEM. n=2. *P< 0.05. Data were presented as percentage of fluorescent 
intensity compared to donor fibroblasts which set as a value = 100. 
 
For the measurement of mitochondrial membrane potential, the IMR90-mRNA-iPS cells 
and the parental IMR90 fibroblasts were treated with membrane-sensitive dye JC-1 and 
the results were analyzed by flow cytometry. The results revealed significant (*p<0.050) 
lower membrane potential in IMR90-mRNA-iPS cells than IMR90 fibroblasts (Fig. 44).  
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Figure 44. Mitochondrial membrane potential in mRNA-iPS cells. Comparison of 
mitochondrial membrane potenial in IMR90-mRNA-iPS cells and IMR90 parental fibroblasts. 
The MMP was measured after treatment of the cells with membrane-sensitive dye JC-1. Graphs 
represent means ± SEM. n=2. *P< 0.05. Data were presented as percentage of fluorescent 
intensity compared to donor fibroblasts which set as a value = 100. 
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6. Discussion
Mature somatic cells can be restored to a pluripotent state through the exogenous
expression of four transcription factors Oct4, Sox2, Klf4, and c-Myc. The resulting cells
are termed induced pluripotent stem (iPS) cells. The ability to derive iPS cells from
diseased and healthy donors have made iPS cells a valuable tool for in vitro disease
modeling, drug discovery and may potentially serve as an unlimited source of cells for
regenerative medicine. However, most of the iPS cells have been generated by
retroviral vectors which raise concerns of viral integration into the genome and
continued expression of potentially oncogenic proteins. These concerns are particularly
important when considering clinical translation. Recently, footprint-free iPS cells have
been generated through repeated transfection of mRNA encoding reprogramming
factors. mRNA-based reprogramming provides plenty of advantages which emphasize
the significance of such technology for translational research. The ability to maintain
high expression levels of reprogramming proteins without genetic manipulation, in vivo
expression of therapeutically active proteins and lineage conversion highlight the role of
mRNA-encoding factors for regenerative medicine and beyond. However, mRNA-based
reprogramming has not yet been used routinely, and some hurdles must be overcome
to enable mRNA to be used widely for successful cellular reprogramming. Hurdles such
as 1) deficiency for scalable production of in vitro transcribed RNA, 2) immune response
activation following mRNA transfection, 3) severe mRNA cytotoxicity, and 4) short-term
existence of mRNA and mRNA-mediated proteins within the cells, must be eliminated to
generate stable mRNA-iPS cells and widespread utility of mRNA for successful
reprogramming.
In this thesis, the goal was to generate stable mRNA-iPS cells by overcoming those
limitations to enable mRNA to be used reliably for cellular reprogramming.
6.1 Robust production of in vitro transcribed RNA
In order to use mRNA-iPS cells for future translational research, therapeutics and iPS
biobanking, the scalable production of in vitro transcribed RNA and consequently
mRNA-iPS cells is necessary. The use of chemical in vitro RNA synthesis was shown to
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be inappropriate for large production of long templates (>20nts) and was only suitable
for short templates (<20nts) (Lu & Li 2012; Nelissen et al. 2012). With the use of
chemical approach for in vitro transcription, the coupling efficiencies at each step is very
high, and this can be even more when it is necessary to do in vitro transcription for long
sequence templates such as hTERT or template with a high G/C content such as c-
Myc. Therefore, it is not feasible to synthesize chemically very long RNA molecules.
The long RNA molecules have recently been shown as essential reprogramming
implements for generation of iPS cells and development of reprogramming (Angel &
Yanik 2010).
In the present study, the large-scale production of in vitro transcribed RNA confirmed
the feasibility of enzymatic in vitro transcription using T7 RNA polymerase for robust
production of larger RNAs. This is supported by other reports which showed widely
utility of enzymatic in vitro transcription for production of larger RNAs (Lu & Li 2012;
Nelissen et al. 2012). Interestingly, the use of PCR template for IVT instead of linearized
plasmid allowed more efficient production of 5’-capped and 3’-polyadenylated mRNA
even for difficult templates with a high G/C content or a long sequence. It has been
reported that the use of PCR product as a template for IVT could facilitate large-scale
production of IVT-RNA without the need for linearization (Lu & Li 2012; Nelissen et al.
2012). In this study, although linearization of plasmids could produce proper templates
for IVT, the function of restriction enzymes was not efficient for difficult samples such
hTERT and c-Myc.
6.2 Reduced immunogenicity and cytotoxicity following mRNA
transfection
It is discussed that the main roadblock in mRNA reprogramming is the activation of
innate immune response which results in decreased proliferation and increased loss of
cell viability (Drews et al. 2012; Angel & Yanik 2010).
The case of immune response activation is important since it is the main barrier for
successful induction of pluripotency (Drews et al. 2012). Exogenous RNAs and
particularly the uncapped 5'-triphosphate (3pRNA) end-RNAs are pathogen-associated
molecular pattern for toll-like receptors and RNA sensors (RIG-I and PKR) (Karikó et al.
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2005; Hornung et al. 2006; Pichlmair et al. 2006; Angel & Yanik 2010; Yoneyama &
Fujita 2010). Therefore, when RNA is detected by those receptors a cascade of
signalling pathways will be initiated that result in translation inhibition, cell growth arrest,
and apoptosis (Karikó et al. 2005). Consequently, a key step in cellular mRNA
processing is the addition of a 5′ cap structure. The detection of 5'-triphosphate RNAs is
abrogated by capping the 5'-triphosphate end. Different capping systems could be
inserted to the 5'-end of RNA. To suppress the immune response following mRNA
transfection, Warren et al., utilized cap analog ARCA with modified nucleosides
(substitution of cytidine and uridine with pseudouridine and 5-methylcytidine). However,
still up-regulation of a number of interferon response genes was still observed on the
gene expression level. Consequently, they applied recombinant B-18-R-protein as a
suppressor of type I interferon to inhibit innate immune response (Warren et al. 2010).
With cap analog ARCA, only ~80% of IVT-RNAs will be capped requiring elimination of
residual 5′-triphosphates from non-capped IVT-RNAs in order to reduce the risk of RNA
recognition by RNA sensors in the cells. In addition, application of interferon
suppressors such as B-18-R-protein might have an effect on reprogramming. Mah et al.,
claimed that B18R supplementation yielded Nanog-positive iPS cells (Mah et al. 2011).
Additionally, some groups have recently clarified the role of B-18-R-protein on
reprogramming (Yoshioka et al. 2013). The use of B-18-R-protein for mRNA-
reprogramming raises the question afterward whether the generated iPS cells are
derived from reprogramming-mRNAs or positive effect of B-18-R-protein.
In this study, no increased levels of hIFN-γ and hIFN-α (hallmarks of immune response)
were detected in the supernatant of transfected cells. For the insertion of cap structure,
the vaccinia virus-derived capping enzyme was used to insert non-modified natural cap
1 to 5' end of RNA. Such system ensures 100% proper cap orientation for the resultant
transcripts compared to cap analog which produces only ~50% capped RNAs in the
correct orientation or even with cap analog ARCA where only ~80% of IVT-RNAs will be
capped. The use of vaccinia virus-derived capping enzyme could ensure 100% correctly
capped RNA transcripts, and might support no activation of immune response following
mRNA transfection.
On the other hand, there was a tendency toward an increased amount of interferon with
single factor mRNA rather than factor combination. It is likely that there is a balance
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between different factor combinations after transfection which does not evoke any
response inside of the cells, while there is no such balance after transfection with single
factor mRNAs.
The low cell survivability is one of the major challenges faced with mRNA-based
reprogramming (Warren et al. 2012; Angel & Yanik 2010; Drews et al. 2012). This is
also due to the activation of immune response after mRNA transfection which induces
the pathways that lead to cellular apoptosis (Warren et al. 2012; Angel & Yanik 2010;
Drews et al. 2012). However, the effect of transfection reagent itself might aggravate
cytotoxicity following mRNA transfection. Drews et al., claimed that activation of innate
immune response made by exogenous RNA combined with cytotoxicity of chemical
agents such as lipofectamine resulted in severe cytotoxicity and cellular apoptosis
(Drews et al. 2012). Hence, we hypothesized that proper capping of all IVT-RNA
(discussed above) along with appropriate transfection reagent might mitigate immune
response, reduce cytotoxicity, enable repeated mRNA transfections, and finally play a
crucial role in successful mRNA reprogramming. Thus polyethyleneimine (PEI)-based
transfection was selected since it was shown to be a very efficient system with low cell
toxicity (Boussif et al. 1995; Pollard et al. 1998). Interestingly, we found cell proliferation
following mRNA-PEI transfection. As reported by a number of studies, application of
some transfection reagents minimize defensive action following foreign nucleic
transfection, and therefore minimize toxicity (Jensen et al. 2014). Probably, jetPEI has
the same effect in our system to mitigate cytotoxicity. On the other hand, some
publications show that the low molecular weight PEI derivatives is less toxic (Wen et al.
2009). Therefore it is reasonable to assume that the molecular weight of the
polyethylenimine might play an important role in reduction of cytotoxicity. Altogether, it
seems that PEI-based transfection is an appropriate candidate for mRNA-iPS
generation with minimal cytotoxicity.
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6.3 Sustained mRNA-mediated proteins
The short half-life of RNA molecules necessitates repeated transfections to generate
mRNA-iPS cells. Thus, highly stable mRNA and mRNA-mediated proteins are desired
to reduce transfection frequencies which are needed to maintain the required level of
reprogramming proteins for iPS cells generation. Previous reports showed a reduction
in expression of mRNA-mediated proteins by 24-36 h after transfection, and they
therefore showed everyday mRNA transfection to generate iPS cells which renders the
method highly stressful for the cells (Warren et al. 2010; Mandal & Rossi 2013).
The high stability and longer existence of reprogramming proteins in the cells enabled
us to perform repeated transfections every 48 h to maintain high levels of transcription
factors for iPS generation. Furthermore, high translation and expression efficiency were
shown following transfection of the reprogramming factor-mRNAs.
The 5′ cap was shown to enhance mRNA stability as well as translation efficiency inside
the cells (Gallie 1991; Kuhn et al. 2012). As discussed above, the uncapped 5′ end of
RNA is a ligand for cellular RNA sensors, and therefore the degradation rate of RNA
molecule is strongly affected by Gcap structure at the 5′ end of RNA molecule. In this
study, the capping system which was used for the insertion of cap structure to 5′ end of
RNA ensures capping of all IVT-RNAs, and therefore might support the high stability of
mRNA and consequently mRNA-mediated proteins. In addition, vaccinia virus-derived
2'-O-Methyltransferase enzyme was used in this thesis generated a cap1 structure
found in higher eukaryotes and could increase the translation efficiency. The Kozak
sequences surrounding the start codon of the mRNA molecule could also enhance the
efficiency of mRNA translation to proteins. Kozak sequences have been shown to play a
crucial role in determining the efficiency of which mRNA is translated into protein (Kozak
1986).
Interestingly, fluorescent intensity and protein level of Klf4 and c-Myc were found to be
elevated compared to the other factors. It is reasonable to assume that roughly the
same amount of mRNA molecules for each factor might enter the cells, as comparable
size of the molecule and transfection efficiency were shown for all factors (OSKMN).
Therefore, it could be possible that the factors with more intensity have more stable
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proteins (Klf4 & c-Myc). In addition, Klf4 and c-Myc proteins might have a slow turnover
which allows them to be more stable in the cells after translation. The stoichiometric
ratio of the individual reprogramming factors was shown to be crucial for iPS generation,
reprogramming efficiency and pluripotency of the resulted iPS cells (Papapetrou et al.
2009; Carey et al. 2011). In two independent studies, Papapetrou et al., and Carey et
al., demonstrated that the success of the reprogramming process was highly dependent
on Oct4 dosage and consequently they increased the ratio of Oct4 in their
reprogramming system. However, that was only on the level of nucleic acid and not
protein. Regarding the stability of reprogramming proteins in this thesis, less Oct4
protein was found than Kl4 and c-Myc. For further experiments to generate iPS cells, it
might help to prepare the reprogramming cocktails based on protein ratio rather than
nucleic acid ratio.
The percentages of GFP and hTERT positive cells were found to be less compared to
the other factors. This could be due to the less efficient translation of GFP and hTERT
mRNA to protein. The toxicity of GFP-mRNA for the cells could also interfere to reduce
the number of GFP positive cells. Induction of apoptosis has been reported in the cells
expressing GFP (Liu et al. 1999). The larger size of hTERT-mRNA could prevent
efficient transfection of mRNA and reduce the number of hTERT positive cells.
The proper capping of in vitro transcribed RNA could contribute to mitigate immune
response, reduce cytotoxicity and increase stability of mRNA within the cells. This could
support repeated mRNA transfections for the iPS generation. Consequently, several
human donor cells were transfected with different mRNA-factor combinations in order to
generate stable mRNA-iPS cells.
6.4 mRNA-reprogramming affected by parental cells
In this thesis it was found that mRNA-reprogramming is highly dependent upon the
primary donor cells. The response to mRNA toxicity, mRNA immunogenicity and even
reprogramming cocktails was extremely donor dependant. It was shown that only some
of the donor cells were able to form cellular aggregates and undergo mesenchymal to
epithelial transition which is the initial step of reprogramming (Samavarchi-Tehrani et al.
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2010; Li et al. 2010). Additionally, only two of the donors formed stable mRNA-iPS
colonies. The more detailed analysis of the donor cells certified high basal expression
level of Klf4 (mRNA-level) in the cells which formed aggregates. This data confirms the
contribution of donors in mRNA-based reprogramming, and highlights the function of
endogenous Klf4 for generation of mRNA-iPS cells. Once the donor cells with high
basal level of Klf4 are transfected with reprogramming factors, the level of Klf4 might
reach the level which is required for initiation of reprogramming and pluripotency, and
could switch the cells to undergo MET transition.
In addition, some of the donors formed only small cell aggregates which grew very
slowly and could not be passaged on to MEFs for several times. This may suggest that
while temporary expression of reprogramming factor-mRNAs could induce a certain
degree of reprogramming from mesenchymal to epithelial (initial step of reprogramming)
to form aggregates, it could also induce cell cycle arrest following transfection.
Observations such as this have been also reported by some other groups (Plews et al.
2010). Plews et al., observed small cell aggregates following mRNA transfection.
Although the cell aggregates were strongly positive for alkaline phosphatase (a marker
of pluripotency), these cells failed to expand. Once they analyzed the small cell
aggregates by RT-PCR, they noticed up-regulation of p21 which is an inhibitor of cell
cycle progression (Plews et al. 2010).
The above observations suggest that the generation of mRNA-iPS colonies, stability of
colonies and mRNA-reprogramming efficiency may vary depend on the origin, age,
proliferative potential and genetic background of different donor cells.
6.5 Characterization of mRNA-iPS cells
After generation of two stable mRNA-iPS cell lines (IMR90-mRNA-iPS & foreskin-
mRNA-iPS) which could be passaged on to MEFs several times, it was necessary to
validate them with the standard pluripotency tests. For this purpose, the colonies were
assessed for expression of pluripotency markers, the ability for teratoma formation,
genetic stability following reprogramming and expression of pluripotency related genes.
The mRNA-iPS cells showed hES cell-typical pluripotency markers, morphology, and
differentiation into all three germ layers. The formation of teratoma shows the feasibility
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of non-modified mRNA (natural cap 1) for generation of fully reprogrammed iPS cells.
To our knowledge, this is the first report of teratoma formation from the mRNA-iPS cells
generated by non-modified RNA. Using non-modified RNA (cap analog), Plew et al.,
could not attain fully characterized iPS cells, since they simply obtained small cell
aggregates which failed to expand on to MEFs (Plews et al. 2010).Similarly, Yakubov et
al., obtained alkaline phosphatase positive colonies after non-modified mRNA (cap
analog) transfection, however; no differentiation analysis and no teratoma formation
were done, and thus it is difficult to evaluate the pluripotency of their iPS cells (Yakubov
et al. 2010).
There is currently conflicting data regarding chromosomal abnormalities of the iPS cells.
Some publications suggest that chromosomal aberrations occur upon reprogramming
process followed by further expansion of the reprogrammed cells (Hussein et al. 2011;
Gore et al. 2011; Lister et al. 2011; Mayshar et al. 2010). Heng and colleagues
demonstrated that chromosomal changes can occur during spontaneous adaptation of
the derived iPS cells to prolong culture conditions (Heng et al. 2013).They reported
chromosomal abnormalities in 4 of out 7 stable iPS cell lines following prolong passages
of iPS cells (Heng et al. 2013). In another study, Taapken and colleagues performed
karyotype analysis on more than 1,700 human iPS cell lines and observed that the
occurrence of chromosomal aberrations was 12.5% (Taapken et al. 2011). Recently,
two reports noticed that reprogramming could restore chromosomal aberrations in the
iPS cells generated from disease-associated chromosomal abnormality (known as a
ring chromosome) (Bershteyn et al. 2014; Kim et al. 2014). Ring chromosomes are
structural chromosomal aberrations that can result in birth defects, mental disabilities,
and growth retardation. The Rings form after fusion of the long and short arms of a
chromosome, and are sometimes found along with large terminal deletions.
In this thesis, the mRNA-iPS cells (IMR90-mRNA-iPS) maintained some of the pre-
existing chromosomal aberrations of the parental IMR90 fibroblasts, and no more
structural and numerical aberrations were acquired upon reprogramming. It has been
reported that IMR90 cells are prone to spontaneous transformation and chromosomal
aberrations (Sherwood et al. 1988; Mason et al. 2006). However, the mRNA-iPS cells
displayed a tendency for more stability and reduction of chromosomal aberrations than
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the parental IMR90 fibroblasts. Numerical chromosomal aberrations such as
hypertriploidy, hypertetraploidy and hypohexaploidy were not observed in mRNA-iPS
cells which might indicate a selective advantage favoring normal karyotypes upon iPS
generation and expansion, or confirm that reprogramming itself reverts chromosomal
aberrations to a more stable karyotype.
Pluripotency related genes were shown to be up-regulated in foreskin-mRNA-iPS as
well as in IMR90-mRNA-iPS cells. Particularly, the up-regulation of Nanog confirms the
feasibility of mRNA-reprogramming approach for up-regulation of pluripotency
associated genes, since Nanog is a crucial factor for pluripotency transcriptional
circuitry and mediating self-renewal and maintenance of stem cells (Silva et al. 2009;
Theunissen et al. 2011).
With foreskin-mRNA-iPS cells, the deficiency in c-Myc up-regulation could be related to
the factor combinations used for generation of iPS cells, since c-Myc were not included
in the reprogramming cocktails (ONT & OSK factor combinations). Furthermore, a
selection process might occur during reprogramming which allows the cells with low
level of c-Myc to be reprogrammed.
The parental fibroblasts of IMR90-mRNA-iPS cells are fetal lung fibroblasts (IMR90);
therefore they could show the pre-existing expression of several pluripotency genes,
particularly Klf4 which has an essential role in fetal lung regulating the differentiation
and proliferation of the cells (Jean et al. 2013; Garrett-Sinha et al. 1996). Furthermore, it
has been shown that expression of Klf4 in fetal lungs is induced by oxygen (Shields et
al. 1996). The primary down-regulation of Klf4 in IMR90-mRNA-iPS at passage three
may be due to cultivation of such colonies in hypoxia with further up-regulation in
passage 36 related to general pluripotency profiles of the proliferating IMR90-mRNA-
iPS cells.
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6.6 Evaluation of mRNA-iPS cells with viral-iPS cells
In the next step after mRNA-iPS generation and characterization, it was necessary to
evaluate them with the iPS cells routinely produced in the labs through conventional
retroviral approaches. The use of hES cells for evaluation was interesting as well.
However; this work was done in Fraunhofer Institute for Cell Therapy and Immunology
(IZI) Leipzig where there was no license for the cultivation of hES cells.
The viral-iPS cells produced from foreskin fibroblasts as well as Huntington dermal
fibroblasts, exhibited morphology, proliferation, pluripotency markers and teratoma
formation comparable to mRNA-iPS cells (discussed previously) and to the viral-iPS
cells described elsewhere (Yu et al. 2007; Takahashi et al. 2007; Park et al. 2008). The
appearance of hES cell-like features in mRNA-iPS cells as well as viral-iPS cells
approved their pluripotency states. However, in gene expression profiling, the mRNA-
iPS and viral-derived iPS cells had different patterns. The incidence of hES cell-like
signatures in both foreskin and Huntington-derived-viral-iPS cells clearly confirm their
fully reprogrammed features. With respect to foreskin-mRNA-iPS cells, the up-
regulation of pluripotency related genes was noted, however, the overall shift from
fibroblasts to hES cell signatures did not occur. This outcome is supported by Plews et
al who showed activation of pluripotency-associated genes following transfection of
reprogramming factor-mRNAs; however, a general switch in global gene expression
from fibroblasts toward a pluripotent cell types was not accrued (Plews et al. 2010). It is
assumed that while pluripotency related genes are up-regulated, the foreskin-mRNA-
iPS cells still are partially reprogrammed and not fully reprogrammed cells. This could
affect the ability of foreskin-mRNA-iPS cells for further expansion. The cells could not
be expanded on MEFs over than 5 passages.
The parental fibroblasts of IMR90-mRNA-iPS cells have been already derived from
embryonic tissues which allows them to show some pluripotency features. Thus, it is
hard to evaluate the difference in general pluripotency state of IMR90-mRNA-iPS cells
and IMR90 fibroblasts with respect to gene expression profiling. However, this was
compensated with the formation of teratoma for IMR90-mRNA-iPS cells. We could not
find any reports which indicate formation of teratoma for IMR90 fibroblasts.
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6.7 Aging signatures of the iPS cells
The potential aging signatures of the iPS cells should be assessed before their use in
clinical applications. Therefore, following the assessment of iPS cells and
reprogramming process the second aim of this thesis was to figure out whether
reprogramming would be able to rejuvenate the aging hallmarks of parental fibroblasts.
Moreover, it was interesting to discover whether the iPS cells exhibit some of the aging
signatures related to parental fibroblasts. The major question is whether the iPS cells
are fully rejuvenated or whether they retain some of the marks of aging from the cells
from which they were derived.
Aging is a physiological process that results in gradual defects of molecular and
organelle hemostasis in different cells and tissues. Aging cells are characterized by
numerous alterations such as telomere shortening, dysfunctional mitochondria,
increased oxidative stress and DNA damage. For several years there was a belief that
aging is a progressive process toward decline; however, the emergence of iPS cells
however could provide a valuable tool to reverse some aspects of aging in somatic cells
of old individuals. There are currently conflicting data regarding the ability of
reprogramming to fully rejuvenate an aged somatic cell. Furthermore, there are mixed
findings regarding whether iPS cells exhibit some of the aging signatures from their
parental cells. This thesis studied the above controversies and discussed the
conclusions that can be drawn. Consequently, three hallmarks of aging including
telomere length, mitochondrial alteration and DNA damage have been investigated for
both iPS cells and their parental somatic cells.
6.7.1 Telomere length
Telomeres are special chromatin structures composed of tandem repeats sequences
(TTAGGG) which are located at the end of the chromosomes (de Lange 2002; Blasco
2005). They shorten with every cell division in a typical somatic cell resulting in
replicative senescence, and therefore they are markers for cellular aging and
senescence (Gourronc & Klingelhutz 2012). Replicative senescence is a state of
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permanent cell cycle arrest resulting from serial passage in culture due to a limited
proliferative lifespan (Hayflick & Moorhead 1961).
Currently, there are controversial data regarding the ability of reprogramming to convert
telomere length to a more youthful state. It has been shown that the iPS cells generated
from senescent and aged-somatic cells display elongated telomeres following
reprogramming (Lapasset et al. 2011). However, some other reports have been
published which showed shortened telomeres in some of the iPS cell lines equivalent to
the parental cells (Vaziri et al. 2010). In this thesis however; the clearly elongation of
telomere length in iPS cells rather than their parental fibroblasts was observed.
Telomere length shows heterogeneity in different iPS cell lines. It is highly sensitive to
the passage number and can be changed following in vitro expansion of the iPS cells.
Some of the studies found that the iPS telomeres already elongated compared to their
parental cells in lower passage (passage five) (Suhr et al. 2009), whereas, some other
groups point out telomere elongation in iPS cells only after subsequent cell divisions
(Marion et al. 2009). In agreement with this, Yehezkel et al and Lapasset et al also
demonstrated long telomeres in iPS cells with high passage number (Yehezkel et al.
2011; Lapasset et al. 2011). The iPS cell lines used in the current study were already in
high passage and still revealed high telomere length compared to the parental cells,
confirming the data exhibited by previous reports.
Furthermore, in the current study telomere elongation was shown in the iPS cells
derived from Huntington-diseased fibroblasts. In some studies however, reprogramming
was able to restore telomere length of some patient-specific-iPS cells (Agarwal et al.
2010) but not all (Batista et al. 2011).
Regarding iPS-derived fibroblasts (iPS-DF), Suhr et al exhibited telomere lengths
comparable to the input fibroblasts. Nevertheless, they found some of the iPS-
differentiated fibroblasts displayed elongated telomeres comparable to the iPS cells
(Suhr et al. 2009). In this thesis, the iPS-derived fibroblasts present shortened
telomeres compared to the iPS cells, but are still longer compared to input parental
fibroblasts. It is likely that the reprogramming process could rejuvenate telomere length
of iPS-derived fibroblasts. In addition, some of the transgenes might be re-activated
following differentiation of iPS cells and cause telomere elongation in iPS-derived
fibroblasts. Moreover, it could be possible that some undifferentiated cells remained in
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culture following differentiation which could affect telomere length of iPS-derived
fibroblasts to be elongated. Whether those possibilities are cell line-dependence or
differentiation protocol requires additional data to determine. However, it is quite clear
that the iPS cells and their differentiated progeny can still be used as an aging in vitro
model.
6.7.2 Mitochondrial alteration upon reprogramming
Aging in somatic cells is accompanied by mitochondrial dysfunction and oxidative stress
(Passos et al. 2007; Moiseeva et al. 2009). The aged somatic cells have more
mitochondrial mass and increased level of ROS (Alemi et al. 2007; Prigione &
Cortopassi 2007). Consequently, the toxic effects of ROS on cellular components leads
to accumulation of oxidative damage which causes cellular dysfunction with age (Alemi
et al. 2007; Prigione & Cortopassi 2007; Piotrowska & Bartnik 2014). Mitochondrial
dysfunction could be one of the main hallmarks of aging since mitochondria-mediated
ROS is the major cause of the aging process. Mitochondrial morphology in aged
somatic cells has also been shown to be more elongated and have developed cristae
(Prigione et al. 2010; Suhr et al. 2010).
It was recently shown that reprogramming process causes mitochondria to adopt the
immature morphology and distribution (Prigione et al. 2010; Prigione et al. 2011; Suhr et
al. 2010; Lapasset et al. 2011). On the other hand, mitochondrial morphology in iPS
cells has been reported to exhibit a mixed phenotype in between immature and somatic
cells (Varum et al. 2011). The iPS cells in this study, however, demonstrate more
immature mitochondrial morphology and localization, while their differentiated
counterparts present more mature phenotypes. The presence of some immature
mitochondria (round-shaped ones) in iPS-derived fibroblasts could be related to the
improvement of mitochondria upon reprogramming. However, it could be possible that
during differentiation of iPS cells to fibroblasts, some undifferentiated cells remained in
culture interfering mitochondrial morphology to be more round-shaped. Interestingly,
acquiring immature mitochondrial morphology by Huntington-derived-iPS cells might
approve reorganization of mitochondria upon reprogramming. It has been previously
shown that Huntington-derived fibroblasts present altered disrupted mitochondria
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(Squitieri et al. 2006). Squitieri et al. showed a significant increase in the number and
percentage of altered elongated mitochondria as well as disarrangement and disruption
of mitochondrial crests in the fibroblasts that were isolated from Huntington patients
(Squitieri et al. 2006).
It is discussed that mitochondria-mediated ROS is the major cause of aging process
through accumulation of oxidative damages (Passos & Von Zglinicki 2006; Piotrowska &
Bartnik 2014). ROS production has been observed to be reduced in iPS cells after
reprogramming (Prigione et al. 2010; Prigione et al. 2011) which confirms the data
related to ROS production in this thesis. The reduced ROS production in iPS cells is
due to the decline in mitochondrial complement and resetting of metabolic pathway
following reprogramming (Armstrong et al. 2010; Prigione et al. 2010). The reduced
ROS production could support telomere elongation and decrease DNA damage of the
iPS cells as demonstrated in this thesis. It has been shown that increased production of
mitochondria-related ROS has a critical effect on telomere shortening resulting in
replicative senescence and increasing DNA damage signals (Passos et al. 2007;
Passos & Von Zglinicki 2006). The iPS-derived fibroblasts showed comparable ROS
level to their iPS cells in this study. This outcome was also demonstrated by Suhr et al.,
who claimed that iPS-derived fibroblasts improved mitochondrial function comparable to
their corresponding iPS cells (Suhr et al. 2010). It could be possible that reprogramming
was able to rearrange mitochondria to a more youthful state.
In this study, the mitochondrial membrane potential was shown to be less in the iPS
cells than their parental fibroblasts confirming the existence of less active mitochondria
in those pluripotent cells. Previously, it has been determined that mitochondria with high
membrane potential revealed more active electron transport chain, whereas less active
mitochondria showed lower membrane potential (Suhr et al. 2010).
The iPS-derived fibroblasts in this study displayed a mixed feature of mitochondrial
membrane potential. This could be related to the presence of different cell types in the
differentiated culture due to the spontaneous differentiation of the iPS cells toward
fibroblasts. Due to the existence of mixed cells in the differentiated culture, the iPS-
derived fibroblasts may differ with regard to their handling of MMP.
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Although the above data reveals a more youthful state of mitochondria upon
reprogramming, further studies are still required to clarify the amount of this
rejuvenation.
The aging studies on mRNA-iPS cells have not been reported by other groups and this
is the first report of such studies in mRNA-iPS cells. As it was discussed above, the
IMR90 fibroblasts have fetal origin and might contain some immature mitochondria with
round-shaped morphology. This could be the reason that we were not able to
distinguish clear differences on mitochondrial morphology among IMR90 fibroblasts and
IMR90-mRNA-iPS cells. With regards to mitochondrial function however, the changes
were more significant which confirms the existence of less active mitochondrial
complement in IMR90-mRNA-iPS cells.
The data concerning aging analysis of mRNA-iPS cells are still preliminary studies. To
properly assess whether mRNA-iPS cells exhibit aging signatures, more detailed
analysis and additional research into other aspects of aging is required. Furthermore,
the aged cell of old individuals needs to be analyzed in the future to determine the
potency of mRNA-reprogramming for rejuvenating of old donor cells.
6.7.3 DNA damage response
One of the hallmarks of aging is tissue degeneration following accumulation of damaged
DNA. DNA damage in aged somatic cells can lead to cellular senescence and age-
related defects (Sikora 2014). Reactive oxygen species, the by-product of mitochondrial
respiration, is considered to be the main source of DNA damage in aged somatic cells
(Balaban et al. 2005; Cooke et al. 2003). Consequently, the use of mitochondrial
respiration in those cells causes large amounts of DNA damage.
Despite reduced levels of DNA damage, the pluripotent cells have been shown to be
more prone to apoptosis than non-pluripotent cells when they are exposed to DNA
damaging agents (Wang et al. 2009; Momcilovic et al. 2010; Luo et al. 2012). This is a
defense mechanism to eliminate the abnormal cells before the next cell cycle (Aladjem
et al. 1998; Lin et al. 2005; Qin et al. 2007).
In this study, the hedgehog comets are representative of apoptosis, and interestingly
they are only shown in the iPS cells and not in their parental fibroblasts. However, the
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appearance of hedgehog comets in iPS cells even before their exposure to a DNA
damaging agent (H2O2) could be related to their sensitivity to preparation procedure or
the recurrence of spontaneous DNA damage.
In support of the results demonstrated in this thesis, previous studies have implied that
the pluripotent cells either ES cells or iPS cells, exhibit less DNA damage than non-
pluripotent cells (Momcilovic et al. 2010; Luo et al. 2012). In line with this, our results
showed that the iPS cells had less DNA damage in both basal level and following
exposure to H2O2. As discussed above, reduced ROS production upon reprogramming
could support the reduced basal DNA damage of the iPS cells. Furthermore, the highly
efficient DNA repair mechanisms in iPS cells (pluripotent cell) might reduce DNA
damage following exposure to DNA damaging agent. It has been reported that the
pluripotent cells possess efficient active DNA repair mechanisms to ensure their genetic
stability (Momcilovic et al. 2010; Fan et al. 2011).
The Huntington fibroblasts present more DNA damage than the foreskin counterparts in
both basal level and following exposure to H2O2. This could be related to the pre-
existing DNA damage in Huntington fibroblasts. It has been reported that Huntington
mutation (CAG repeats stretch) causes a number of damage in mitochondria which
might induce production of ROS and generate DNA damage mainly mediated by ROS
(Panov et al. 2002; Browne & Beal 2006; Squitieri et al. 2006). In this regard, the
Huntington-derived-iPS cells were shown to have more DNA damage than foreskin-
derived-iPS cell. It is likely that the ROS produced by mitochondria in parental
Huntington fibroblasts as well as basal DNA damage of the parental cells could affect
the level of DNA damage in the resultant iPS cells. However, the decline in ROS
production was shown upon reprogramming of Huntington fibroblasts to the iPS cells
(discussed previously). It could be possible that the Huntington-derived-iPS cells feature
incomplete epigenetic reprogramming and retain some signatures that are characteristic
of their parental Huntington fibroblasts.
Although the above results confirm that the iPS cells are more resistant to DNA
damage, it is necessary to further investigate their DNA repair capacities as well as the
specific pathways for DNA repair. Currently, minimal data exists for multiple human iPS
cell lines which could serve as better candidates for clinical use than ES cells. However,
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such investigation provides a basis for evaluating DNA repair capacities of different iPS
cell lines prior their use in laboratory and clinical objectives.
6.8 Conclusion
In the current study, the feasibility of enzymatic in vitro transcription as well as PCR
templates for large-scale production of in vitro transcribed RNA was confirmed.
Reduced immunogenicity of mRNA was indicated on the protein level (decreased level
of IFNs). The use of vaccinia virus-derived capping enzyme could ensure capping of all
RNA transcripts, and consequently could support no activation of immune response
following mRNA transfection. PEI-based transfection was shown to be an appropriate
candidate for mRNA-iPS generation with minimal cytotoxicity. The reduced cytoxicity by
PEI likely occurs via alleviation immune reaction or low molecular weight of PEI. The
high stability of mRNA and consequently mRNA-mediated proteins were likely due to
correct capping of all IVT-mRNAs. It seems that the proper capping of in vitro
transcribed RNA could contribute to mitigate immune response, reduce cytotoxicity and
increase stability of mRNA within the cells. This could support repeated mRNA
transfections for the iPS generation. The generation of mRNA-iPS cells was found to be
highly donor dependant which suggest mRNA-reprogramming may depend on the
origin, age, proliferative potential and more importantly the endogenous expression of
pluripotency factors. Accordingly, the generation of two stable mRNA-iPS cell lines was
shown. Characterization and evaluation of such cells proved their pluripotency states
comparable to viral-iPS cells produced by conventional retroviral vectors. Telomere
elongation was indicated in both healthy and diseased iPS cell lines. The telomere
length of iPS-derived fibroblasts was shown to be in a more youthful state than the
parental input fibroblasts. This likely occurred via telomere rejuvenation upon
reprogramming or re-activation of some transgenes following differentiation.
Mitochondrial morphology and function were improved into more immature features in
both healthy and diseased iPS cell lines as well as iPS-derived fibroblasts. This
suggests the ability of reprogramming to rearrange mitochondria to a more youthful
state. Interestingly, acquiring immature mitochondrial features by Huntington-derived-
iPS cells approved reorganization of mitochondria upon reprogramming, since it was
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previously reported that Huntington-derived fibroblasts exhibit altered mitochondria. The
mitochondrial complement was noticeably less active in IMR90-mRNA-iPS cells
compared to their parental cells. The basal level of DNA damage was shown to be less
in both healthy and diseased iPS cells than their parental fibroblasts, probably due to
the reduced ROS production after reprogramming. Decreased DNA damage following
exposure to DNA damaging agent confirmed the presence of highly efficient DNA repair
mechanisms in iPS cells. The Huntington-derived-iPS cells have noticeably more DNA
damage than the healthy foreskin-derived-iPS cells. This suggests that the Huntington-
derived-iPS cells might retain some aging signatures of their parental Huntington
fibroblasts. The Huntington fibroblasts were previously shown to be more prone to DNA
damage. Overall, it seems that the iPS cells are more resistant to DNA damage
compared to the parental fibroblasts.
Altogether, it is apparent that the generation of mRNA-iPS cells is largely affected by
reprogramming factors-mRNA as well as the parental cells from which they are derived.
Furthermore, the two mRNA-iPS cell lines generated in this thesis were derived from
the cells which were already from young donors. The more aged cells of old individuals
need to be analyzed in the future to figure out the potency of mRNA-reprogramming for
rejuvenation of old donor cells. Furthermore, our data shows reversion of aging
signatures to a more youthful state upon reprogramming process. However, aging is a
complex process marked by innumerable changes and, only some set of age-related
alterations was investigated in this thesis. To properly assess whether the iPS cells
exhibit an aging signature and are more youthful than their parental somatic cells,
additional research into other aspects of aging is required. Additionally, more
comprehensive testing of several iPS cell lines and their potential aging signature
should be conducted before their use for further translation and laboratory research.
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7. Summary
The ability to reprogram adult somatic cells into induced pluripotent stem (iPS) cells
could provide a valuable implement for in vitro disease modeling and drug discovery.
More importantly, they may potentially serve as an unlimited source of cells for
regenerative medicine. However, most of the iPS cells have been generated by
retroviral vectors, and therefore they carry the risk of viral integration into the host
genome. This problem prevents their use for clinical applications and regenerative
medicine. mRNA-mediated delivery of reprogramming factors is an alternative approach
for cellular reprogramming. mRNA-based reprogramming offers the advantage of being
completely free of genomic integration and is therefore highly suitable for clinical
translation. However, there are some limitations which must be overcome so that mRNA
can be widely used for successful cellular reprogramming. In the current thesis, the
attempt was to generate stable mRNA-iPS cells through overcoming those limitations.
Several human donor cells were transfected with mRNA encoding reprogramming
factors and the generation of two stable mRNA-iPS cell lines was shown. The resultant
mRNA-iPS colonies were assessed for pluripotency markers. Their pluripotency
features were evaluated by the viral-iPS cells produced by conventional retroviral
vectors. It was noticed that the generation of mRNA-iPS cells was largely affected by
the parental cells from which they were derived. However, characterization and
evaluation of the generated mRNA-iPS cells proved their pluripotency states
comparable to the viral-iPS cells.
On the other hand, the aging hallmarks of the iPS cells were assessed in the second
part of this thesis. The potential aging signatures of the iPS cells should be conducted
before their use in clinical applications. Currently, there are controversial data regarding
the ability of reprogramming to fully rejuvenate an aged somatic cell and reverse age-
related changes such as shortened telomeres, dysfunctional mitochondria and DNA
damage. Moreover, mixed findings have been published regarding whether the iPS cells
are fully rejuvenated or they might retain some of the aging hallmarks from the cells
which they were derived. This thesis studied these controversies through the
investigation of three hallmarks of aging including telomere length, mitochondrial
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alteration and DNA damage. Telomere elongation was indicated in the iPS cells.
Furthermore, mitochondrial morphology and function were improved into more immature
features in iPS cell lines than their corresponding fibroblasts. Moreover, the iPS cell
lines were shown to have less amount of DNA damage compared to their parental
fibroblasts.
In summary, it can be concluded that generation of mRNA-iPS cells is largely affected
by the primary donor cells from which they are derived. Furthermore, it seems that
reprogramming enables reversion of aging signatures to a more youthful state.
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7. Zusammenfassung
Die Reprogrammierung adulter, somatischer Zellen hin zu induzierten, pluripotenten
Stammzellen (iPS) kann ein nützliches Hilfsmittel für in vitro Krankheitsmodelle und die
Arzneimittelforschung darstellen. Zusätzlich könnte es als unbegrenzte Zellquelle für die
regenerative Medizin dienen. Gegenwärtig wird jedoch ein Großteil der iPS Zellen durch
virale Vektoren erzeugt, was das Risiko einer Integration des virale Genoms in das
humane mit sich bringt. Diese Problematik begrenzt derzeit den Einsatz von iPS Zellen
in der regenerativen Medizin sowie in klinischen Anwendungen. Ein alternativer Ansatz
Zellen zu reprogrammieren beinhaltet eine mRNA-basierende Freisetzung von
Reprogrammierungsfaktoren. Diese Herangehensweise hat den Vorteil, dass die
Methode frei von einer möglichen genomischen Integrierung ist und folglich geeignet für
klinische Studien wäre. Hierbei existieren jedoch Limitierungen, welche überwunden
werden sollten, damit die aussichtsreiche mRNA Methode vielfältig eingesetzt werden
kann.
Ein Ziel der vorliegenden Studie war es stabile mRNA iPS Zellen zu erzeugen um die
Begrenzungen der Methode zu überwinden. Hierzu wurden verschiedene Donorzellen
mit mRNA, welche Reprogrammierungsfaktoren codierte, transfiziert. Die Generierung
von zwei stabilen mRNA iPS Zelllinien wurde im Rahmen dieser Studie gezeigt. Die
erhaltenen mRNA iPS Kolonien wurden auf Pluripotenzmarker geprüft. Außerdem
wurden deren pluripotente Eigenschaften mit denen viraler iPS Zellen, welche durch
konventionelle retrovirale Vektoren erzeugt wurden, verglichen. Im Zusammenhang
damit wurde nachgewiesen, dass die Erzeugung von mRNA iPS Zellen deutlich von
den parentalen Zellen, von denen sie abgeleitet wurden, beeinflusst wurde. Dennoch
wurde durch Charakterisierung und Evaluierung der generierten mRNA iPS Zellen
festgestellt, dass ihre pluripotenten Stadien vergleichbar mit denen konventionell
erzeugter, viraler iPS Zellen waren.
In dem zweiten Teil der Studie wurden die Alterungskennzeichen der iPS Zellen
analysiert. Generell sollte die potentielle Alterungssignatur der iPS Zellen vor deren
Einsatz in klinischen Anwendungen erfasst werden. Derzeit existieren kontroverse
Daten bezüglich der Fähigkeit des Reprogrammierens gealterte, somatische Zellen zu
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regenerieren und altersabhängige Veränderungen wie verkürzte Telomere,
funktionsgestörte Mitochondrien und DNA Schäden positiv zu beeinflussen. Weiterhin
wurden heterogene Ergebnisse veröffentlicht zu der Frage, ob die iPS Zellen vollständig
verjüngt werden können oder ob sie möglicherweise einzelne Altersmerkmale der
Donorzellen, von denen sie abgeleitet wurden, beibehalten. Die vorliegende Studie hat
diese verschiedenen Ansätze durch die Untersuchung von drei Kennzeichen des
Alterns beleuchtet. Dies beinhaltete die Analyse von iPS Zellen auf Veränderung der
Telomerlänge, der Mitochondrien sowie auf DNA Schäden. Dabei zeigten sich Hinweise
auf eine Telomerverlängerung in den generierten iPS Zellen. Zudem waren die
mitochondriale Morphologie sowie deren Funktion verbessert und die iPS Zellen trugen
vermehrte Merkmale unreifer Zellen im Vergleich zu deren korrespondierenden
Donorfibroblasten. Ferner wurde gezeigt, dass die iPS Zelllinien weniger DNA Schäden
verglichen zu deren parentalen Fibroblasten hatten.
Zusammenfassend ist zu sagen, dass es denkbar ist, dass die Erzeugung von mRNA
iPS Zellen deutlich durch die primären Donorzellen, von denen sie abstammen,
beeinflusst wird. Des Weiteren gibt es Hinweise, dass das Reprogrammieren eine
Umkehrung der Alterssignatur hin zu einem eher jugendlichen Stadium ermöglichen
kann.
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9.1 Supplementary information
9.1.1 mRNA-reprogramming efficiency
The mRNA-reprogramming efficiency was calculated at the end of two weeks repeated
transfections (day 13 post-transfection), and the results revealed 0.09% efficiency for
ONT and 0.06% efficiency for OSKMNT (Supplementary fig. 1).
Supplementary figure 1. mRNA-reprogramming efficiency. The pictures show
reprogramming efficiency for different mRNA-factor combinations. The reprogramming
efficiency was calculated by dividing the average count of colonies per well by the initial number
of cells plated.
9.1.2 Mitochondrial localization and distribution in iPS cells
The mitochondrial localization and distribution were assessed in iPS cells and their
fibroblasts counterparts (donor fibroblasts and iPS-derived fibroblasts). The results
showed that in fibroblast cells the organelles were distributed in cytoplasm (donor
fibroblasts and iPS-derived fibroblasts), while in iPS cells, the mitochondria were mostly
localized around the nuclei (peri-nuclear structures) (Supplementary fig. 2). This pattern
was similar in all three iPS cell lines and their differentiated counterparts.
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Supplementary figure 2. Mitochondrial localization in iPS cells and their fibroblasts
counterparts. The pictures show mitochondrial distribution in donor fibroblasts, iPS cells and
iPS-derived fibroblasts.
9.1.3 Aging signatures of different iPS cell lines
Currently, there are controversial data regarding whether reprogramming rejuvenates
aged somatic cells or iPS cells exhibit aging signatures. The potential aging signatures
of different iPS cell lines reported from previous publications have been summarized in
supplementary table 1.
Supplementary table 1. Aging signatures of different iPS cell lines and derivatives
(Rohani et al. 2014).
Species Donor cell
type
Donor age *Aging
signature
iPS cells
*Aging
signature
iPS-
derived
cells
§Premature
senescence
iPS-derived
cells
Reference
Mouse Embryonic
fibroblasts
Adult
fibroblasts
Adult
fibroblasts
Embryonic
Young (22
weeks)
Old (121
weeks)
(>p8): 1/2
0/1
0/1
-
-
-
-
-
-
Marion et
al. 2009
Mouse Adult
fibroblasts
Not
mentioned
(p36): 0/1 - - Huang et
al. 2011
Mouse &
Human
Mouse
embryonic
Embryonic 0/2 - - Mathew et
al. 2010
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fibroblasts
Human
adult
fibroblasts
Human
foreskin
fibroblasts
Human fetal
fibroblasts
Not
mentioned
Young
Fetal
1/3
1/3
0/3
-
-
-
-
-
-
Human Fetal
fibroblasts
Adult
fibroblasts
Fetal (16
weeks)
Old (70
years)
0/1
0/1
1/1
1/1
-
-
Suhr et al.
2009
Human Adult
fibroblasts
Old (70
years)
0/5 4/5 - Suhr et al.
2010
Human Foreskin
fibroblasts
Young 0/3 3/3 - Yehezkel
et al. 2011
Human Proliferative
and
senescent
adult
fibroblasts
Very old
adult
fibroblasts
Old (74
years)
Very old (96
years)
0/4
0/2
2/2
2/2
No
No
Lapasset
et al. 2011
Human Fetal
fibroblasts
Foreskin
fibroblasts
BJ
fibroblasts
FLF
ES cell-
derived cell
line EN13
Fetal
Young
Young
Unpublished
data
Not
mentioned
1/4
1/4
1/4
1/4
2/4**
-
-
-
-
-
-
-
-
-
-
Vaziri et
al. 2010
Human DKC mutant
fibroblasts
TERC+/-
mutant
fibroblasts
Adult
fibroblasts
(wt)
Diseased
Diseased
-
0/3***
0/3
0/2
-
-
-
-
-
-
Agarwal et
al. 2010
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Human TERT
mutant
fibroblasts
TCAB1
mutant
fibroblasts
DKC1
mutant
fibroblasts
Adult
fibroblasts
(wt)
Diseased
Diseased
Diseased
-
1/3
1/3
3/4
0/3
-
-
-
-
-
-
-
-
Batista et
al. 2011
Human Adult
fibroblasts
AD
fibroblasts
PD
fibroblasts
Very old
(106 &109
years)
Diseased
Diseased
0/1
-
-
0/4
0/4
1/4
-
-
-
Yagi et al.
2012
Human Adult
fibroblasts
DCM-
diseased,
aWS-
diseased,
and HGPS-
diseased
0/2 5/5 - Ho et al.
2011
Human Foreskin
fibroblasts
Young 0/10 10/10 - Prigione
et al. 2010
Human Foreskin
fibroblasts
Adult
fibroblasts
Young
Old (84
years)
0/7
0/7
-
-
-
-
Prigione
et al. 2011
Human Adult
fibroblasts
Not
mentioned
0/7 4/4 - Armstrong
et al. 2010
Human Foreskin
fibroblasts
Fetal
fibroblasts
Young
Fetal
#0/7
#0/7
-
-
-
-
Varum et
al. 2011
Human Fetal
fibroblasts
Foreskin
fibroblasts
Adult
fibroblasts
Fetal
Young
Not
mentioned
-
-
-
3/3
1/1
1/1
Yes
Yes
Yes
##Feng et
al. 2010
Human Adult
fibroblasts
Not
mentioned - 0/3 No Gokoh etal. 2011
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Fetal
fibroblasts
Young - 0/3 No
*Aging signature = Tests displayed signs of cellular aging among different aging tests
§This is the conclusion mentioned in the reference.
(>p8) & (p36) = Passage of iPS cells at the time of analysis
DKC = Dyskeratosis congenita
TERC = Telomerase RNA component
TERT = Telomerase reverse transcriptase
wt = wild-type
AD = Alzheimer’s disease
PD = Parkinson’s disease
DCM = Dilated cardiomyopathy
aWS = Atypical Werner syndrome
HGPS = Hutchinson Gilford progeria
**Only one clone showed a level of telomerase activity comparable to ES cells.
***DKC-mutant iPS cell line displayed telomere lengthening only with continued passage
#The iPS cell lines are not completely identical to hES cells in terms of mitochondrial
morphology and metabolic gene expression.
# #Because of the very low efficiency reported for most hiPS cell lines, the differentiation analysis
and most of the aging analysis was done using fetal-fibroblast-derived iPS cells.
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